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There is an urgent need for new antimalarials following the emergence of Plasmodium 
falciparum strains with reduced sensitivity to the currently used artemisinin combination 
therapies. Classical aminoquinoline-based drugs inhibit the formation of haemozoin (HZ) 
thereby causing parasite death from the cellular accumulation of toxic ‘free’ haem. 
Coincidentally, this immutable pathway also exists in Schistosoma mansoni, and presents a 
vulnerable target for drug design in these haematophagus organisms. Therefore, it would be 
of interest to explore novel scaffolds that can inhibit HZ formation as well as exploit the 
merits of established drugs via structural modifications that would harness their 
pharmacological and pharmacokinetic advantages while circumventing their therapeutic 
shortcomings. 
 
This project investigated the physicochemical, biological and mechanistic profiles of pyrido-
dibemequine (pDBQ) and pyrido[1,2-a]benzimidazole (PBI) derivatives whose structural 
motifs were informed by previously synthesised prototype molecules. Specifically, the 
aqueous solubility, membrane permeability, lipophilicity, metabolic stability and potential 
for cardiotoxicity of seven pDBQs, their metabolites and ten PBIs were tested through 
computational and experimental methods. In addition, their antiplasmodial and 
antischistosomal activities were determined and correlated with their respective 
physicochemical properties. As regards mechanistic evaluation, their ability to inhibit 
formation of abiotic HZ, β-haematin (βH), was assessed and intracellular inhibition of HZ 
formation probed. 
 
The pDBQs constitute reversed chloroquines with a 4-aminoquinoline nucleus hybridised to 
a dibenzylmethylamine side group that serves as a chemosensitising moiety. The pDBQ 
derivatives showed moderate to high solubility (52 – 197 µM) and permeability (LogPapp: -4.6 
– -3.6) at pH 6.5. Their lipophilicity, indexed by cLogP, ranged between 3.7 and 5.6 while the 
mean LogD at both cytosolic (7.4) and vacuolar (5.0) pH was 3.15 and 0.93, respectively. The 
compounds also showed low-nanomolar range antiplasmodial activity against both 
chloroquine (CQ)-sensitive (CQS) and resistant (CQR) strains (IC50 range CQS: 14.4 – 126.6 
nM, CQRDd2: 44.5 – 162 nM and CQR7G8: 69.6 – 307.1 nM), with no discernible cross-
resistance with CQ and the antiplasmodial activity directly correlated with lipophilicity. 
Mechanistically, all the pDBQs inhibited βH formation (IC50: 13 – 25 µM) and haem-pyridine 
fractionation profiles revealed they produced a CQ-like dose-dependent increase in toxic 
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‘free’ haem with corresponding decrease in HZ levels. Predicted human-Ether-a-Go-Go-
Related Gene (hERG) channel inhibition pIC50 ranged between 6.2 and 6.6, and correlated 
strongly with the cLogP and molecular weight. The derivatives were also highly 
susceptibility to microsomal metabolism, with N-dealkylation identified as the main 
biotransformation route.  
 
The pDBQ metabolites exhibited solubility and membrane permeability profiles similar to 
the parent compounds at pH 6.5, albeit with reduced lipophilicity (cLogP range: 2.3 – 3.5). 
Their βH inhibition activity (IC50: 15 – 24 µM) was also comparable to the parent compounds 
as were the haem-pyridine fractionation profiles. However, they showed greater 
antiplasmodial activity, with 4/7 derivatives exhibiting IC50 < 80 nM against PfDd2 (CQR 
strain). The metabolites had reduced hERG channel inhibition potential (pIC50: 5.0 – 5.7) and 
significantly improved metabolic stability upon incubation with mouse and human liver 
microsomes. 
 
The PBIs comprise molecules with structural likeness to CQ, including a planar heterocyclic 
moiety and a basic amine side group. PBI analogues showed low to moderate solubility (<5 
– 80 µM) and were moderately lipophilic (mean LogD7.4: 3.04). Although most of the 
derivatives were stable in liver microsomes, their predicted hERG channel inhibition 
potential was higher (pIC50: 6.11 – 7.50), presumably due to their high molecular weights. All 
but one derivative had submicromolar activity against CQS and CQR strains, with 
analogues bearing halo-substituents on the left of the PBI core showing the best 
antiplasmodial activity (mean IC50: CQS = 26.7 nM and CQR = 30.0 nM), highest selectivity 
(188 – 341) as well as complete cures in P. berghei-infected mice. The PBIs also inhibited βH 
formation (IC50: 6.8 – 120 µM) but did not all display intracellular inhibition of HZ 
formation. All derivatives were active against juvenile (mean IC50: 1.97 µM) and adult (mean 
IC50: 4.38 µM) schistosomes, with the 3, 4-dichloro-substituted analogue exhibiting 48% 
reduction of worm burden in vivo. 
 
In summary, the pDBQs evaluated in this project constitute potent antiplasmodial inhibitors 
of HZ formation but whose activity is compromised by metabolic and hERG liability while 
their metabolites seem to possess improved biological and physicochemical features. The 
observed activity of the PBIs against P. falciparum and S. mansoni complements the already-
established broad antimicrobial potency of this chemotype. 
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1.1 Chapter Overview 
This Chapter starts with a review of aspects of the epidemiology, pathophysiology and 
chemotherapy of human malaria. Within the life cycle, the blood stage of the causative agent 
Plasmodium falciparum is discussed, with particular focus on the processes of haemoglobin 
degradation and haemozoin formation in this human malaria parasite and another 
hematophagous organism, Schistosoma mansoni, the causative agent of human 
schistosomiasis. A recap of haemozoin-inhibiting antimalarials is provided as well as 
justification for drug designs that target this pathway. Within this context, literature is 
reviewed on dual-functioning reversed chloroquines and non-quinoline based chemotypes 
as potential antimalarial agents. The relevance of physicochemical features required for 
improved drug-likeness for these compounds is also highlighted. Justification, the research 
question and specific objectives are provided at the end of the chapter. 
 
1.2. Global Burden of Malaria in 2017 
Malaria is an infectious disease that poses a major public health challenge, mainly in tropical 
and sub-tropical regions of the world. Malaria is caused by protozoan parasites of the genus 
Plasmodium,1 under which there are five recognised species of the parasite that cause the 
disease in humans, namely P. falciparum, P. vivax, P. ovale, P. malariae, and P. knowlesi. 
Despite concerted efforts aimed at reducing incidence and case-related deaths, the disease 
still remains one of the leading causes of death especially among poor populations.2 
According to the World Health Organisation (WHO) 2016 World Malaria Report, there were 
an estimated 212 million new cases of malaria (range 148 – 304 million) worldwide in 2015, 
with 90% of these in Africa, 7% in south East (S.E.) Asia and 2% in the eastern 
Mediterranean region.3 In the same year, there were an estimated 429, 000 malaria deaths 
(range 235, 000 – 639, 000) worldwide, 92% of which occurred in Africa while 6% and 2% 
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occurred in S.E. Asia and the eastern Mediterranean region, respectively. Children under the 
age of 5 are particularly susceptible to malaria infection and death, with an estimated 
303, 000 deaths in 2015.3  Encouragingly, these figures nonetheless represent improvements 
from 2014, when there were 214 million new malaria cases (range 149 – 303 million) and an 
estimated 438, 000 malaria deaths (range 236 000 – 635 000) worldwide.4 Furthermore, they 
corroborate a trend of decreasing global malaria incidence and child mortality in the last 15 
years (Figure 1.1). However, though the overall burden of P. falciparum malaria is gradually 
declining, it is characterised by spatio-temporal variability that presents new and evolving 
challenges for control programs. Moreover, the consistent threat of asymptomatic (chronic) 
infections, which serve as sub-microscopic parasite pools in endemic populations,5 
necessitates the need for sustained efforts aimed at comprehensive malaria control. 
 
Figure 1.1: Percent decrease in malaria deaths between 2000 and 2015 by World Health 





1.3 The Malaria Parasite Lifecycle 
Of the five aforementioned species, P. falciparum is considered the most virulent due to the 
clinical outcomes of its infection. This species has a complicated lifecycle, which can be 
divided into two parts – the sexual lifecycle within the female Anopheles mosquito and the 
asexual lifecycle within the vertebrate host (Figure 1.2). The asexual lifecycle is further 
divided into a liver stage during which the parasites reside in hepatocytes and an 
erythrocytic stage when they grow, divide and differentiate within the host red blood cells 
(RBCs).   
During a blood meal, male and female gametocytes may be ingested by a female Anopheles 
mosquito, marking the beginning of the vector-host stage of the lifecycle. In the stomach of 
the mosquito, these gametocytes fuse to form zygotes, which morph into elongated and 
motile ookinetes. The ookinetes invade the walls of the mosquito mid-gut where they 
develop into oocysts, which grow, rupture, and release sporozoites, which travel to the 
mosquito’s salivary glands where they can be passed on to a human host in a subsequent 
blood meal via dermal tissue.6, 7 The motile sporozoites enter the host bloodstream and 
access the liver where they invade hepatocytes to initiate an asymptomatic infection during 
which the parasites grow, and each sporozoite multiplies into thousands of merozoites that 
are again released into the bloodstream. This marks the onset of the asexual cycle which is 
responsible for most of the clinical manifestations associated with malaria, and is 
characterised by the adhesion of infected RBCs to endothelial cells, reducing the clearance of 
infected cells by the spleen, thus resulting in potentially fatal placental and cerebral 
malaria.8, 9 Though each point in the parasite’s lifecycle is potentially exploitable as a drug 
target, the scope of this literature review and subsequent body of work described herein is 
limited to the intraerythrocytic asexual stage, and the designing of drugs that target 




Figure 1.2: The malaria lifecycle showing the vector and mammalian host stages. 1) Infection 
begins when sporozoites, deposited by an Anopheles mosquito during its blood meal, 2) 
invade the liver and mature over 6 days before rapturing the liver cells to 3) release 
merozoites which invade RBCs.  During the intraerythrocytic stage, 4) parasites grow 
through the trophozoite (immature and mature) and schizont stages, rapturing in the latter 
stage to release more merozoites. 5) Some trophozoites differentiate into gametocytes which 
may be 6) taken up in a blood meal by a female Anopheles mosquito to 7) develop through 
the gamete, ookinete, oocyst and ultimately sporozoite stages. This image was reproduced 
from Cho et al., (2012) Trends in Biotechnology Feb; 30(2):71-79 with the permission of Elsevier 





1.3.1. Asexual Erythrocytic Stage 
Upon release from the liver cells into the bloodstream, the merozoites invade the host RBCs 
where they undergo an asexual erythrocytic cycle (Figure 1.3). This invasion process is 
characterised by adhesion of the merozoites to the RBC surface using a cluster of secretory 
organelles, micronemes, rhoptry and surface membrane proteins.10 The merozoites first 
develop into an immature stage aptly named rings, owing to appearance of the parasites at 
this stage as a signet ring when viewed as a Giemsa-stained slide under a light microscope. 
The rings develop into mature trophozoites which represent a stage marked by high 
metabolic activity, and during which large volumes of host RBC cytosol are enzymatically 
digested within the acidic digestive vacuole (DV) to release essential amino acids and toxic 
by-products.11 This process of haemoglobin (Hb) degradation is discussed in greater detail 
in the next section.  
 
Figure 1.3: Schematic illustration of P. falciparum asexual erythrocytic cycle showing the 
invasion of RBCs by merozoites and the development and maturation of ring, trophozoite and 




The mature trophozoites progress into a schizont stage where the ingestion of host cell 
cytoplasm and consequent elimination of toxic waste products proceeds and almost expends 
the Hb content of the RBC. The schizont stage is characterised by nuclear division, resulting 
in 16 - 24 nuclei each of which moves towards the surface of the parasite and assembles as 
daughter merozoites for exit. This ultimate egress from the erythrocyte is preceded by the 
rupture of the parasite membrane and RBC membrane, and is presumably triggered by 
secretions from the merozoite apical organelles.12 At this stage, merozoites can either infect 
new RBCs to begin the erythrocytic cycle again, or, develop into gametocytes which are the 
hallmark of the sexual stage. 
 
1.3.1.1. Haemoglobin Degradation 
During this asexual stage, the parasite ingests and degrades ~75% of host Hb for 
nourishment and to gain physical space for growth and division so that the lytic volume of 
the host RBC is not exceeded.13-15 This proteolytic process by acidic and alkaline enzymes 
leads to the release of essential amino acids and toxic haem or iron(II)protoporphyrin IX 
(Fe(II)PPIX) 16 (Figure 1.4). Due to the absence of a functional haem oxygenase that 
oxidatively cleaves haem, the parasite consequently faces a unique waste disposal dilemma 
since it cannot enzymatically degrade Fe(II)PPIX. Instead, Fe(II)PPIX undergoes auto-
oxidation in the parasite to Fe(III)PPIX which, in its solubilised form, is equally toxic.17 Since 
unhindered degradation of Hb leads to subsequent generation of vast amounts of 
Fe(III)PPIX, the parasite converts this toxic product into inert and highly insoluble crystals 
called haemozoin (HZ).18 Inhibition of this process in P. falciparum and other 
haematophagous organisms is discussed later in detail as it constitutes an established target 




Figure 1.4: An illustration of the process of haemoglobin (Hb) degradation within a host red 
blood cell (RBC) infected with P. falciparum. Also indicated are the resultant formation of 
peptides and essential amino acids as well as the cytotoxic Fe(III)PPIX and its conversion to 
the non-toxic haemozoin (HZ). 
 
1.3.1.2. Haemozoin Formation in P. falciparum and other Hematophagous Organisms 
In higher eukaryotes and eubacteria, Fe(III)PPIX is degraded through the haem-
oxygenase/biliverdin reductase pathway.19, 20 The malaria parasite and other blood-feeding 
parasites like the bilharzia-causing trematode Schistosoma mansoni have, however, evolved a 
unique detoxification mechanism, which involves converting haematin into dimerised, non-
toxic, insoluble HZ crystals. In P. falciparum, HZ formation occurs in the DV where the 
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negatively charged propionate group of one haematin moiety is thought to associate with 
the positively charged Fe(III) centre of an adjacent haematin molecule via the carboxylate 
group, consequently initiating the assembly of HZ crystals by the repetitive association of 
haematin molecules in this fashion.21 Slater and Cerami suggested an enzyme-catalysed 
model of HZ formation and showed that P. falciparum trophozoite extracts promoted 
formation of β-haematin (βH), abiotic HZ .22 This was, however, challenged by Dorn et al. 
who noted that heat treatment of the extracts had little effect on the reaction and suggested 
the likely involvement of a reaction-promoting haem-derived material associated with HZ 17 
which Bendrat et al. suggested is a lipid.23 Though Sullivan et al. managed to identify and 
clone two histidine-rich proteins (HRP-2 and HRP-3) in purified DVs 24 and Choi et al. 
demonstrated the role of HRP-2 in complex formation with Fe(III)PPIX,25 later findings 
suggested that parasite clones lacking the genes encoding HRP-2 or 3 can still competently 
form HZ. Further, orthologs of HRP-2 are absent in P. vivax as well as in rodent malaria 
parasites, which also form HZ,26 ruling out a role for this protein. The current hypothesis on 
HZ formation in P. falciparum centers around lipid initiation originally proposed by Bendrat 
et al. 23 and later corroborated by Dorn et al. 17, 27 and lately by many other researchers.21, 28, 29 
Recent work in Plasmodium linked neutral lipid bodies on both the interior and the exterior 
of the DV with haem crystallisation 30-32 and more recently Pisciotta and co-workers 
identified neutral lipids closely associated with HZ.33 Growth of βH under biomimetic 
conditions have confirmed its efficient formation in a lipid environment,21, 33, 34 particularly 
when Fe(III)PPIX is directly introduced at or near the interface between the lipid and 
aqueous solution.21 This efficient formation of βH suggests that the lipid-water interface 
itself probably suffices in bringing about HZ formation within the parasite.35 In 2008, Jani et 
al. described the identification and characterisation of a haem detoxification protein (HDP) 
that is extremely potent in converting haem into HZ.36 This protein is refractory to 
disruption and is conserved across all Plasmodium genus. To illustrate that HDP is indeed 
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involved in crystallisation of haem into HZ, the authors demonstrated HDP-mediated dose-
dependent conversion of toxic haem into inactive HZ. This activity that was lost when HDP 
was protease-treated, suggesting intact protein is required for this activity. Exploring this 
hypothesis further, Chugh et al. more recently showed that HDP functions in concert with 
falcipain 2 (a major haemoglobinase) to efficiently convert Hb to HZ.37 Thus, the jury is still 
out as to whether HZ formation in P. falciparum is protein or lipid mediated. 
 
Using methods previously described for malarial HZ extraction, Oliveira et al. described 
what they observed as a dark-brown insoluble pelleted pigment from homogenised adult 
females of S. mansoni.38 Polarised light microscopy revealed that this pellet had a crystalline 
structure and was readily solubilised in 0.1 M NaOH to give an absorption spectrum 
identical to that of monomeric haem. Fourier transform infrared spectroscopy (FTIR) of this 
schistosomal pigment in potassium bromide pellets revealed a pattern identical to HZ 
from Plasmodium. Comparing the solubility of haem and this pigment showed ready 
dissolution of haem in sodium bicarbonate buffer, pH 9.1, whereas this pellet was virtually 
insoluble. Taken together with powder XRD measurements, these findings unequivocally 
identified the pigment isolated from S. mansoni as HZ. In female adult S. mansoni worms, HZ 
formation has been demonstrated to occur within the gut,38 in a process presumably 
catalysed by the extracellular lipid droplets present in the gut lumen,39, 40 which provide the 
requisite hydrophilic-hydrophobic interface for the crystallisation process.  
 
 
1.4. An Update on Current Malaria Treatment and Prevention Strategies 
The reduction in malaria burden mentioned in section 1.2 has largely been attributed to a 
scale-up of combinations of control strategies. In the main, these comprise long-lasting 
insecticide-treated nets (LLINs), indoor residual spraying (IRS) and intermittent preventive 
therapy for pregnant women (IPTp) for prevention, better diagnostics for case 
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ascertainment, and effective treatments using artemisinin-based combination therapies 
(ACTs). Admittedly, significant progress has also been made in malaria vaccine 
development, with the imminent roll-out of the pre-erythrocytic vaccine RTS, S/AS01 in 
large-scale, pilot projects following a large Phase III clinical trial in seven African countries.41 
In addition, the irradiated sporozoite vaccine, PfSPZ, is closer to pivotal Phase III trials 42 
while a number of other pre-erythrocytic and blood stage vaccines have shown efficacy in 
challenge experiments in volunteers and in endemic populations. However, efficacy has 
only been limited hence highlighting the significance of chemotherapy and vector control. 
The sophistication of the lifecycle of P. falciparum (Figure 1.2 and 1.3) presents different 
stages of the parasite’s development that can be targeted using drugs or drug combinations 
to treat malaria. Current antimalarial drugs (Figure 1.5) can be grouped into multiple classes 
namely: 4-aminoquinolines, 8-aminoquinolines, arylaminoalcohols, antifolates, artemisinins, 
antibiotics and inhibitors of the cytochrome bc1 complex in the parasitic electron transport 
chain. Several antibiotics that are prokaryotic protein synthesis inhibitors have antimalarial 
activity because of their action against the protein synthesis machinery of the apicoplast 
organelle.43 Antibiotic antimalarials, like doxycycline (DOX) or clindamycin, usually 
constitute partner drugs to faster-acting antimalarials such as artemisinins or quinine 
because they are slow-acting. Antifolates include sulfadoxine (SDX) and pyrimethamine 
(PYR) which respectively inhibit dihydropteroate synthase (PfDHPS) and dihydrofolate 
reductase (PfDHFR) in the folate pathway.44 Halofantrine (HLF) and mefloquine (MFQ) are 
examples of arylaminoalcohols. HLF is not widely used due to severe cardiotoxic effects 
while MFQ is generally combined with artesunate (AS) since, alone, it is associated with 
neurotoxicity.45 Atovaquone (ATQ) represents inhibitors of the respiratory chain, mostly 
used for chemoprevention and the treatment of uncomplicated P. falciparum malaria as 
exemplified by the ATQ-proguanil combination, Malarone.46 
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The 8-aminoquinoline class of antimalarials is unique due to the efficacy against relapsing 
forms of malaria.47, 48 These drugs act against the sexual as well as the pre-erythrocytic stage 
of the Plasmodium parasites. Primaquine (PMQ) is currently the only 8-aminoquinoline drug 
available, and is the drug of choice against P. vivax. Tafenoquine (TFQ) is a more potent and 
less toxic analogue of PMQ 49 originally synthesised by the Walter Reed Army Institute of 
Research in the USA and has since been tested in Phase II and III clinical studies.50-52 In 
addition, it is longer-acting and therefore, unlike PMQ, does not need to be taken frequently. 
This class of antimalarials forms part of the quinoline-based drugs, the most-widely known 
of which is the 4-aminoquinoline, chloroquine (CQ). 
ACTs constitute the current WHO-recommended treatment option for uncomplicated 
malaria. Artemisinins, exemplified by AS and artemether (ART) act on both the early and 
late stages of the malaria parasite’s lifecycle in the human host.53 They are fast-acting, 
efficacious and safe, and are commonly combined with other longer-acting antimalarials in a 
strategy aimed at delaying the onset of resistance. Though still effective in most endemic 
regions, there is growing evidence of delayed parasite clearance following treatment with 
ACTs in S.E. Asia,54, 55 and a recent case report of indigenous artemisinin-tolerant strain from 















Figure 1.5: Chemical structures of current antimalarials grouped according to their classes  
 
1.5. Quinolines and related antimalarial compounds 
Quinine (QN) was the first quinoline to be isolated from extracts of the bark of the Cinchona 
tree in 1820 by Pelletier and Caventou. However, extensive use during World War I led to 
exceedingly high demand, and its severe undesirable side effects further precipitated the 
need for research into the production of synthetic alternatives. This led to the development 
of CQ,57 which, in 1943, was taken into clinical trials and subsequently used widely due to 
its effectiveness and low risk side effect profile. Since then, many quinoline-based drugs 
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(Figure 1.5) have been important antimalarials. In fact, the quinoline nucleus is an important 
motif in heterocyclic compounds found in many natural and synthetic products with 
pharmacological activities such as anti-inflammatory,58 anticancer,59 antimycobacterial 60 and 
antiviral.61 
CQ has numerous pharmacokinetic (PK) and pharmacological advantages over all other 
antimalarial drugs. These comprise fast action, low toxicity, water solubility of its salt form 
and good oral bioavailability.62 However, CQ causes gastrointestinal disturbances due to its 
rapid absorption.63 Following the emergence and spread of CQ resistance, amodiaquine 
(AQ) was designed as an alternative against low CQ-resistant (CQR) parasites. However, 
prolonged use of this drug has been shown to possess an unacceptably high risk of 
agranulocytosis and hepatitis, with fatal outcomes in some cases.64, 65 Further development 
led to the discovery of piperaquine (PQ), a bis-4-aminoquinoline with two 4-aminoquinoline 
moieties attached by a linker and proven potency against both CQ-sensitive (CQS) and CQR 
parasite strains. Its activity against CQR parasites is thought to be due to its steric bulk 
which presumably prevents it from being expelled out of its site of action by transporter 
proteins.66 PQ is currently used as part of an ACT treatment regimen with 
dihydroartemisinin (DHA) in a fixed dose combination, which has shown excellent 
tolerability and high cure rates in malaria endemic settings.67-69 Discovered more recently is 
ferroquine (FQ), which has completed Phase IIA clinical trials,70 and has exhibited low 
toxicity as well as no cross-resistance with CQ.71 
 
1.5.1. Mechanism of Action of CQ and related 4-Aminoquinolines 
CQ and AQ have been shown to be mostly active only against the early to mid-
intraerythrocytic stage of the parasite lifecycle when Hb degradation is optimal.53 Similarly, 
treatment of parasites with pharmacologically-relevant concentrations of CQ was shown to 
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cause swelling of the DV. These two aforementioned phenomena provide the clearest hint 
that the mechanism of action (MoA) of CQ and related 4-aminoquinolines involves halting 
events linked to Hb degradation and accumulation within the DV. Nonetheless, a number of 
theories on the MoA of CQ and related aminoquinolines have been put forward. 
1.5.1.1. Inhibition of phospholipase 
Phospholipases play central roles in regulating signalling during numerous cellular events 
including proliferation, G protein-coupled receptor signalling and neuronal activation by 
catalysing the lysis of phosphorylated lipids. In P. falciparum, phospholipase enzymes have 
been identified within the DV and are thought to be responsible for degrading endocytic 
vesicle membranes in order to facilitate release of their Hb content into the DV. Ginsburg 
and Krugliak, (1992) showed that CQ inhibits the activity of phospholipase in vitro, albeit at 
substantially higher concentrations than those likely to occur within the parasite’s DV.72 
 
1.5.1.2. Inhibition of protease enzymes 
All parasitic protozoa contain multiple proteases, some of which are attractive drug targets. 
CQ has also been shown to inhibit partially purified aspartic protease activity from P. 
falciparum extracts.73 However, this too was only at concentrations above the therapeutic 
range. Moreover, haem itself is a competent low-dose inhibitor of acid proteases and this 
activity is unaltered even in the presence of CQ, thus making the evidence for this MoA less 
compelling. 
 
1.5.1.3. Binding to Nucleic Acid 
CQ, presumably due to its planar structure, was originally thought to exert its antimalarial 
activity through intercalation into planar bases of deoxyribonucleic acid (DNA) leading to 
inhibition of DNA replication and ribonucleic acid (RNA) synthesis, hence leading to cell 
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death.74 However, this hypothesis has since been refuted on grounds that though in vitro 
binding to DNA has been observed, this has been at markedly higher concentrations (100 
µM) than the pharmacological concentration, typically 10 nM.75 Using super-resolution 
analysis of fluorescent derivatives of QN and QD attached to 7-nitrobenz-2-oxa-1,3-diazole, 
Woodland et al. recently showed no co-localisation of these drugs with the nucleus, thus 
further rejecting disruption of DNA replication as a possible MoA of these quinoline-based 
drugs.76 Moreover, this theory fails to explain why MFQ, with no binding affinity to DNA,77 
is a potent antimalarial or the non-selective CQ-DNA binding between parasite and host 
nucleic acids. 
 
1.5.1.4. Inhibition of Polyamine Synthesis 
In P. falciparum, polyamines are synthesised by the bifunctional ornithine decarboxylase/S-
adenosylmethionine decarboxylase enzyme.78 Konigk et al. reported inhibition of ornithine 
decarboxylase activity in trophozoite extracts of infected RBCs by quinoline antimalarials.79 
However, this hypothesis is hazy as no follow-up studies have been conducted and it also 
fails to convincingly account for the specific activity of CQ on the blood stage but not liver 
stage parasites, which presumably also harbour this enzyme. 
 
1.5.1.5. Inhibition of Haem Detoxification 
Due to their ability to adopt planar conformations, CQ and related 4-aminoquinolines are 
thought to impede haem crystallisation and consequent HZ formation by docking onto the 
fastest growing face of haem or haem-drug complex thus blocking attachment of the next 
haem dimer (Figure 1.6). This inevitably leads to accumulation of toxic haem which, in its 
‘free’ form, can inhibit parasite growth and lead to death by inducing formation of oxygen-
derived free radicals,80 lipid peroxidation,81 and DNA oxidation.82, 83 First indications of 
haem-drug complex formation were reported by Cohen and colleagues,84 with later evidence 
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provided by other researchers.17, 27, 85, 86 Dorn et al., (1995) demonstrated that HZ formation is 
autocatalytic,17 and further confirmed previous observations by 
Egan et al., (1994) that this process could be directly inhibited by CQ. Ginsburg et al., (1998) 
also put forward the hypothesis that CQ acts as a competitive inhibitor of haem degradation 
by glutathione, thus allowing haem to partition into membranes 87 while Loria and 
colleagues demonstrated the decomposition of haem in the presence of hydrogen peroxide, 
hence suggesting that CQ is an efficient inhibitor of the peroxidative degradation of haem by 
complex formation.88 However, total iron measurement following cell fractionation, 
Mössbauer spectroscopy and electron spectroscopic imaging showed that haem is not 
decomposed in the parasite.18 The latest and more compelling evidence of inhibition of HZ 
formation by CQ was provided by Combrinck et al. who showed that CQ led to a significant 
dose-dependent increase in the levels of haem in the parasite and this correlated with a 
corresponding decrease in the levels of HZ.89 Further analyses revealed that this increase in 
haem, measured as the amount of total haem Fe in the cell, directly correlated with 
decreasing parasite survival. The crystal structure of the Fe(III)PPIX−HLF complex has 
revealed that coordination to the iron(III) center of the haem monomer, π-π interaction, and 
hydrogen bonding constitute the key interactions between arylmethanol HZ  inhibitors and 
Fe(III)-PPIX.90  
 
Additionally, as a weak diprotic base, CQ in its unprotonated form has been shown to move 
down the pH gradient into the acidic DV where once protonated, becomes trapped due to 
membrane impermeability91, 92 thereby accumulating several thousand-fold.93, 94 Aside from 
this pH trapping phenomenon, CQ has also been shown to accumulate in the DV as a result 
of interaction with ‘free’ haem in the DV, which acts as a CQ receptor.95 This body of 
evidence of CQ accumulation in the DV corroborates the theory that the MoA of CQ and 
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related 4-aminoquinolines is linked to the DV-localised process of Hb degradation and 
inhibition of the subsequent detoxification of haem. 
 
Figure 1.6: Proposed mechanism of action of chloroquine and related 4-aminoquinolines. 
This image was reproduced from Kouznetsov V and Gomez-Barrio A., Recent Developments in 
the Design and Synthesis of Hybrid Molecules Based on Aminoquinoline Ring and Their 
Antiplasmodial Evaluation. Eur J Med Chem ; 2009;, Aug; 44(8): 3091-113. Copyright© (2009) 
Elsevier Masson SAS. All rights reserved 
 
1.5.1.5.1. Measuring Inhibition of Haem Detoxification as a Mechanism of Action of CQ 
This inhibition of HZ formation can be quantified in vitro, by measuring the formation of βH 
within a cell-free environment under abiotic conditions that mimic the lipid-mediated 
process of HZ formation in the DV. This determination relies on UV-vis absorbance 
measurements for detection of a bis-pyridyl-haem complex,96 with optimum results 
demonstrated when the detergent Nonidet P-40 (NP-40) is used as the imitator of the neutral 
lipids involved in this process.97 In addition, this NP-40 assay is amenable to high 
throughput screening (HTS) due to its incorporation of the non-interfering aqueous acetone 




This mechanistic hypothesis can be validated using a pyridine-haem cellular fractionation 
assay to convincingly confirm true inhibitors of HZ formation.98 In this assay, it was 
demonstrated that true inhibitors of HZ formation cause a significant concentration-
dependent increase in ‘free’ haem and corresponding decrease in HZ in treated whole cell 
parasite cultures relative to untreated controls.89, 98 Crucially, using CQ as an example, 
Combrinck et al. showed that this increase in the proportion and amount of toxic ‘free’ haem 
corresponded to a decrease in parasite growth. This trend was, however, not observed in 
non-βH inhibitors exemplified by PYR and sulfadoxine/pyrimethamine.89 At this juncture, it 
is noteworthy that there are several key elements in the structure of CQ that are requisite for 
its antiplasmodial potency. 
 
1.5.2. Structure Activity Relationship (SAR) Profile of CQ 
The 4-aminoquinoline pharmacophore of CQ plays a critical role with respect to 
accumulation of the drug in the DV, formation of a drug-haem complex and exertion of 
cytotoxic effects by the complex. The structure activity relationship (SAR) profile of CQ 
(Figure 1.7) identifies and maps out the individual moieties responsible for these activities. 
The basic amino group in the lateral side chain has been demonstrated to be crucial for the 
accumulation of the drug in the DV where, upon protonation, CQ becomes membrane 
impermeable and subsequently trapped, a process referred to as pH trapping.99, 100 Indeed, 
replacement of the 4-quinolinyl amino moiety with an ether 101 and sulphur or oxygen atom 
102 led to reduction of the basicity of the quinolinyl nitrogen and diminished the 
antiplasmodial activity of the compound.  
Kaschula et al., using different substituents at carbon 7 (C7), investigated the effect of 
replacing the chloro (-Cl) group at this position on the inhibition of βH formation and 
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antiplasmodial activity.100 The antiplasmodial activity of 4-aminoquinoline derivatives with 
short diaminoalkane side chains ranged from low when -Cl was replaced at this position 
with 7-OMe to moderate in the 7–F and 7–CF3 derivatives tested against Haiti 135 (CQS) and 
Indochina I (CQR) strains of P. falciparum.103 Different studies have established that the 
group at C7 is also critical for βH inhibition, with compounds bearing a -Cl atom at this 
position exhibiting the most potent inhibition.99, 100, 103 An ideal group at C7 was previously 
proposed to be (i) moderately electron withdrawing, which will cause only a moderate 
decrease in the acid dissociation constant (pKa) of the molecule, thus enabling compound 
accumulation at the site of action while ensuring inhibition of βH formation and (ii) be 
strongly lipophilic. A strongly lipophilic group will enable a stronger association of the 
compound with haematin, which would presumably translate to stronger inhibition of βH 
formation.100 It is noteworthy, however, that in the Kaschula et al. study, the 7–NO2 
substituent showed strong inhibition of βH formation, without being very lipophilic.100  
The 4-aminoquinoline nucleus was identified to be the haematin-associating nucleus as the 
introduction of an alkyl side chain to the amino group of the 4-aminoquinoline has been 
shown to have no significant effect on the association strength.99, 100, 104 In addition, formation 
of the CQ-haematin μ-oxo dimer was found to be dominantly a function of the 4-
aminoquinoline core with the lateral side chain only contributing minimally to the 
binding.105. Alongside the terminal nitrogen, the quinoline nitrogen was also identified as 
essential for pH trapping.100 In summary, Egan and colleagues concluded from these studies 
that the 4-aminoquinoline nucleus of CQ, the chloro (-Cl) group at C7 and basic nitrogen 
attached to the aminoalkyl side chain are essential for antiplasmodial activity.100 These 
studies lay a platform to further investigate and map possible modifications to the SAR that 




Figure 1.7: Chloroquine structure-activity relationship (SAR) profile as proposed by Egan 
and colleagues.99 
 
1.5.3. Resistance to CQ and related 4-aminoquinolines 
Resistance to CQ emerged in the 1960s in S.E. Asia and South America and by the 1980s, had 
spread across Africa 106 and in effect, significantly increased the global cost of controlling 
malaria since new drugs have had to be continually developed to replace those that had lost 
efficacy. CQ resistance is attributed to polymorphisms in the ‘Plasmodium falciparum CQ 
resistance transporter’ (PfCRT) and other DV membrane proteins, resulting in reduced CQ 
accumulation.107-109 Compared to CQS strains, CQR parasites have been shown to 
accumulate up to 10-fold less CQ in the DV, falling outside the effective therapeutic range of 
the drug.110 Though several mutations in PfCRT have been reported in CQR strains, 
substitution of the positively charged lysine for the neutral hydrophobic threonine in codon 
76 (K76T) has been shown to be most essential in conferring CQ resistance.107, 111 While 
protonated CQ is unable to interact with wildtype K76 PfCRT, it can interact with 76T PfCRT 
allowing transport of previously trapped CQ down the electrochemical gradient and out of 
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the DV, with resistance consequently arising from the reduction in the concentration of 
accumulated CQ in the DV.112 
 
The existence of CQS strains associated with the 76T mutation suggests existence of other 
loci involved in CQ resistance in P. falciparum. Indeed, mutations in proteins other than 
PfCRT have also been identified as contributors to CQ resistance. For instance, a homologue 
of the eukaryotic ATP-binding cassette (ABC) protein, the Plasmodium falciparum multidrug 
resistance transporter 1 (PfMDR1) has been linked to reduced CQ sensitivity where allelic 
exchange experiments have demonstrated that mutations on this DV membrane transporter 
modulate the degree of sensitivity to CQ.113 Furthermore, variant parasites bearing pfmdr1 
86Y, 1034C, 1042D and 1246Y alleles have been shown to exhibit impaired transportation 
and accumulation of CQ into the DV, hence reduced sensitivity of the drug.114 
 
Based on their ability to inhibit βH formation, compounds which share structural similarity 
to CQ are postulated to share a similar mode of resistance, though this is not always a given. 
For instance, resistance to the more hydrophobic MFQ has been associated with increased 
copy number of the pfmdr1 gene, resulting in increased expression of its cognate PfMDR1 
protein.115-117 Similarly, while resistance to AQ is also linked to polymorphisms in both 
PfCRT and PfMDR1,118 the drug retains activity against most CQR parasites. This 
phenomenon could be attributable, on one hand, to its retention in the hydrophobic lining of 
the PfCRTCQR channel 119 and on the other, to the observation that the PfCRT haplotypes that 
mediate AQ and CQ resistance are in fact different.120 These studies highlight the fact that 
structurally similar compounds, which share common putative MoAs may exhibit markedly 





1.6. Strategies to Counter Resistance to Quinoline-based Drugs 
Though alternative therapies for treating CQR malaria parasites have been developed, 
including ACTs, most do not match CQ’s ease of use and low cost or are reportedly losing 
efficacy. Crucially, the MoA of CQ involves inhibition of a critical, parasite-specific event 
that is amenable to inhibition by small molecules, not under genomic control (hence 
immutable) and leads to cidality at low-concentration. Strategies to reverse resistance to CQ 
or design new inhibitors with favourable physicochemical properties that target the same 
pathway have potential to contain drug-resistant malaria. One approach involves exploring 
the antimalarial potential of ‘reversed chloroquines’ (rCQs) which exploit reversal agents 
(RA) to restore sensitivity to CQ.121 The RAs are chemosensitising agents that generally work 
as efflux pump inhibitors, and have previously been shown to restore susceptibility of CQR 
parasites to a CQS-like phenotype,122, 123 and in whose presence the in vivo antimalarial 
activity of CQ against CQR strains can be reinstated.124, 125 These compounds, examples of 
which are shown in Figure 1.8, prevent the expulsion of CQ from the DV leading to local 
drug accumulation and attendant antiplasmodial effect in CQR strains. Using 3D 
quantitative SAR and quantum chemical structure-activity analysis, Bhattacharjee et al. 
proposed a pharmacophore model for these RAs which comprised the requirement of two 
aromatic hydrophobic interaction sites linked by an aliphatic chain to a hydrogen bond 





Figure 1.8: Chemical structures of examples of different reversal agents, highlighting their 
pharmacophore comprising two phenyl head groups linked to a hydrogen bond acceptor 
(nitrogen shown in red) via an aliphatic chain of variable length. 
 
1.6.1. Reversed Chloroquines: SAR and Antimalarial Potential  
Peyton and colleagues postulated that linking a RA-like moiety to a CQ-like moiety can 
create a class of hybrid molecules with both antimalarial and resistance-reversing properties 
(Figure 1.9).121 The basis of this concept is the preservation of the fundamental 
pharmacophore for haem-binding (4-aminoquinoline), inhibition of HZ formation (4-amino-
7-chloroquinoline) and drug accumulation by pH trapping (a tertiary amino group in the 
side-chain) 99 as well as the resistance-reversal pharmacophore, namely two suitably 
positioned aromatic groups with an amino group separated by a short chain.126 As a single 
hybridised unit, the rCQs could directly inhibit the ability of PfCRT to transport the CQ-like 
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moiety out of the DV 127 or completely fail to be recognised by the efflux machinery, thus 
rendering the drug active in the DV. As suggested by Warhurst using verapamil as a model, 
the RAs (in their protonated form) could alternatively reduce the transport of CQ via 
PfCRTDd2 by restoring the positive charge that was removed by the 76T mutation.128 
 
Various groups have subsequently explored the concept of rCQ to design compounds with 
improved in vitro and in vivo activity against CQS and CQR parasites. For instance, October 
et al. used the chemistry of 3,4-Dihydropyrimidin-2(1H)-ones to construct rCQ molecules.129 
Although the molecules lacked the protonatable nitrogen of the classical RA 
pharmacophore, these structures exhibited excellent potency against CQS and CQR strains. 
Musonda et al. designed another set of molecules, linking an astemizole-derived moiety to 
the CQ quinoline end and likewise proving active.130 Substitution of adamantyl groups for 
the phenyls in the RA pharmacophore has also resulted in compounds showing potency.131 
The acridine skeleton has been also been hybridised to the chloroquinoline moiety to 
generate related rCQ structures,132 while the dibenzylmethylamine group was also 
appended to quinolines to generate hybrids, which further showed an ability to inhibit 
PfCRT-mediated efflux of CQ.127 A recent ex vivo evaluation of two rCQs against multidrug-
resistant P. falciparum and P. vivax clinical isolates in Indonesia revealed high efficacy against 
CQR isolates of both species.133 Even more recently, a series of simplified rCQs exhibited 
oral efficacy when tested in vivo against P. yoelii in a murine malaria model.134 The study 
further evaluated single-dose toxicity and showed a favourable safety margin at doses as 
high as 150-fold the ED50, suggesting their potential for antimalarial drug development. 
Indeed, one advantage of a rCQ is that it could be administered at a lower dose than the RA 
component of a cocktail, since the strong accumulation of CQ in the DV would lead to 
equally improved accumulation of the linked RA (compared to unlinked) due to a 1:1 
drug:RA ratio. Low-dose administration could thus potentially make the hybrid cheaper 
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and reduce the side effects, including toxicity, often associated with administering two 
separate drugs. 
 
Figure 1.9: Structure activity relationship profile of a simple reversed CQ molecule: PL01 - 
the first hybrid molecule synthesised by Peyton and colleagues that combines the CQ-like 
portion and a RA-like moiety (i.e. an imipramine-like portion).121 
 
1.6.2. Exploring Non-quinoline βH-Inhibiting Scaffolds 
It has previously been shown that the efflux mechanism, described in section 1.5.3, is 
specific to quinoline-based antimalarials.135 Inhibition of HZ formation, therefore, remains 
an important drug target for potential development of new non-quinoline antimalarials. In 
2010, a pilot HTS using the NP-40 assay was carried out at Vanderbilt University Institute of 
Chemical Biology (VUICB) where 38, 400 compounds were tested at a concentration of 19.3 
μM for their βH inhibition potential.136 From this screening effort, 161 hits (compounds with 
UV-vis absorbance at 405 nm above 3 standard deviations of the negative DMSO control) 
were identified. These were further tested for antiplasmodial activity using the SYBR Green 
I fluorescence assay where 48 of the 161 hits exhibited ⩾90%inhibition of parasite growth at 
23 μM. The success of this pilot study led to evaluation of the 144, 330 commercially 
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available compounds in the VUICB library using a similar approach.137 From this set, 729 βH 
inhibitors were identified as hits (0.5% hit rate), with dose-response analysis showing 530 
hits had IC50s ⩽27 μM. Further evaluation revealed that 171 of these βH inhibitors identified 
in the primary screen were also active against the parasite cultures (32.2% hit rate), with 25 
in fact showing activity in the nanomolar range. While the initial pilot screen of this VUICB 
library identified 6 unique βH-inhibiting scaffolds,136 the subsequent larger and more 
refined analysis discovered 14 predominant scaffolds representing 246 of the 530 βH 
inhibitors identified (Figure 1.10).137 
 
Of the 530 βH inhibitors, 129 were noted to have a quinoline-based scaffold, with 
approximately one-third of these active against the parasite. Importantly, however, several 
non-quinoline scaffolds which had not previously been reported as inhibitors of βH 
formation were also discovered. For instance, 33 βH-inhibiting phenyl benzamides were also 
identified from this screen. Though benzamides have previously been reported as inhibitors 
of the P. falciparum pyrimidine biosynthetic enzyme dihydroorotate dehydrogenase 
(PfDHODH),136, 138, 139 their activity in this study resulted in drastic increases in intracellular 
‘free’ haem levels corresponding to parasite death. These observations could be due to the 
specific interactions of the compounds with ‘free’ haem or HZ crystal. The benzylethene 
group comprised 12 compounds that grouped into scaffolds with an ethene-bridged phenyl 
group to either a quinoline or benzimidazole scaffold. Some compounds within this 
category have been reported to have in vitro antiplasmodial activity through inhibition of the 
M1 alanyl aminopeptidase and the M17 leucine aminopeptidase targets.138 The screening 
also yielded 7 triaryl imidazoles with IC50 values ranging from 2.4 to 22.9 μM, six of these 




Figure 1.10: The primary scaffolds identified in the high throughput β-haematin inhibitory 
screen using the Vanderbilt University Institute of Chemical Biology compound library. 
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In addition to the 14 scaffolds, several other interesting compounds were not associated with 
a specific scaffold type, or only accounted for a very small proportion of the overall hit rate. 
In particular, 284 βH inhibitors that did not cluster into a specific scaffold were identified 
including 92 with antiplasmodial activity. The structural diversity of these miscellaneous 
compounds includes pyridines, amides, indoles, acridinediones, amides, ethers and thiols, 
among others.  
 
In addition, Fong et al. recently evaluated 400 compounds from the MMV Malaria Box using 
the same βH formation assay to detect inhibitors of this crystallisation process.140 Of the 400 
compounds, 9 compounds (Figure 1.11) were identified to have dose–response βH 
inhibitory activity more potent than that of CQ, with activities from 8.7 to 22.7 μM. Indeed, 
the Malaria Box compounds identified as βH inhibitors in this study were reflective of the 
previously described scaffolds. For instance, consistent with the findings of Sandlin et al., 
three benzimidazole, one quinoline, two benzamide and three triaryl imidazole scaffolds 
constituted the 9 hits. Furthermore, this analysis validated inhibition of HZ formation in the 
parasite as the target of seven of the nine in vitro βH-inhibiting hits by demonstrating 
significant (p < 0.05) increases in ‘free’ haem levels from baseline, corresponding to 
decreases in HZ and parasite survival.140  
 
That some of these scaffolds have been reported elsewhere to afford compounds which 
target other proteins and pathways within P. falciparum presents an added incentive to 
explore these chemotypes for multi-target inhibition in the parasite. Moreover, the non-
quinoline scaffolds provide a basis for designing new drugs which can circumvent the 
liabilities commonly associated with quinolines namely; the notoriety of cross-resistance to 





Figure 1.11: Chemical structures of 9 βH inhibitors representing the 4 main scaffolds 
identified by Fong et al., (2015) through screening the MMV Malaria Box library.140  
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1.7. Medicinal Chemistry Outlook of 4-aminoquinoline and Non-quinoline βH Inhibitors 
1.7.1. Absorption-related physicochemical properties 
In drug discovery and development, absorption-related physicochemical properties of a 
compound constitute some of the most significant features of a drug entity.142 
Physicochemical properties like aqueous solubility and lipophilicity are critical in drug 
discovery because they influence the rate and extent of absorption through biological 
membranes, an important determinant of bioavailability (and ultimately efficacy) of a 
compound. On the other hand, this permeation-enhancing lipophilicity has the potential to 
predispose a drug to rapid metabolic clearance hence the need for a trade-off between these 
properties. In the example of CQ and other 4-aminoquinolines, the nitrogen in the quinoline 
core and in the lateral side chain are crucial in the pH trapping process due to their basicity. 
Indeed, the degree of association with Fe(III)PP1X, acid dissociation constant , and 
lipophilicity (indexed by distribution and partitioning coefficients) of the drugs are some of 
the physicochemical properties known to play an important role in their antiplasmodial 
activity and βH inhibition.99, 143 Using a principal component analysis and orthogonal 
molecular descriptors of ~30, 000 diverse GlaxoSmithKline (GSK) compounds, Gleeson 
reported qualitative predictions of absorption, distribution, metabolism, and excretion 
(ADME) properties likely to be exhibited by a molecule based its ionisation state, molecular 
weight (MW) and logarithm of the partitioning coefficient (cLogP).144 For basic molecules, 
like most quinolines, increased MW > 400 and cLogP > 4 were predicted to lower solubility 
and bioavailability while significantly raising in vivo clearance and potential for hERG 





Table 1.1: The influence of molecular weight and cLogP on absorption-related parameters in 
basic compounds. Green colour code denotes favourable effects, yellow denotes tolerable 
effects while red highlights undesirable outcome. Reprinted (adapted) with permission from 
Gleeson P, (2008); J. Med. Chem. 51: 817 – 834. Copyright (2008) American Chemical Society 
 
 
1.7.2. Potential for Cardiotoxicity 
Owing to their lipophilicity and basic nature, quinoline antimalarials are thought to possess 
hERG channel inhibition liabilities. The hERG gene encodes a potassium (K+) channel that 
creates the rapidly activating delayed rectifier K+ current called IKr, an important 
component that regulates the duration of the cardiac action potential.145 Inhibition of the 
hERG K+ channel by pharmaceutical agents or as a result of inherited dysfunction results in 
the obstruction of the flow of K+ thus lengthening the time required to repolarise the cell,146 
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which is manifested as an elongation of the QT interval in electrocardiograms. A life 
threatening ventricular arrhythmia, torsades de pointes, is implicated in the blockade of the 
hERG K+ channel,147 and as a result, several commercial drugs have been withdrawn prior to 
marketing or have had to contend with major labelling changes that have restricted their 
use.148 Computational predictions of hERG liability are in agreement that basic and/or 
lipophilic compounds are strongly implicated in hERG channel inhibition.147 Predictive 
analysis through comparative field molecular analysis and comparative field similarity 
analysis using 31 and 28 molecules, respectively, identified aromatic (hydrophobic) and 
central nitrogen as well as ionisable centres as key features for potential binding to hERG.149, 
150 These features are intrinsic to CQ and other 4-aminoquinoline substructures, which have 
been shown to exert toxic effects by interacting with the hERG K+ channel causing the 
elongation of the QT interval resulting in potentially fatal outcomes.151 The high lipophilicity 
of some of the quinoline derivatives (cLogP > 3.0) that are extensively distributed in tissues, 
likely ensures that drug levels in the heart are sufficient to interact with the K+ channels.152  
As a result of its notorious ligand promiscuity, the hERG channel has emerged as an important 
anti-target in early drug discovery and development as preclinical drug candidates are 
routinely screened against it very early in the drug discovery process. Crucially, the rational 
design of 4-aminoquinoline related antimalarials bearing modifications that would reduce 
lipophilicity, basicity and/or electron releasing properties is a strategy to be vigorously 
pursued in drug discovery and development to rid drug candidates of the physicochemical 
properties likely to make them prone to undesirable side effects. Finally, it is instructive to 
consider all the results from in vitro determination of hERG channel inhibition in the context 
of cardiac safety indices which use the ratio of IC50 values of hERG inhibition to the 
compound’s free therapeutic plasma concentration to assess the likelihood of inducing 
cardiac toxicity.153, 154 To illustrate this point, Traebert and colleagues observed that 
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differential inhibition of HEK293 cells stably transfected with hERG complimentary DNA 
(cDNA) by MFQ (IC50 = 2.63 µM) and LM (IC50 = 8.13 µM) yielded comparable cardiac safety 
indices of 53 and 48, respectively.155 This finding demonstrated that, though informative, 
hERG inhibition IC50 on its own cannot sufficiently predict a compound’s potential for 
cardiac toxicity. 
 
1.8. Background to Current Research Question and Hypothesis 
1.8.1 Reversed Chloroquines with Improved Physicochemical and Drug-Like Properties.  
There is a need to advance the understanding of structural specificity of rCQs based on the 
4-aminoquinoline scaffold with regard to the inhibition of βH formation, antiplasmodial 
activity and physicochemical ADME descriptors. A major limitation of the first prototype 
compound synthesised by Burgess et al. (Figure 1.9) was its high lipophilicity (cLogP 
~9.0).121 Further exploration of the SAR gave rise to molecules with improved water 
solubility, activity against CQS and CQR parasites, which were shown to be orally curative 
in mice.156, 157 These compounds, however, still lacked modifications in the quinoline ring 
system that would reduce hERG channel inhibition. Among the series of compounds that 
have been designed from this model were the recently reported dibemequines (DBQs), 
which contain the 7-chloroquinoline nucleus attached to dibemethin-type side chain via a 
shortened linker, instead of a three carbon aminoalkyl chain positioned between the two 
aromatic rings (Figure 1.12a).127, 158 These compounds were reported to enhance biological 
activity through accumulation in the DV via pH trapping. Further modifications were 
suggested for these molecules to enhance basicity and improve vacuolar accumulation, 
reduce lipophilicity and lower the MW of the resultant molecules while retaining 
antiplasmodial and βH-inhibiting activities. These changes included replacing one of the 
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aromatic rings in the side chain of aminomethyl dibemethin with a pyridine ring (Figure 
1.12b) to improve accumulation within the DV and further enhance aqueous solubility. The 
new series of compounds, pyrido-dibemequines (pDBQs), were envisaged as potential rCQs 
which would be active against both CQS and CQR strains. Additionally, proposals were 
made for structural alterations that would potentially mitigate the hERG liability in the 
resultant compounds without compromising their potency. Among the changes for this 
effect involved replacement of the –Cl group at C7 with a cyano (-CN) group to afford 
analogues with lower MW and lipophilicity while still retaining βH inhibiting potential. By 
using different substituents with diverse steric and electronic properties, Kaschula et al. had 
previously defined the characteristics of the groups at C7.100 However, while it is known that 
a 4-aminoquinoline compound with the chloro group at C7 will inhibit the formation of βH, 




Figure 1.12: Chemical structure of a) compound 6 from Zishiri et al., (2011b) showing its 
SAR127 and b) alterations on the compound to lower MW and lipophilicity, and improve DV 
accumulation 
 
1.8.2. Pyrido[1,2-a]benzimidazoles a βH-Inhibiting Antimalarial Chemotype 
The studies by Sandlin et al. using 144, 330 compounds in the VUICB library and Fong et al. 
using compounds in the MMV Malaria Box recognised the benzimidazole scaffold as a 
potent inhibitor of βH formation.136, 137, 140 The benzimidazole nucleus is a structural unit of 
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naturally occurring purine nucleotides 159 and as such, possesses the capacity to interact with 
many biological systems, leading to a variety of biological activities. The benzimidazole 
motif is therefore a recognised privileged scaffold in medicinal chemistry due to its capacity 
to interact with numerous biological systems. Indeed, research and optimisation of 
substituents around the benzimidazole core has led to compounds with antifungal,160 
antiviral,161 antitubercular,162, 163 and anxiolytic activity.164 
 
Recently, benzimidazole analogues with potent in vitro antiplasmodial activity have been 
reported.165  In 2015, Keurulainen et al., illustrated the synthesis and potent antiplasmodial 
activities of benzimidazole aminopropylamides,166 while highly potent benzimidazole-2-
pyridinyl analogues with in vitro antiplasmodial IC50 values of 0.16 – 3.0 μM against P. 
falciparum were synthesised and evaluated by Saify et al. in 2012.167 Camacho and colleagues, 
in 2011, investigated potent benzimidazole-5-carbohydrazide derivatives.168 On the other 
hand, pyrido[1,2-a]benzimidazoles (PBIs) represent a novel antimalarial chemotype that has 
previously been investigated for antibacterial, antifungal, antiviral and antitumor 
activities.169 In 2011, Ndakala et al. reported on the synthesis and antimalarial activity of PBIs 
from a collaborative screening of a library of 1,440 chemically diverse non-proprietary 
chemicals against a protozoa panel.170 From this, the PBI compound TDR15087 with 
moderate activity against P. falciparum GHA (CQS) and W2 (CQR) strains (IC50: 0.17 and 0.37 
μM respectively) was identified. Further SAR exploration on this core on an additional 535 
PBI analogues in a medium throughput screen against the K1 (CQR) strain yielded 49 
compounds with IC50 below 0.1 μg/ml, notably analogues TDR35885 and TDR44047 
(Figure 1.13). All three were, however, inactive in the P. berghei mouse model up to high 




Figure 1.13: Chemical structures of PBI screening hits with potent antiplasmodial activity 
 
In an attempt to identify compounds that would retain activity in the P. berghei model, 
Ndakala et al., embarked on SAR optimisation around the PBI core focusing on 3-aryl 
derivatives with alkylamino side chains possessing submicromolar activity against K1 
(CQR). The most active was compound 4c (IC50 = 0.047 μM). Compound 4c was, however, 
metabolically unstable in liver microsomes, rapidly forming the mono-desethyl metabolite, 
4h through N-dealkylation (Figure 1.14). Although compound 4h retained activity and 
stability in murine microsomes, pharmacokinetic pitfalls curtailed in vivo activity, most 
notably low bioavailability presumably resulting from solubility-limited absorption. Single- 
and multi-dose in vivo efficacy studies of the orally administered salt of 4h against P. berghei 
also indicated that the activity plateaus with doses above 25 mg/kg (50.2%, 71.2% and 79.8% 
reduction in parasitemia on days 3, 4 and 5, respectively, at 50 mg/kg dose), and the 





Figure1. 14: Chemical structures of the lead PBI compound 4c and its metabolite 4h 
identified by Ndakala and colleagues in 2011.170 
 
The findings by Ndakala et al., as illustrated above, were crucial because they constituted the 
seminal published literature related to the antimalarial activity of PBIs, and therefore laid 
the foundation for further optimisation of the lead PBI to identify analogues with improved 
pharmacokinetic profiles. SAR investigations on the core structure of compound 4h (Figure 
1.15) aimed at exploring effects of modifications around parts of the scaffold not previously 
investigated for effects on the biological and physicochemical properties. SAR1 comprised 
replacement of the alkylamino side chain in 4h with various moieties containing water-
solubilising H-bonding groups, encompassing imidazole, hydroxypyrrolidine or piperidinyl 
moieties. SAR2 involved distortion of molecular planarity through introduction of a small 
hydrophobic substituent at C2 thus lowering the crystal packing energies, and consequently 
improving aqueous solubility.171 In this regard, fluorine was preferred since, due to the 
small size, it is less likely to interfere with protein-drug interactions and hence more likely to 
increase the dihedral angle without loss of biological activity.171 SAR3 comprised two 
derivatives bearing replacement of the 4-trifluoromethylphenyl (4-CF3Ph) group at C3 with 
meta- and di-substituted phenyl rings. Finally, SAR4 involved introduction of substituents on 
the previously unexplored left hand side (LHS) aromatic ring, including mono- and di-




Figure 1.15: Chemical structure of compound 4h showing the different SAR explorations 
that aimed at designing compounds with improved pharmacokinetic features 
 
The PBIs have a remarkable structural likeness to CQ, which includes a planar heterocyclic 
moiety and a basic amine side group. These features make them candidates for π-π 
interactions, which is one of the hallmark features of haem-drug complex formation. As 
such, PBI derivatives lend themselves evaluable as potential inhibitors of βH formation in 
vitro and HZ formation within P. falciparum and S. mansoni cells. Additionally, the 
identification of related benzimidazole and acridine scaffolds as βH inhibitors,137, 140 





1.9. General Aims & Objectives 
The aims of this project were to profile a series of pDBQ and PBI derivatives using in vitro 
and in silico analyses in order to determine their physicochemical properties and correlate 
these with activity of the derivatives against different P. falciparum strains. As part of 
mechanistic investigations, the ability of the compounds to perturb HZ formation was 
investigated through analysis of their βH inhibiting potential as well as their effect on the 
fate of parasite-derived haem. In addition, their safety profiles with respect to the inhibition 
of mammalian cell growth and the hERG channel were evaluated  using predictive 
computational tools as well as through direct experimentation (for the pDBQs). Finally, the 
in vivo antimalarial and antischistosomal efficacy of derivatives with favourable features was 
tested in the relevant mouse models. 
 
1.9.1. Specific Objectives  
 
The primary objectives of the project with respect to pDBQs and/or PBIs were: 
 
(i) To predict and experimentally determine aqueous solubility, permeability and 
lipophilicity (LogD). 
(ii) To test in vitro antiplasmodial activity against CQS and CQR P. falciparum strains 
and their cytotoxicity in Chinese Hamster Ovarian (CHO) cells. 
(iii) To test in vitro microsomal metabolic stability in mouse and human liver 
microsomes and identify the resultant metabolites. 
(iv) To test ability to inhibit in vitro formation of βH as well as HZ formation in 
synchronised P. falciparum cultures. 
(v) To use computational prediction and a heterologous expression system to 
determine hERG toxicity. 
(vi) To investigate in vivo efficacy in malaria and schistosomiasis mouse models.   
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2.1 Materials (Reagents and Solvents)  
All materials used were of AR grade or higher and unless specified, used without further 
purification. The materials are listed according to the methods for which they were needed. 
All consumables were purchased from Lasec, Millipore, Merck South Africa and Sigma 
Aldrich. The water used throughout this work was double distilled deionised Millipore® 
Direct-Q water. 
2.1.1. Materials for Biological Experiments  
A list of materials is presented in Tables 2.1 – 2.13 




RPMI 1640 with glutamine but without sodium bicarbonate (R6504) Sigma Life Science 
D-(+)-Glucose Sigma Life Science 
(N-2-[hydroxyethyl]piperizine-N’-2-[ethanesulfonic acid]) HEPES Sigma Life Science 
Phosphate buffered saline (PBS) tablet Sigma Life Science 
Albumax II Gibco 
Potassium chloride Sigma 
Sodium bicarbonate Sigma Life Science 
Sodium chloride Sigma Aldrich 
Sodium L-lactate Sigma Life Science 
Gentamicin solution Sigma Life Science 
D- Sorbitol Sigma Life Science 
Sodium dihydrogen phosphate Merck 
Glycerine (1,2,3 – propantriol) Sigma Aldrich 
Oil for immersion lenses Merck 
Giemsa’s azur eosin methylene blue solution Merck 









Dimethyl sulfoxide (DMSO)  Merck  
Triton X 100  Merck  
Saponin  Sigma Life Sciences  
Trizma base (Tris)  Sigma Life Sciences  
Calcium L-lactate hydrate Sigma Life Sciences  
Phenazine ethosulphate Sigma Aldrich  
Nitro blue tetrazolium salt (NBT)  Sigma Aldrich  
Hydrochloric acid 32%  Sigma Aldrich  
Ethylenediaminetetraacetic acid (EDTA)  
3-Acetylpyridine adenine dinucleotide (APAD) 
BDH  
Sigma Life Science  
 
 




Dimethyl sulfoxide (DMSO) Fluka  
Resazurin Sigma Aldrich  
Medium 199 Invitrogen 
RPMI 1640 Invitrogen 
5% heat-inactivated fetal calf serum (FCS) Sigma  
Penicillin (100 U/ml) Sigma Aldrich  
Streptomycin (200 μg/ml) Sigma Aldrich  
Phosphate buffered saline (PBS) tablet Sigma Life Science 
Hanks Balanced Salt Solution (HBSS) Sigma Aldrich 
2% amphotericin B Sigma Aldrich 
70% Percoll® Sigma Aldrich 
Sodium chloride (1.5M) Sigma 
5% glucose Sigma Aldrich 
Ethanol Fischer Scientific 
7% Tween 80 Sigma Aldrich 
Control: Praziquantel (C19H24N2O2, Mw = 312.41 g/mol) Sigma Life Science 
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45% Dulbecco’s Modified Eagle Medium (DMEM) 
45% HAMS F-12 
Gibco 
Gibco  
10% inactivated foetal calf serum Sigma Aldrich  
Crystal Violet Dye  Sigma Aldrich  
Dimethyl sulfoxide (DMSO)  Merck 
3-(4,5)-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) Thermo Fisher Scientific 
Control: Emetine hydrochloride (C29H40N2O4 .2HCl Mw = 553.56 g/mol) Sigma 
 
 




Dimethyl sulfoxide (DMSO)  Merck 
Sodium chloride Sigma Aldrich 
Potassium chloride Sigma Aldrich 
Potassium flouride Sigma Aldrich 
HEPES (N-2-[hydroxyethyl]piperizine-N’-2-[ethanesulfonic acid]) Sigma Life Science 
Magnesium chloride Sigma Aldrich 
Calcium chloride Sigma Aldrich 
EGTA (ethylene glycol-bis(β-aminoethyl ether)-N,N,N',N'-tetraacetic acid) Sigma Aldrich 
D-(+)-Glucose Sigma Aldrich 
Magnesium salt of ATP (Mg2ATP) Sigma Aldrich 










Human liver microsomes  Xenotech 
Mouse liver microsomes Xenotech 
Nicotinamide adenine dinucleotide phosphate (NADPH) Merck  
Potassium dihydrogen phosphate (KH2PO4, Mw = 136.09 g/mol)   Merck 
Dipotassium hydrogenphosphate (K2HPO4, Mw = 174.18 g/mol) Merck 
Dimethyl sulfoxide (DMSO) Sigma Aldrich  
Acetonitrile (LC-MS grade)  Merck/Sigma  
Formic acid  Sigma  
Ammonium formate Sigma  
Carbamazepine (Mw = 236.3 g/mol) Sigma 
Control 1: Propranolol hydrochloride (Mw = 295.8 g/mol)  









Phosphate buffered saline (PBS) tablet Sigma Life Science 
Dimethyl sulfoxide (10%) Sigma Aldrich  
Ethanol (10%) Fischer Scientific 
Propylene glycol (40%) Sigma Aldrich 
Hydroxypropylmethylcellulose (HPMC) Sigma Aldrich 
Purified water (HPLC grade) Merck Millipore 












Dimethyl sulfoxide (DMSO)   
Sodium acetate trihydrate  
Sigma Aldrich  
Sigma Aldrich  
Acetic acid  Sigma Aldrich  
Haemin (> 98%)  Fluka  
Acetone  Sigma Aldrich  
Pyridine  Sigma Aldrich  
Nonidet P-40 (NP-40), 305.5 μM  Pierce Biotechnology  
Control 1: Chloroquine (C18H26ClN3.2H3PO4, Mw = 515.87 g/mol) Sigma Life Science 
Control 2: Amodiaquine (C20H24Cl3N3O.2H2O, Mw = 464.81 g/mol) Sigma 
Control 3: Pyrimethamine (C12H13ClN4 Mw = 248.71 g/mol) Fluka Analytical 
 
 
Table 2.9: Materials used for fluorescence-activated cell sorting (FACS) analysis 
Materials for FACS analysis 
  
Supplier  
Phosphate buffered saline (PBS) tablets 
SYBR Green I nucleic acid gel stain 
Sigma Life Science  
Sigma Aldrich 








(N-2-[hydroxyethyl]piperizine-N’-2-[ethanesulfonic acid]) HEPES 
Sodium Dodecyl Sulfate (SDS)  
Sigma Life Science  
Sigma Aldrich 
Sodium chloride Sigma Aldrich 
Pyridine  Sigma Aldrich  
Sodium hydroxide  Sigma Aldrich 




2.1.2. Materials for Physicochemical Experiments  




2-(N-morpholino) ethanesulfonic acid (MES) 
Dimethyl sulfoxide (DMSO)   
Sigma Aldrich  
Sigma Aldrich 
n-Octanol Sigma Aldrich 
Purified water (HPLC grade) Merck Millipore  
 
 





Potassium dihydrogen phosphate (KH2PO4, Mw = 136.09 g/mol) 
Sigma  
Merck 
Dipotassium hydrogenphosphate (K2HPO4, Mw = 174.18 g/mol)  Merck 
Dimethyl sulfoxide (DMSO)  Sigma Aldrich  
Acetonitrile (LC-MS grade)  Sigma 
Formic acid  Sigma  
Purified water (HPLC grade) Merck Millipore 
Control 1: Ouabain (C29H44O12, Mw = 584.65 g/mol) Sigma 
Control 2: Hydrocortisone (C21H30O5, Mw = 362.46 g/mol) Sigma 









MultiScreen Filter plates   (Millipore, 0.4 μM PCTE Membrane) 
Potassium dihydrogen phosphate (KH2PO4, Mw = 136.09 g/mol)  
Merck  
Merck  
Dipotassium hydrogenphosphate (K2HPO4, Mw = 174.18 g/mol)  Merck  
Dimethyl sulfoxide (DMSO)  Sigma Aldrich  
Acetonitrile (LC-MS grade)  Anatech 
Formic acid  Sigma  
Carbamazepine (Mw = 236.3 g/mol) Sigma  
Acetic acid Merck 
Sodium monohydrogen phosphate heptahydrate (Mw = 268.1 g/mol) Sigma 
Lucifer Yellow CH dipotassium salt (Mw = 521.57 g/mol) Sigma 
Control 1: Propranolol hydrochloride (Mw = 295.8 g/mol) Sigma 
Control 2: Testosterone (Mw = 288.42 g/mol) Sigma 
Control 3: Warfarin (Mw = 308.34 g/mol) Sigma 
Control 4: Hydrocortisone (Mw = 362.5 g/mol) Sigma 






2.2. Sample Preparation  
2.2.1 Tissue culture of Plasmodium falciparum  
Incomplete culture medium: Incomplete culture medium was prepared by dissolving 10.4 g 
RPMI 1640 (with glutamine but without sodium bicarbonate), 4 g D-(+)-glucose, 6 g HEPES, 
0.088 g hypoxanthine, 5 g albumax II, and 1.2 mL (0.05 g/L) gentamicin in 1 L of distilled 
water. The solution was pre-filtered through a 0.45 μm filter then sterile-filtered through a 
0.22 μm membrane into autoclaved glass bottles before being stored at 4 °C until further use.  
Sodium bicarbonate (5%): The solution was prepared by dissolving 50 g of NaHCO3 in 1 L 
of distilled water and sterile filtered through a 0.22 μm membrane into 100 mL autoclaved 
glass bottles before storage at 4 °C until further use.  
Complete culture medium: Solution of complete culture medium was prepared by adding 8.4 
mL of 5% NaHCO3 to 200 mL of the incomplete culture medium before use then stored at 4 
°C until further use. 
5% Sorbitol: A solution of 5% D- Sorbitol was prepared by dissolving 50 g of D-sorbitol in 1 
L of distilled water. The solution was sterile filtered through a 0.22 μm membrane into 250 
mL autoclaved glass bottles and stored at 4 °C until further use.  
Phosphate Buffered Saline (PBS): PBS was prepared by dissolving 1 tablet in 200 mL of 
distilled water. The final preparation yielded a solution containing 0.01 M phosphate buffer, 
0.0027 M KCl and 0.14 M NaCl with a pH of 7.4 at 25 °C. 
Washed O+ human red blood cells: The human blood used in the experiments was obtained 
from the blood bank (Groote Schuur Hospital). The blood was washed by adding wash 
medium to whole blood in a 1:1 ratio. The solution was centrifuged at 1200 relative 
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centrifugal force (rcf) for 5 min and the supernatant aspirated. This process was repeated a 
second time and the washed blood stored at 4 °C. 
Giemsa stain (10%): Giemsa stain was prepared before use by diluting the stain 1:10 in PBS.  
 
2.2.2 Antiplasmodial assays  
Malstat solution: Malstat was prepared by dissolving 400 μL Triton X100, 4 g L-lactate and 
1.32 g Tris buffer in 150 mL of distilled water. To this, 22 mg of APAD was added and the 
pH adjusted to 9 with 32% HCl. The final volume was made up to 200 mL with distilled 
water then stored at 4 °C.  
NBT solution: A solution of NBT was prepared by dissolving 160 mg of NBT and 8 mg 
phenazine ethosulphate in distilled water to a final volume of 100 mL. The storage container 
was covered with foil as NBT is light sensitive and stored at 4 °C. 
 
2.2.3 Detergent mediated assay for β-haematin inhibitors  
DMSO: NP-40: water / 10: 20: 70 (v/v): The solution (20 mL) was prepared by mixing 14 mL 
of water with 4 mL of NP-40 (305.5 μM) and 2 mL of DMSO and used immediately.  
Acetate buffer (1 M): The acetate buffer was prepared by weighing 4.1 g of sodium acetate 
and dissolving in approximately 30 mL of water before adding 2.4 mL of acetic acid and 
diluting the solution to 50 mL with water. The final pH was adjusted to 4.80 using 5 M 
NaOH.  
Haemin stock solution: A 25 mM haemin stock solution was prepared by weighing 16.30 mg 
of haemin into a 2 mL Eppendorf tube and dissolved in 1 mL of DMSO. The solution was 
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sonicated for 1 min and 178.80 μL was immediately added to 20 mL of 1 M acetate buffer. 
The solution was vortexed well and used immediately, ensuring the haem remained 
uniformly suspended in the buffer during use.  
HEPES buffer pH 7.5 (2 M): A solution of 2 M HEPES buffer was prepared by dissolving 
47.66 g of HEPES in 80 mL of distilled water. The pH was adjusted to 7.5 with 5 M NaOH 
before diluting to a final volume of 100 mL with distilled water. The solution was stored at 
room temperature.  
Pyridine solution in HEPES (50% v/v): Buffered pyridine was prepared by mixing 10 mL of 
pyridine with 4 mL of acetone, 4 mL of water and 2 mL of 2 M HEPES (pH 7.5). 
 
2.2.4 Haem-pyridine fractionation assay  
Glutaraldehyde (0.125%): A stock solution of 50 % glutaraldehyde was diluted in a 1: 400 
ratio with 0.22 μm filtered PBS (pH 7.5) before use.  
1 × SYBR® green I: This solution was prepared away from direct light and used 






2.3.1 Tissue culturing of Plasmodium falciparum  
The chloroquine sensitive (CQS) strains of Plasmodium falciparum NF54 (originally derived 
from a patient near Schiphol, Amsterdam presumed to be of West African origin) and the 
chloroquine resistant (CQR) strains Dd2 and K1 obtained from the MR4 were used 
throughout this study. Parasites were cultured using a modified method of Trager and 
Jensen.172 Cultures were maintained under sterile conditions in the prepared washed O+ 
human RBCs in complete medium at 2% haematocrit.  
Assay procedure: Every 24 h, medium with parasitised RBCs (pRBCs) was transferred to 
sterile 50 mL centrifuge tubes and centrifuged at 750 rcf for 5 min. The supernatant was 
aspirated and the parasitemia and predominant phase in the remaining pRBC pellet was 
determined by viewing a Giemsa stained blood smear under a light microscope. Briefly, a 
thin blood smear on a glass slide from the culture was fixed to the glass with methanol and 
stained for 10 min with freshly prepared 10% Giemsa stain. The slide was rinsed with tap 
water and dried before viewing with an oil immersion lens under a light microscope. 
Parasitemia was determined by counting the number of pRBCs as a percentage of the total 
number of cells (erythrocytes and pRBCs) counted. Trophozoite cultures were diluted to 5% 
parasitemia with washed O+ human RBCs while ring cultures were synchronised as 
described by Lambros and Vanderberg 173 with 5x volume of 5% sorbitol at 37 °C for 10 min. 
After synchronisation, cultures were centrifuged at 750 rcf for 5 min and the layer of debris 
corresponding to lysed cells and dead parasites was carefully aspirated off the culture. 
Lastly 40 mL of complete culture medium was added to 1 mL of pRBC pellet in a 200 mL flat 
bottomed culture flask and gassed with a mixture of 4% CO2, 3% O2, and N2 for 1 min, 
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sealed and incubated at 37 °C. The cycle was repeated until parasite material sufficient to set 
up an assay was obtained. 
2.3.2 Parasite lactate dehydrogenase (pLDH) antiplasmodial assay  
Compound antiplasmodial activity against the PfNF54, PfDd2 and PfK1 strains of P. 
falciparum was determined via a modified method of the parasite lactate dehydrogenase 
(pLDH) assay described by Makler et al., which colourimetrically measures Plasmodium 
enzyme lactate dehydrogenase.174 Lactate dehydrogenase (LDH) is present in both the 
parasite and erythrocyte, and catalyses the conversion of lactate to pyruvate during 
glycolysis, with nicotinamide adenine dinucleotide (NAD) as a co-enzyme. The activity of 
NAD in the parasite is indistinguishable from the erythrocyte; during glycolysis, the NAD 
analogue, 3-acetyl pyridine dinucleotide (APAD) is selectively and rapidly used by 
Plasmodium as a coenzyme instead of NAD and forms APADH. In the presence of APAD, 
erythrocyte LDH converts lactate to pyruvate at a much slower rate.174  
Assay procedure: During assay development, plates are supplemented with Malstat™ 
reagent containing both APAD and lactate and the yellow NBT reagent. Viable parasites 
rapidly form APADH as the reaction proceeds and this reduces yellow NBT to its purple 
formazan salt which is measurable at 620 nm and corresponds to parasite viability. The 
assay was carried out by preparing 2 mg/mL solutions of test samples in 100% DMSO and 
storing at -20 °C. On the day of use, samples were diluted in medium to a starting 
concentration of 1000 ng/mL or 100 ng/mL and serially diluted two-fold in medium in 96-
well plates. All samples were tested in triplicate at ten concentrations, with 0.2 ng/mL 
representing the lowest concentration. The blank column contained unparasitised 
erythrocytes at 1% haematocrit while the positive control and the drug testing wells all 
contained pRBCs at 2% parasitaemia and 1% haematocrit. The highest concentration of 
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DMSO to which the parasites were exposed was 0.5%. The plates were covered with a sterile 
lid and gassed in an airtight chamber with a mixture of 4% CO2, 3% O2, and N2 for 5 min and 
incubated at 37 °C for 48 h. After incubation, the plates were frozen at -20 °C then thawed (to 
facilitate cell lysis) and developed by adding 100 μL of Malstat solution and 25 μL of NBT to 
15 μL of the re-suspended pRBC pellet. The absorbance of each well on the plate was 
measured at 620 nm using a Modulus™ Microplate Multimode Reader (Turner Biosystems) 
and IC50 values determined using non-linear dose-response curve fitting analysis via Graph 
Pad Prism v.4.0 software. 
2.3.3 Cytotoxicity assay  
Compounds were screened for in vitro cytotoxicity against a Chinese Hamster Ovarian 
(CHO) mammalian cell-line, using the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazoliumbromide (MTT)-assay which measures cellular growth and survival, 
and compares well with other available assays.175 The tetrazolium salt MTT was used to 
measure all growth and chemosensitivity. In active mitochondria, the tetrazolium ring is 
cleaved, thus only viable cells are able to reduce the water-soluble yellow coloured MTT to 
water-insoluble purple coloured formazan.  
Assay procedure: The assay was conducted by first preparing the test compounds to 20 
mg/mL stock solutions in 100% DMSO followed by further dilutions in complete medium. 
The initial concentration of the compounds was 100 μg/mL, which was serially diluted in 
complete medium with 10-fold dilutions to give 6 concentrations, the lowest being 0.001 
μg/mL. Emetine was used as the reference drug in this experiment and the same dilution 
technique was applied to the control, and testing performed in triplicate on each occasion. 
The 50% inhibitory concentration (IC50) values were obtained from full dose-response 
58 
 
curves, using non-linear dose-response curve fitting analysis via GraphPad Prism v.4 
software (GraphPad Software Inc., La Jolla, USA). 
2.3.4. Microsomal Metabolic Stability and Metabolite Identification 
The microsomal stability of the test compounds was investigated using a single point 
metabolic stability assay described by Di and colleagues, which involves incubation with 
human and/or mouse liver microsomes in the presence of phosphate buffer and NADPH 
(as co-factor) at 37 °C.176 
Assay procedure: Test compounds (1 μM) were incubated at 37 °C in a solution containing 
0.35 mg/ml microsomes (MLM; male Mouse BALB/c, Xenotech, or HLM, mixed gender, 
Xenotech) and metabolic reactions were initiated by the addition of NADPH (1 mM) in 
phosphate buffered saline (100 mM, pH 7.4), and incubated for 30 min. The samples were 
then prepared by ice-cold acetonitrile precipitation containing 0.1 µM carbamazepine 
(internal standard), centrifuged and filtered for LC-MS analysis. The incubations of 
compounds and controls (midazolam and MMV390048) were performed in triplicates. LC-
MS/MS analysis were then performed on a 4000 QTRAP® (AB Sciex) equipped with a 
Turbo V™ ion source and coupled to an Agilent 1200 Rapid Resolution HPLC system (600 
bar, Agilent technologies, USA). Aliquots (2 µL) of samples stored on a sample tray set at 
8°C were injected onto a Kinetex C18 column, 2.1 mm x 50 mm, 2.6 µm particles 
(Phenomenex) or Kinetex PFP, 2.1 mm x 50 mm, 2.6 µm particles (Phenomenex) at 40°C. 
Compounds were separated using a gradient solvent system consisting of 0.1% formic acid 
and 0.1% formic acid in acetonitrile. The relative loss of parent compound over the course of 




Phase 1 metabolite profiling was conducted by incubating 10 µM of the test compounds at 
37 °C in a solution containing 1 mg/mL mouse liver microsomes (MLM male BALB/C, 
Xenotech), magnesium chloride (5 mM) and NADPH (1 mM) in phosphate buffered saline 
(100 mM, pH 7.4), for 1 h while shaking. The samples were then prepared by protein 
precipitation using 2 volumes of acetonitrile, centrifuged and filtered for LC-MS/MS 
analysis. Controls containing all the sample constituents (not incubated), and in which 
NADPH or microsomes were individually excluded were also prepared and handled 
similarly to the test sample. LC-MS/MS analysis was performed on the same LC-MS/MS 
instrument as used for metabolic stability analysis where 10 µL of samples stored on a 
sample tray set at 8 °C were injected onto a Supelco Ascentis C18 column, (4.6 mm x 150 
mm, 2.6 µm particles) at 40 °C. Metabolites were separated using a gradient solvent system 
consisting of 0.1% formic acid in water (A) and 0.1% formic acid in acetonitrile (B). The 
gradient was as follows: 10% B for 0.5 min, 10 - 90% B for 8.5 min, 90% B held for 3 min, and 
returned to initial conditions for 4 min to re-equilibrate the column. The flow rate was 0.4 
mL/min. The total run time per sample was 16 min. All mass scans were operated under 
electrospray positive ionisation mode and the operation parameters were as follows: curtain 
gas, 30 psi; collision gas, 6 psi; nebulizer gas (GS1), 50 psi; turbo gas (GS2), 60 psi; source 
temperature, 500 °C; ion- spray voltage, 5000 V; declustering potential, 46V for 675615/31 
and 121V for 674850/19; collisionally activated dissociation (CAD) gas setting: high. 
Enhanced mass spectrum was used as a survey scan to trigger information dependent 
acquisition of MS/MS spectra. Metabolites formed were identified by comparison of 
chromatograms at 30 min with chromatograms at time 0 and with no NADPH controls 
using Lightsight v2.3. The tentative metabolite identities were deduced by comparison of the 
product ion spectra of the [M +H]+ ions of each metabolite with that of parent compound 
using Analyst 1.5.1. The retention time and fragmentation pattern was also compared to that 




2.3.5. Detergent mediated β-haematin inhibition assay  
Cellular lipid-mediated inhibition of HZ formation can be mimicked synthetically under 
physiological conditions in a detergent-mediated assay which substitutes neutral lipids for 
the commercially available lipophilic detergent NP-40 and used to assess the efficiency of a 
compound to inhibit βH formation.97 Based on a pyridine haemochrome inhibition method 
developed by Ncokazi and Egan, this assay quantifies, at an absorbance of 405 nm, 
unreacted haematin that complexes with pyridine.96 
Assay procedure: Stock solutions of control and test compounds were prepared to 20 mM in 
100% DMSO (CQ diphosphate salt was, however, prepared to the same initial concentration 
in HPLC grade water). A 100 µL solution containing water/305.5 μM NP-40/DMSO at a v/v 
ratio of 7:2:1, respectively, was added to every well in columns 1-11 of the 96-well micro titre 
plate while 140 μL of water and 40 μL of 305.5 μM NP-40 were added to column 12 to 
mediate the formation of βH. Twenty microliters of drug (20 mM) was added to column 12 
and 100 μL of this solution serially diluted up to column 2 to create a concentration range, 
with column 1 left as a blank (0 μM of compound). A hundred microliters of freshly 
prepared homogenous suspension of haematin in 1 M acetate buffer pH 4.8 was added to all 
wells, including the blank column, such that the final concentration of haematin in all wells 
was 100 μM. Plates were then covered and incubated for ~5 h at 37 °C in a Labcon 508 IU 
incubator. Post incubation, 32 μL of 50 % pyridine solution (20% water, 20% acetone, 10% 
2M HEPES buffer (pH 7.4), 50% pyridine) was added to all wells, followed by addition of 60 
μL of acetone to help in the dispersion of the haematin. Plates were read at 405 nm using a 
SpectraMax plate reader after 5 s of shaking. The 50% βH inhibitory concentration for each 
test compound was computed from the blank corrected absorbance values at 405 nm using a 
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sigmoidal dose-response curve fitting analysis via Graph Pad Prism v.4.0 software 
(GraphPad Software Inc., La Jolla, USA). 
2.3.6. Cellular Haem Fractionation Assay 
This is a cellular fractionation technique based on the ability of neutral aqueous pyridine to 
selectively form a low spin haem-pyridine complex with ‘free’ haem in the presence of HZ,96 
and examines the dose-dependent effect (if any) of an inhibitor on the fate of total haem in 
the parasite. True inhibitors of HZ formation like CQ exhibit a dose-dependent signature 
characterised by a decrease in the cellular content of HZ matched by a corresponding rise in 
both ‘free’ haem and haemoglobin (Hb).89  
2.3.6.1. Parasite Incubation and Harvesting  
Sorbitol-synchronised ring stage PfNF54 parasites (5% parasitemia and 2% haematocrit) 
were incubated at 37 °C in varying concentrations of test compounds and controls for 32 h. 
The assay was then stopped, the cultures centrifuged at 750 rcf for 5 min and the 
supernatant containing cell debris and a black layer on top of the pRBC pellet was 
discarded. A 10% (v/v) Giemsa stained blood smear of each culture was viewed under a 
light microscope to confirm the presence of trophozoites. Trophozoites were isolated 
afterwards through lysis by adding 1.8 mL of PBS pH 7.5 and 100 μL of 1% saponin to the 
settled erythrocyte pellet, left to stand for 2 min then spun at 750 rcf for 15 min. The 
supernatant was carefully aspirated off and this wash repeated 3 more times with 0.5 mL 
PBS to remove all traces of Hb and the trophozoite pellet re-suspended in 100 μL PBS. To set 
up a counting plate, 10 μL of the re-suspended trophozoite pellet was added to 190 μL of 
counting diluent (10 mL 0.22 μM filtered PBS pH 7.5, 2.5 μL of 50% gluteraldehyde and 50 
μL DNAse). This counting plate was stored at 4 °C and used for cell counting through flow 
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assisted cell sorting (FACS) analysis the next day. The plate containing the remaining 90 μL 
of the trophozoite pellet was then stored at −80 °C. 
2.3.6.2. Flow Assisted Cell Sorting (FACS) Analysis 
Cell counts in each well of the counting plate were determined using fluorescent staining 
and flow cytometry.177-179 Samples were prepared by diluting 100 μL of cells from the 
counting plate with 800 μL of 1 x SYBR Green I in PBS pH 7.5 and incubated at 37 °C for 30 
min in the dark. Each sample was subsequently spiked with 100 μL of Trucount™ beads 
such that each sample contained a known fixed amount of fluorescent beads in a final 
volume of 1 mL. Samples were mixed well in a vortex machine and analysed on a Becton 
Dickinson FACS Calibur using SSC/FL1 530 nm with CellQuestPro software. All samples 
were analysed using FlowJo software version 10 (Tree Star Inc). The concentration of cells in 
the acquisition tube was calculated according to equation 1:  
CF = (T/B) x CB  (Equation 1) 
Where: 
CF = concentration of cells per mL as determined with flow cytometry  
T = number of trophozoites gated  
B = number of fluorescent beads gated  
CB = concentration of fluorescent Trucount™ beads in the acquisition tube per mL 
(calibrated bead count per acquisition is unique to each lot of Trucount™ tubes obtained 
from the supplier) 
Gating was established for trophozoite populations, rings and cell debris. However, it was 
difficult to distinguish rings from the debris accumulated during the isolation and 
harvesting procedure hence only intact trophozoites gated were used to determine cell 
counts, with 10,000 events typically counted for each sample.  
63 
 
2.3.6.3. Measurements of different haem species/fractions 
This analysis was done on the plate containing the remaining 90 μL of the trophozoite pellet 
from section 2.3.6.1. Samples were thawed and 50 μL of water was added before 5 min of 
sonication. This was followed by addition of 50 μL of 0.2M HEPES buffer (pH 7.5) and 50 μL 
water then centrifuged at 3600 rpm for 20 min. To the separated supernatant, 50 μL of 4% 
SDS was added, the sample sonicated, and incubated at 25 ºC (30 min). Fifty microliters of 
0.3 M NaCl and 50 μL of 25% pyridine (v/v) were added and the UV−visible spectrum of 
this fraction (Hb) was recorded. Fifty microliters of water was added to the pellet, followed 
by 50 μL of 4% SDS. After re-suspending the pellet, the solution was sonicated and 
incubated (30 min) at 25 ºC. Fifty microliters of 0.2 M HEPES, 50 μL of 0.3 M NaCl, and 50 
μL of 25% pyridine were added and the sample centrifuged. The supernatant was diluted to 
300 μL with water and the UV−visible spectrum recorded (haem fraction). The remaining 
pellet was treated with 50 μL of water and 50 μL of 0.3 M NaOH, sonicated (15 min), and 
incubated (30 min) at 25 ºC. Fifty microliters of 0.2 M HEPES, 50 μL of 0.3 M HCl, and 50 μL 
of 25% pyridine were added and the supernatant was diluted to 300 μL. The UV−visible 
spectrum of this fraction (HZ) was recorded and percentages of the three haem species i.e 
Hb, haem and HZ fractions determined from the absorbance values. 
2.3.6.4. Haem standard curve 
To quantify the total amount of haem in each fraction, a haem standard curve was prepared 
from a 100 μg/mL haem standard solution of haematin (porcine) in 0.3 M NaOH. The 
standard solution was serially diluted in a 96-well plate with 100 μL 0.3 M NaOH as a blank. 
Each haematin standard was diluted with 50 μL of each of the following solutions: 4% (w/v) 
SDS, 0.3 M NaCl, 0.2 M HEPES pH 7.5, 0.3 M HCl, 25% pyridine in 0.2 M HEPES pH 7.5 and 
water. All measurements were performed in triplicate and the visible spectra of haem as 
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Fe(III)haem-pyridine complex was measured in a multi-well plate reader. The amount of 
haem present in each sample was determined using a calibration curve and amount of haem 
per cell subsequently calculated by dividing the total haem in each fraction by the number of 
cells determined in each fraction. All results were expressed as the amount of haem Fe (fg) 
per cell. 
2.3.7. Speed of Action (Killing Kinetics) Assay 
This experiment involves measuring the time-scaled effect of a compound on parasite 
viability by determining its speed of action from the ratio of IC50 after either 24 h or 48 h of 
incubation against the standard 72h.180  
Assay procedure: Unsynchronised PfNF54 cultures (80% rings) of pRBC at 2% haematocrit 
and 0.5% parasitemia with 5 µM hypoxanthine were exposed to 2-fold serial dilutions of the 
compounds. For each compound, three incubation times were employed: 72 (standard assay 
time), 48 and 24 h. In the case of the 24 h assay, [³H] hypoxanthine was added during the last 
8 h while in the case of the 72- and 48-h assays, radioactive labelling was done for the last 24 
h. After incubation and addition of [³H] hypoxanthine, plates were harvested on glass fiber 
filters (Wallac 1450-421) using a cell harvester 96 (TOMTEC, Perkin Elmer). Filters were 
dried and melt-on scintillator sheets (MeltiLex A, PerkinElmer 1450-441) used to determine 
the incorporation of [3H]-hypoxanthine on a microbeta counter (Perkin Elmer). The data 
were normalised using the incorporation of the positive control, (PRBC without drug) and 
IC50 values were determined using GraFit version 5 (Erithacus Software Ltd, UK). This assay 
was validated by inclusion of 3 standard antimalarials – CQ, artesunate (AS) and 
(pyrimethamine) PYR, with known speeds of action and performed in at least three 
independent experiments. The IC50 values at 24 and 72 h were expressed as a ratio to 
highlight any shifts between early or late stage activities, i.e. a ratio close to 1 would be 
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indicative of comparable activity between the two periods while a larger value clearly 
deviating from unity hints at late stage activity. 
2.3.8. In vivo Efficacy Screening in Plasmodium berghei-infected mice 
All efficacy studies were approved by the respective institutional animal experimentation 
ethics committees at the University of Cape Town and Swiss Tropical and Public Health 
Institute. Testing was conducted at the Swiss Tropical and Public Health Institute. The 
antimalarial activity of the test compounds was assessed for groups of 3 (treatment group) 
and 5 (untreated control group) female NMRI mice (20 - 22 g) intravenously infected on day 
0 with a GFP-transfected Plasmodium berghei ANKA strain (donated by A. P. Waters and C. J. 
Janse, Leiden University, The Netherlands) (2 x 107 pRBCs per mL) (Roche).  
Assay procedure: Compounds were formulated in SSV (70/30 Tween 80/ethanol and 
diluted 10 x with water) and administered orally in four consecutive daily doses (24, 48, 72 
and 96 h after infection) at either 30 mg/kg or 100 mg/kg. Blood smears were collected and 
stained on day 4 after infection and degree of infection (parasitemia expressed as per cent 
infected erythrocytes) was determined using microscopy and FACS on the FACSCalibur™ 
instrument using CellQuestPro software. Antimalarial activity was calculated as the 
difference between the mean per cent parasitemia for the control and treated groups 
expressed as a per cent relative to the control group. The survival time in days was also 
recorded up to 30 days after infection. A compound was considered curative if the animal 




2.3.9. Antischistosomal Screening 
All antischistosomal screening was carried out at the Swiss Tropical and Public Health 
Institute in Basel, Switzerland. Animal studies were carried out in accordance with Swiss 
national and cantonal regulations on animal welfare at the Swiss Tropical and Public Health 
Institute (Basel, Switzerland) under the permission number 2070. 
2.3.9.1. In vitro screening against newly transformed schistosomula (NTS) 
Compounds and control (praziquantel) were dissolved in 100% DMSO to obtain stock 
solutions of 10 mM. Schistosoma mansoni cercariae, obtained from infected intermediate host 
snails, Biomphalaria glabrata, were mechanically transformed to newly transformed 
schistosomulae (NTS) by placing the snails under light to stimulate cercarial shedding.181 
The cercarial suspension was collected and tails separated from the heads by rinsing three 
times with cold Hank’s Balanced Salt Solution. The NTS were then incubated overnight in 
culture medium and used the next day where 100 were then incubated in each well of a 96-
well plate with culture medium and the test compound for a final well volume of 250 μL. 
Culture medium was composed of Medium 199 (Invitrogen, Carlsbad, CA) supplemented 
with 5% fetal calf serum (iFCS, 100 U/mL) and 1% penicillin/streptomycin mixture 
(Invitrogen, 100 U/mL). Compounds were tested at 10 μM in triplicate with NTS incubated 
in no more than 1% DMSO serving as control. NTS were kept in an incubator at 37 °C and 
5% CO2 for up to 72 h after which the condition of the NTS was microscopically evaluated 
using a scale from 3 (normal activity and no tegument alteration) to 0 (dead, completely 
granulated). IC50 determination assays for the compounds were subsequently performed in 




2.3.9.2. In vitro screening against Adult S. mansoni worms 
Female NMRI mice (age 3 weeks, weight ca. 14 g) were purchased from Charles River 
(Sulzfeld, Germany) and allowed to adapt for 1 week under controlled conditions (22 °C, 
50% humidity, 12 h light, and free access to water and rodent diet) before experimental 
handling. To obtain adult schistosomes, mice were infected subcutaneously with 80 - 100 
cercariae. The mice were then euthanised after 7 - 8 weeks with CO2 and the worms 
collected from the hepatic portal and mesenteric veins. Two pairs of adult worms were 
incubated in each well of a 24-well plate with 2 mL culture medium and the test compound. 
Culture medium was composed of RPMI 1640 (Invitrogen, Carlsbad, CA) supplemented 
with 5% foetal calf serum (iFCS, 100 U/ml) and 1% penicillin/streptomycin mixture 
(Invitrogen, 100 U/mL). Only compounds with > 70% activity against NTS were evaluated 
against adult worms at 10 μM with incubation at < 1% DMSO used as control. Worms were 
kept in an incubator at 37 °C and 5% CO2 for up to 72 h after which their condition was 
microscopically evaluated using a scale from 3 (normal activity and no tegument alteration) 
to 0 (dead, completely granulated). IC50 determination was conducted for compounds with 
>60% activity. For the in vitro drug sensitivity assays, all viability scores were averaged 
across replicates and normalised to the average viability scores of the control wells 
(Microsoft Office Excel 2010). IC50 values were calculated using CompuSyn2® (ComboSyn 
Inc., Paramus, New Jersey, 2007). 
2.3.9.3. In vivo studies in S. mansoni-infected mice 
Female mice (NMRI strain) were purchased from Charles River, Germany, kept under 
environmentally controlled conditions (temperature ~ 25 °C; humidity ~70%; 12 h light and 
12 h dark cycle) with free access to water and rodent diet and acclimatised for one week 
before infection. Groups of 3– 4 NMRI mice harbouring chronic schistosomal infection were 
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treated 49 days post-infection with single oral doses of 400 mg/kg of test compounds 
dissolved in 7% Tween 80 and 3% ethanol in water (v/v/v) while untreated mice served as 
controls. At 21 days post-treatment, animals were euthanised by the CO2 method and 
dissected. Surviving schistosomes residing in the mesenteric veins and the liver were 
counted and sexed. 
2.3.10. Determination of hERG toxicity 
Inhibition of the hERG channel can often be predicted using computational techniques. 
However, due to the promiscuous inhibition of the hERG channel by therapeutically and 
structurally diverse drugs, and the high flexibility of the hERG protein, computational 
prediction of inhibition can only be used as guide and should often be complemented with 
experimental data.  
2.3.10.1. Computational prediction using StarDrop TM 
StarDrop™ was used to predict hERG pIC50s of the compounds whereby molecules were 
imported into the analysis software in spatial data file (sdf) format and the hERG pIC50 
directly predicted. Chloroquine, dihydroartemisinin, halofantrine and desbutyl-
halofantrine, all of whose predicted ranges of pIC50s are known, were used as control. 
2.3.10.2. Experimental determination of hERG toxicity using QPatch Clamp System 
Experimental analysis was performed by Metrion Biosciences, UK on the QPatch gigaseal 
automated patch clamp platform. Chinese hamster ovarian (CHO) cells stably expressing 
hERG protein were prepared for assays using proprietary dissociation protocols designed to 
optimise cell health, yield and assay quality. Test compounds (including verapamil 
hydrochloride as positive control) were screened at four concentrations (0.3, 1, 3 and 10 μM) 
against a minimum of three separate CHO cells. The percent inhibition values from each cell 
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were used to construct concentration-response curves employing a four parameter logistic 
fit with 0 and 100% inhibition levels fixed at very low and very high concentrations, 
respectively, and a free Hill slope factor. The IC50 and Hill coefficient were then determined, 
with only data with Hill slopes within 0.5< nH <2.0 included. The IC50 data was then 
reported as the mean ± standard deviation (S.D.) of at least 3 separate cells (n ≥ 3). 
2.3.11. Kinetic solubility assay 
The aqueous solubility of all test compounds was determined at pH 6.5 using a kinetic 
solubility assay based on a miniaturised shake flask method previously described.182  
Assay Procedure: The assay was performed by first preparing 10 mM stock solutions of 
reserpine (6.09 mg/mL), hydrocortisone (3.63 mg/mL) and each of the test compounds in 
100% DMSO. This was followed by preparation of 100 mL PBS at pH 6.5 by weighing out 0.8 
g NaCl, 0.2 g KCl, 0.115 g Na2HPO4.7H2O and 0.2 g KH2PO4 into a volumetric flask, topping 
up to the 100 mL mark then adjusting the pH to 6.5. Next, fasted state simulated intestinal 
fluid (FaSSIF) buffer was prepared by dissolving 2.042 g KH2PO4 and 3.728 g KCl in 
approximately 400 mL of HPLC grade water. Addition of 50 mL of 0.1M NaOH followed 
before the buffer was brought to the mark with water and adjusted to pH 6.5. The stock 
solutions were then used to prepare calibration standards in DMSO, and to spike (1:50) 
duplicate aqueous samples of FaSSIF buffer with a final DMSO concentration of 2%. Once 
the samples and standards were prepared, the plates were mixed for 2 h on an orbital shaker 
at 200 rpm at 25 °C. The plates were then centrifuged at 3500 rpm for 15 minutes at 22 ºC 
and the solutions filtered and analysed by means of HPLC-DAD (Agilent 1200 Rapid 
Resolution HPLC with a diode array detector). Best fit calibration curves were constructed 
using the calibration standards, which were used to determine the samples’ aqueous 
solubility. Solubility is reported in the range 0 – 220 μM and ranked as ‘very low’ if < 5 µM, 
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‘low’ if 5 -49 µM, ‘moderate’ if 50 -150 µM and ‘high’ if > 150 µM. At pH 6.5, the controls 
reserpine and hydrocortisone have solubility concentrations of < 5µM and >150 µM, 
respectively. 
2.3.12. Membrane Permeability Assay 
The parallel artificial membrane permeability assay (PAMPA) is an in vitro model of passive, 
trans-cellular permeability of drug-like compounds to screen for their oral absorption 
potential across a hexadecane liquid layer at physiologically relevant pH’s representative of 
the gastro-intestinal tract. Apparent permeability (Papp) is determined by detecting the 
appearance of the test compound in the acceptor compartment of the artificial membrane 
plate following incubation. 
Assay Procedure: The PAMPA assay was performed in triplicate in 96-well MultiScreen 
Filter plates (Millipore, 0.4 μM PCTE Membrane). Membrane filters were pre-coated with 
5% hexadecane in hexane and allowed to dry prior to the assay. Membrane integrity marker, 
Lucifer yellow was added to the apical wells of the pre-coated MultiScreen plate 
donor/drug solutions containing test compound. Phosphate buffer (pH7.4) was added to 
the 96-well acceptor plate. 10 mM test compound was used to spike (1 μM) the donor buffer 
at physiologically relevant pH's (pH 4, 6.5 and 8), the donor plate slotted into the acceptor 
plate and incubated (4 h at room temperature) with gentle shaking (40 - 50 rpm). Following 
the incubation, sample from the acceptor wells and theoretical equilibrium wells were 
transferred to the analysis plate and matrix matched with blank donor buffer. Acetonitrile 
containing internal standard (carbamazepine, 0.0236 μg/mL) was added to all samples and 
they were analysed by LC-MS/MS (Agilent Rapid Resolution HPLC, AB SCIEX 4500 MS). 
The normalised (analyte/internal) peak areas were used to calculate the Papp. Membrane 
integrity was assessed by calculating the Papp of Lucifer Yellow (acceptable values <50 
nM/s) using a Modulus microplate reader (Excitation 490nm/Emission 510 - 570nm) 
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(Wohnsland and Faller, 2001). The permeability data was then classed according to the low 
(< -6.5), moderate (-6.5 to -5.5) and high (> -5.5) categories. 
2.3.13. Determination of lipophilicity (LogD) 
2.3.13.1. LogD (pH 5.0) determination using shake-flask method  
For the determination of the distribution coefficient (Log D) between organic and aqueous 
phases at pH 5.0, compounds were evaluated by the shake-flask method at room 
temperature. Compounds were dissolved in DMSO to constitute 10 mM stock solutions. 
Each compound was mixed in a glass tube with equal volumes of pre-saturated 0.02 M 2-(N-
morpholino) ethanesulfonic acid (MES) buffer and n-octanol to achieve a final concentration 
of 75 µM. This solution was then shaken vigorously for 2 h, centrifuged at 3,500 rpm and 
allowed to equilibrate for 6 h. Each phase was then carefully separated and final drug 
concentrations in each layer determined by computing absorbance values measured with the 
extinction coefficients obtained from linear Beer’s Law UV-vis spectroscopy plots in each 
phase within the concentration range tested. The concentrations in the two phases were used 
to obtain LogD at pH 5.0 using equation 2 shown below.  
 
LogD5.0 = Log 
[Compound in n-octanol] µM 
Equation 2 
[Compound in MES buffer] µM 
 
2.3.13.2. LogD (pH 7.4) determination using HPLC method  
For LogD measurements at pH 7.4, HPLC analysis was used instead since signal to noise 
ratio confounded UV-vis spectroscopic analysis of compound concentrations in the aqueous 
layer which were very low. In this analysis, the standards verapamil, hydrocortisone and 
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ouabain were included as controls. A 10 mM stock solution of each compound was prepared 
in DMSO and 10 µL of this was used to spike a 1:1 mixture of phosphate buffer (pH 7.4) 
and n-octanol in a square-welled 96-deep-well plate. The solutions were shaken vigorously 
(1500 rpm) on an orbital shaker for 2 h at room temperature and thereafter, centrifuged 
(3500 rpm, 2700× g) in order to fully separate the two immiscible phases. Carefully, 300 µL 
from each layer was transferred to a new analysis plate and analysed on the HPLC-DAD 
(Agilent 1200 Rapid Resolution HPLC) with 0.1 % formic acid in 95 % acetonitrile as the 
organic mobile phase and 0.1 % formic acid in 5 % acetonitrile as the aqueous mobile phase. 
LogD7.4 was calculated from the areas of integrated UV chromatogram peaks using equation 
3 below 
LogD7.4 = Log 
(peak area of n-octanol phase/n-octanol phase injected volume) 
Eqn 3 
(peak area of buffer phase/buffer phase injected volume) 
 
2.3.14. Calculation of vacuolar accumulation ratios (VARs) 
Since the digestive vacuolar pH in the malaria parasite is regulated to an acidic value to 
provide optimal conditions for haemoglobin degradation, the potential vacuolar 
accumulation ratio (VAR) for drugs can be calculated from their distribution coefficients 
(LogD) in the vacuole (pH 5.0) and the aqueous medium external to the cell (pH 7.4). This 
can be predicted from equation 4 below proposed by Warhurst and co-workers.119  





2.3.15. Software  
GraphPad Prism version 4 (GraphPad Software Inc., La Jolla, USA) for windows was used to 
analyse all data and calculate statistical significance. ChemDraw Professional v15.0.0.0.16 
(PerkinElmer) was used to generate chemical structures and figures. All flow cytometry data 
was analysed using FlowJo software version 10 for which Tree Star Inc. donated an annual 
subscription (Tree Star Inc). StarDropTM and MarvinSketch v5.9.4 were used to make in silico 
















3.1 Chapter Overview 
This chapter explores the relationship between seven pyrido-dibemequine (pDBQ) 
derivatives and their mechanistic inhibition of βH, within the context of their biological and 
physicochemical properties. As introduced in Chapter 1, rCQ compounds combine the basic 
pharmacophore for haem-binding and inhibition of HZ formation (4-amino-7-
chloroquinoline) and a resistance reversal pharmacophore. The feasibility of this approach 
has since been confirmed by different studies that have generated various modifications of 
these compounds,129, 157, 183 among them dibemequines (DBQs) - a series containing a 4-
amino-7-chloroquinoline with a dibenzylmethylamine side chain, exemplified in Figure 3.1. 
Indeed, these compounds were shown to possess strong in vitro antiplasmodial and in vivo 
antimalarial activity, and also inhibited PfCRT-mediated extrusion of CQ from the parasite 
digestive vacuole (DV).127 
 
Figure 3.1: Structure-activity relationship profile of the prototype dibemequine molecule 
with the quinoline nucleus (red grid) hybridised to the resistance reversal moiety (blue grid) 
 
In an attempt to further improve the physicochemical and biological properties of these 
compounds, a number of modifications were made to the prototype molecule. First, one of 
the aromatic rings on the dibenzylmethylamine side chain was replaced with a pyridine to 
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improve aqueous solubility due to the higher polarity of pyridine. This would also introduce 
an additional protonatable centre that would be anticipated to serve as an extra hydrogen 
bond acceptor and consequently improve vacuolar drug accumulation through pH trapping. 
Secondly, the chloro-substituent at carbon 7 (C7) on the 4-aminoquinoline nucleus was 
replaced by a cyano group in an effort to afford analogues with reduced molecular weight 
(MW) and lipophilicity while retaining βH inhibition activity (Figure 3.2). The lowered 
lipophilicity and MW could reduce the potential for hERG inhibition and improve 
druggability in multiple other ways such as decreasing plasma protein binding and 
lowering potential of the compounds to inhibit cytochrome p450 (CYP) enzymes.144 
 
Figure 3.2: Generic structure of one of the new series of dibemequine molecule 
 
Six of the seven compounds evaluated in this section of the thesis were synthesised as free 
bases by Dr Mukesh Joshi, while one compound, due to previous solubility challenges with 
its corresponding free base, was synthesised as a hydrochloride salt by dissolving in a 1.25 





Figure 3.3: Chemical structures of the 7 derivatives evaluated in this chapter of the project. 
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Using direct experimental analyses and predictive in silico simulations, this chapter 
describes in detail the physicochemical features and biological activity of these 7 pDBQ 
compounds and provides a full cellular haem fractionation profile of each in an effort to 
establish their HZ-inhibiting mechanism of action (MoA). Finally, data on biotransformation 
analysis of the compounds and potential for hERG toxicity is explored. All results are 
subsequently discussed and a conclusion on the chapter presented. 
 
3.2. Materials and Methods 
All materials and methods used throughout this chapter are described in detail in Chapter 2. 
The compounds discussed herein were synthesised and characterised by Dr. Mukesh Joshi. 
 
3.3. Results and Discussion 
3.3.1. Aqueous Solubility. 
Solubility is a key determinant of absorption, and by extension, bioavailability of orally-
administered drugs.184 Often, poorly soluble compounds are riddled with setbacks including 
false negative bioassay results in vitro due to precipitation, poor absorption and difficulty in 
intravenous administration. They also present challenges in formulation design and an 
increased likelihood for adverse effects due to the need for frequent, high-dose 
administration. Since oral administration presents the cheapest and most convenient route, 
focus has been on prioritising the optimisation of solubility, among other physicochemical 
properties. There was no correlation between the predicted and experimental solubility (R2 = 
0.0933, p = 0.5053) of the pDBQs, and this is likely attributable to the differential pH in assay 
conditions. Indeed, experimental solubility (pH 6.5) was higher than that predicted (pH 7.4), 
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with compounds 3, 4 and 5 showing comparable solubility to hydrocortisone (Table 3.1) as 
the compounds are likely to exist in their ionised form at lower pH. The solubilities of these 
compounds therefore show that they are likely to stay in solution under assay conditions, 
hence supporting the signals obtained from biological evaluations as a true reflection of their 
activity. Though substitution at C7 on the quinoline ring did not seem to influence 
solubility, there was a discernible pattern of increasing solubility related to the left hand ring 
of the side chain, with the para- and ortho- analogues in both the chloro- and cyano-
substituted sets of compounds exhibiting higher solubility than the meta-. As anticipated, the 
introduction of a pyridine in place of the right hand phenyl ring in the dibenzylmethylamine 
side group improved aqueous solubility relative to 1. This is likely due to the nitrogen center 
in the pyridine ring being available for H-bonding to water molecules. 
3.3.2. Determination of artificial membrane permeability. 
Excluding first-pass hepatic metabolism, oral bioavailability is most highly dependent on 
intestinal absorption, which in turn is a function of compound solubility and membrane 
permeability.185 Therefore, in vitro permeability assays can be invoked to help in the 
interpretation of both in vivo pharmacokinetic data as well as cell-based assay results. 
Permeability of the pDBQs was determined using the PAMPA assay, which uses 
phospholipid-coated filters to estimate membrane permeability over different physiological 
pH values representative of the gastrointestinal tract. As described in section 2.4.5 of Chapter 
2, logarithm of apparent permeability (Log Papp) values > -5.5 were classified as ‘high’ while 
Log Papp < -6.5 was considered ‘low’. Compounds exhibiting LogPapp values ranging from -
6.5 to -5.5 were classified as ‘moderately permeable’. All the compounds had high permeability 
(Log Papp > -5.5) at the physiologically relevant pH 6.5 (Table 3.1). This indicates that greater 
permeation and absorption would be expected in the lower gut than in other parts of the 
gastrointestinal tract (GIT). However, this assertion is likely to hold true when only passive 
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diffusion is taken into account. Neither the modifications on the core quinoline ring nor on 
the side group appeared to have any significant influence as all compounds had 
comparatively high permeability at pH 6.5. 








 Lipophilicity b 
Compound R X Observed Predicted  pH 6.5  cLogP LogD7.4 LogD5 
            
1 Cl CH 51.8 3.0  -3.60 (0.16)  5.60 3.56 1.33 
2 (meta-) Cl N 59.8 15.1  -4.10 (0.26)  4.46 2.47 0.82 
3 (para-) Cl N 196.6 11.7  -4.56 (0.10)  4.46 2.85 0.84 
4 (ortho-) Cl N 164.7 14.5  -4.56 (0.03)  4.46 3.79 0.90 
5 (ortho-) CN N 172.4 17.0  -4.01 (0.06)  3.71 3.80 0.81 
6 (para-) CN N 143.5 13.8  -4.60 (0.04)  3.71 2.84 0.99 
7 (meta-) CN N 72.4 17.4  -3.60 (0.16)  3.71 2.75 0.85 
Warfarin      -3.80 (0.35)     
Propranolol      -4.40 (0.28)     
Testosterone      -3.70 (0.33)     
Reserpine   <5        
Hydrocortisone   >150 520     1.50  
Verapamil         2.50  
a Kinetic solubility was determined at pH 6.5 in 0.1M phosphate buffered saline while predicted 
solubility was obtained from StarDrop by computing the antilog of the LogS provided at pH 7.4 
b cLogP was predicted using MarvinSketch v5.9.4 while LogD was experimentally determined using 
HPLC analysis (for pH 7.4) and shake-flask method with UV-spectroscopy (for pH 5).   
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3.3.3. Predicted and Experimental Lipophilicity. 
In the absence of special transport mechanisms, the accumulation of weak bases like CQ in a 
particular organelle can be described in terms of their physicochemical behaviour through 
the partitioning theory.186, 187 Indeed, the flux of a molecule at the interface of two immiscible 
solvents is largely influenced by its lipophilicity. The lipophilic, diprotic CQ is believed to 
passively diffuse across membranes in its unprotonated form and accumulate after 
protonation in the parasite DV. However, an obvious challenge associated with high 
compound lipophilicity is the negative effect on aqueous solubility, where poorly-soluble 
drug candidates increasingly rely on enabled formulations to overcome dissolution- and 
solubility-limited oral bioavailability. The partition (cLogP) and distribution coefficients 
(LogD) of a molecule observed in a water/n-octanol system have therefore been adopted as 
standard indices of lipophilicity, and these can be quantitatively related to a molecule’s SAR, 
physicochemical or biological behaviors.  
With regards to predicted cLogP, compound 2, 3 and 4 (chloro- at C7) and 5, 6 and 7 (cyano- 
at C7) showed no quantitative differences (Table 3.1) presumably due to the isostructural 
nature of each group and identical protonation pattern when the compounds are in their 
neutral state. However, a clear deviation was observed relative to 1 (cLogP = 5.60), and this 
could be explained by the presence of the less lipophilic pyridyl group compared to the 
phenyl hydrophobic rings in the side-chain structure of 1. Compounds 5, 6 and 7 had an 
even more diminished cLogP due to the presence of the nitrile at C7 which has greater 
electron-withdrawing nature but less lipophilicity than a chloro- group. Analysis of the 
relationship between cLogP and predicted solubility (pH 7.4) reveals a strong correlation 
between decreasing solubility and increasing cLogP (R2 = 0.8085, p = 0.0061). Though this 
trend was still maintained when the analysis was performed using experimental solubility 
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(pH 6.5), the correlation diminished (R2 = 0.1503, p = 0.3902). A more structurally diverse 
and larger sample set would probably be more revealing.  
Results for LogD7.4 for the compounds ranged from 2.47 – 3.80 (mean: 3.15 ± 0.55), with 
compound 5 exhibiting the highest distribution coefficient (3.80) and compound 1, the 
lowest (2.47). This narrow range in the LogD at cytosolic pH can be explained by the 
minimal variation in their acid dissociation constants (pKas). In view of the acidic milieu 
existing in the P. falciparum DV, LogD at pH 5.0 was also determined. These values were 
markedly lower (mean: 0.93 ± 0.19) and showed minimal differences. The acidic 
environment of the DV results in substantial ionisation of the aromatic and aliphatic N of 
these compounds, with enhanced aqueous solubility as shown by the marked drop in 
vacuolar LogD (Table 3.1). Therefore the compounds are trapped within the DV, causing 
their concentration to increase in the low pH environment. 
 
3.3.4. Antiplasmodial Activity and Correlation with Physicochemical Properties 
The compounds were screened for antiplasmodial activity against the CQS (PfNF54) and 
CQR (PfDd2 and Pf7G8) strains of P. falciparum and the results are presented in Table 3.2. 
All compounds showed potent antiplasmodial activity in the nanomolar range against both 
parasite strains (IC50 range CQS: 14.4 – 126.6, CQRDd2: 44.5 – 162 and CQR7G8: 69.6 – 307.1). 
Chloro-substituted analogues (1 – 4) had higher potency across all strains (mean ± SE IC50 
CQS: 34.4 ± 8.3 nM, CQRDd2: 114.0 ± 23.8 nM and CQR7G8: 113.0 ± 25.5 nM) than the cyano-
substituted analogues (5 - 7) (mean ± SE IC50 CQS: 90.6 ± 12.9 nM, CQRDd2: 132.3 ± 22.0 nM 
and CQR7G8: 178.2 ± 64.5 nM). This was an unsurprising observation as it has been 
previously shown that halogens exert optimum influence at C7 on the quinoline ring due to 
their strong lipophilicity and a moderately strong electron-withdrawing capacity.100 
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Table 3.2: Antiplasmodial activity and cytotoxicity profiles of the 7 pDBQ derivatives 
 
 
   IC50 (nM) 
  Cytotoxicity 
Compound R X NF54 Dd2 7G8 R.I Dd2 R.I 7G8 CHOIC50 (μM) S. Index 
          
1 Cl CH 14.4 44.5 69.6 3.1 4.8 9.5 660.2 
2 (meta-) Cl N 30.1 124.0 83.8 4.1 2.8 8.3 275.1 
3 (para-) Cl N 38.5 150.7 114.2 3.9 3.0 15.7 408.0 
4 (ortho-) Cl N 54.4 136.6 184.3 2.5 3.4 40.2 739.8 
5 (ortho-) CN N 116.3 162.0 307.1 1.4 2.6 27.6 237.1 
6 (para-) CN N 76.4 145.5 115.3 1.9 1.5 11.2 145.9 
7 (meta-) CN N 79.1 89.4 112.1 1.1 1.4 50.6 639.5 
Chloroquineb   8.3 226.4 88.7 27.3 10.7   
Artesunate   5.6 14.3 7.7 2.6 1.4   
Emetine        0.095  
          
R.I = Resistance index = [IC50 CQR strain] ÷ [IC50 CQS strain]; 
CHO = Chinese Hamster Ovarian cells;  
S. Index= Selectivity index = [IC50 CHO] ÷ [IC50 NF54]; Chloroquine diphosphate salt b 
 
Against PfDd2, all compounds were more active than CQ while only compounds 1 and 2 
were more potent against Pf7G8. This could be due to any one or more of the seven amino 
acids that differ between the forms of PfCRT expressed in the two strains (Table 3.3) and/or 
the differential regulation in the pathways that compensate for these mutations in the 
strains.188 In addition, while most of these derivatives affirmed their designation as rCQs 
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through an appreciably higher activity than CQ against PfDd2, their potency was lower 
compared to some published rCQs.129, 134, 157 It is possible that this discrepancy reflects 
inherent differences in the CQR strains evaluated, variations in antiplasmodial testing 
protocols (with the confounding influence of starting parasitemia) or even dissimilarities in 
the choice of chemosensitising scaffolds in these studies. Nonetheless, these derivatives were 
more active against PfDd2 compared to some pentacycloundecylamine analogues (PfDd2 
IC50: 28 – 253 nM) 183 and more importantly, exhibit considerably lower lipophilicity than 
most of their published counterparts. 
There was no indication of cross-resistance between the compounds and CQ in the two 
strains of CQR parasites as indicated by their low resistance indices. This potential low 
cross-resistance with CQ could be due to the modifications on the quinoline scaffold using a 
RA side chain thereby possibly allowing for direct interaction of the molecule with PfCRTCQR 
in a manner unattainable with CQ. 
Table 3.3: Resistance-conferring polymorphisms within different Pfcrt and Pfmdr1 codons in 
CQSNF54, CQR7G8 and CQRDd2 
  PfCRT Codons  PfMDR1 Codons 
Strain Origin 72 74 75 76 220 271 326 356 371  86 184 1034 1042 1246 
NF54 Amsterdam C M N K A Q N I R  N F S D D 
7G8 Brazil S M N T S Q D L R  N F C D Y 
Dd2 Thailand C I E T S E S T I  Y Y S N D 
 
Additionally, the compounds showed low cytotoxicity in the mammalian cell line (CHO 
cells) with a selectivity index range between 146 and 740 (Table 3.2). There was, however, no 
discernible trend in toxicity attributable to any structural features of the molecules. Emetine 
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(control), a potent inhibitor of protein synthesis in eukaryotic cells exhibited cellular toxicity 
at very low concentrations (IC50 = 0.095 µM).  
Analysis of the correlation between antiplasmodial activity and lipophilicity showed a direct 
association between the two, meaning that the most lipophilic compound is likely to diffuse 
through the intracellular membrane barriers and into the site of action. With regards to 
cLogP (Figure 3.4a), this association was strongest and significant for PfNF54 (R2 = 0.9005; p 
= 0.0011) compared to PfDd2 (R2 = 0.5160; p = 0.0690) and Pf7G8 (R2 = 0.3420; p = 0.1679) in 
which the parasite resistance machineries are likely to be in play thus reducing local drug 
concentrations. This trend was maintained when a correlation was attempted with LogD5 
(Figure 3.4b) which is physiologically more relevant with respect to activity of these 
compounds in the DV.  Though the R2 value improved in PfDd2 (R2 = 0.7032; p = 0.0184), it 
slightly diminished in PfNF54 (R2 = 0.4639; p = 0.0920) and Pf7G8 (R2 = 0.2903; p = 0.2121). 
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Figure 3.4: Plot showing the association between compounds’ predicted lipophilicity and 
antiplasmodial activity against PfNF54 (black solid dots), PfDd2 (red solid dots) and Pf7G8 




3.3.5. β-Haematin Inhibition and Correlations with Antiplasmodial Activity 
Due to the presence of the planar quinoline ring system, these compounds were able to 
inhibit βH formation in a CQ-like manner in the in vitro NP-40-based assay that mimics the 
conditions of the parasite’s DV. The derivatives were equipotent to AQ but slightly more 
active than CQ (Table 3.4). There was no pattern in the activity of this series of compounds 
implying that the inhibition of βH formation is likely contingent primarily on the presence 
of the planar quinoline core common to all the derivatives. The orientation of the adjacent 
side chain on the quinoline nucleus did not have any significant influence on βH inhibition 
activity (βHIA) presumably due to the presence of aromatic ring systems in the 
dibenzylmethylamine scaffold.  
Table 3.4: βH inhibition (βHI) and antiplasmodial activity of the 7 pDBQ derivatives 
 
 










LogD7.4 cLogP a 
         
1 Cl CH 13.4 (1.8)  0.014  3.56 5.60 
2 (meta-) Cl N 20.8 (0.6)  0.030  2.47 4.46 
3 (para-) Cl N 17.2 (0.3)  0.039  2.85 4.46 
4 (ortho-) Cl N 17.9 (3.2)  0.054  3.79 4.46 
5 (ortho-) CN N 16.6 (0.4)  0.116  3.80 3.71 
6 (para-) CN N 24.8 (2.1)  0.076  2.84 3.71 
7 (meta-) CN N 16.7 (0.1)  0.079  2.75 3.71 
Chloroquine   26.0 (3.4)  0.008   3.93 
Amodiaquine   13.9 (2.3)     4.53 
Pyrimethamine   No inhibition  0.021    
a cLogP predicted using MarvinSketch v5.9.4 
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Substituting the nitrile for a chloro group at C7 did not appear to impact activity either. 
Indeed, the influence of different functional groups at C7 on βHIA has been previously 
investigated using CQ as a model.100 The ideal properties of best candidate groups at this 
position for inhibition of βH formation included moderately strong electron-withdrawing 
capacity and strong lipophilicity, a combination best exhibited by halogens.100 The electron-
withdrawing potentials of cyano and chloro groups compare, hence no radical difference in 
the βHIA of the analogues from the two groups (mean ± SE βHIA IC50 chloro analogues: 17.3 
± 1.5 µM and cyano analogues; 19.4 ± 2.7 µM). Investigations on association between βHIA 
and compound lipophilicity showed weak but positive correlations (Figure 3.5a), which 
were, however, not significant (LogD7.4: R2 = 0.2608; p = 0.2416, LogD5: R2 = 0.1202; p = 
0.4461, cLogP: R2 = 0.2943; p = 0.2084). 
a )  H I A c t iv ity  v s  L ip o p h il ic i ty
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Figure 3.5: Plot of correlation between βHI activity and a) lipophilicity and b) 
antiplasmodial activity. In a), association between βHI activity and LogD7.4, LogD5 and 
cLogP are represented in black, blue and red, respectively. 
 
Further, analysis of the relationship between antiplasmodial activity and inhibition of βH 
formation reveals a general trend of decreasing biological activity as βHIA decreases (Figure 
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3.5b). This correlation was nonetheless weak and not statistically significant (R2 = 0.1700; 
p=0.3579), implying there could be additional factors to HZ inhibition that influence 
biological activity. The hypothesis that HZ inhibition correlated with antiplasmodial activity 
was first tested by Dorn and co-workers by analysing a set of common antimalarials 
including quinoline methanols, 4-aminoquinolines, acridines, and non-quinolines.27 In their 
analysis, the authors established linearity between potency of inhibition of HZ formation 
and antiplasmodial IC50s using the PfNF54 strain. In contrast, however, Hawley and 
colleagues, using a similar series of quinoline methanols, 4-aminoquinolines, and acridines 
on Pf3D7 and PfK1 observed no apparent correlation between the two activities when 
comparing raw IC50 data for either the CQS or CQR strains.86 However, after correcting for 
accumulation in the DV, Hawley et al., observed a correlation, but only for the CQS strain. 
Similarly, Kaschula and colleagues, using a series of 2-carbon side chain 4-aminoquinoline 
derivatives with variable functional groups at C7, also only observed a correlation between 
antiplasmodial activity and βHIA after the antiplasmodial IC50 was scaled to the relative 
vacuolar accumulation ratio (VAR).100 In these studies, though, the use of dissimilar 
chemotypes (e.g., quinolines versus acridines), differences in strains of P. falciparum analysed 
and the non-physiological conditions in the HZ formation assays can be highlighted as 
reason for the inconsistent results, a more plausible explanation could be the requirement 
for such molecules to accumulate to very high concentrations within the parasite DV for 
antiplasmodial, but not necessarily βH inhibition effect. Since these compounds theoretically 
inhibit HZ formation, the VAR (and by extension the accumulation-normalised IC50) would 
be the more informative property to correlate with βHIA. Nonetheless, a better 
understanding of the correlation between antiplasmodial IC50 activity and HZ inhibition 
would require more detailed chemical information on the nature of solid-state aggregates of 
haem and planar quinoline-based compounds like these pDBQs. 
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3.3.6. Vacuolar Accumulation 
As a follow up on the results of Hawley et al. and Kaschula et al. that observed linear 
correlation between βHI and antiplasmodial activity in CQS strains upon correction for 
differential drug accumulation in the DV, the vacuolar accumulation of the pDBQs was 
investigated.  Since the wide structural diversity of the compounds examined was one of the 
critical factors that complicated interpretation of results in the previously mentioned studies, 
the pDBQs provided an opportunity to test for possible correlation using a series of 
isostructural analogues with a wide range of antiplasmodial IC50s. Additionally, these 
derivatives span the effective dibasic and tribasic character and thus would be expected to 
diverge in calculated VARs. Vacuolar accumulation was determined by calculating the 
antilogarithm of the difference in the experimentally determined LogD values at external 
and DV pH considered to be 7.4 and 5.0, respectively. The use of the Henderson-Hasselbalch 
equation, often invoked to predict VAR, was avoided due to its reliance on acid dissociation 
constants which are not accurately predicted and the potentially confounding assumptions 
inherent to this method whereby the equation assumes that these weak bases, once 
protonated, become membrane impermeable. The VAR values ranged from 44.7 to 997.2 
(Table 3.5), with derivatives having ortho- orientation of the RA side group exhibiting 
highest accumulation in the vacuole (compound 4 and 5; VAR = 776.2 and 997.2, 
respectively). Though compounds 2, 6 and 7 exhibited the lowest accumulation ratio in the 
vacuole (44.7 – 79.4), their antiplasmodial activities still ranked among the highest, 
potentially due to other intrinsic features (like solubility and permeability) that confer on 
them better inhibitory interactions with parasite proteins. 
Interestingly, analysis of the VAR with antiplasmodial activity revealed a strong significant 
correlation in the CQR strain, Pf7G8 (R2 = 0.8475; p = 0.0033) but not in PfNF54 (R2 = 0.3218; p 
= 0.1842) or the other CQR strain, PfDd2 (R2 = 0.1721; p = 0.3548). Further, no association was 
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observed with βHIA when the accumulation ratios were scaled using in vitro IC50 values for 
PfNF54 (R2 = 0.0127; p = 0.8097), PfDd2 (R2 = 0.0160; p = 0.7872) or even Pf7G8 (R2 = 0.0744; p 
= 0.5541), further confirming that while accumulation in the organelle is requisite for 
antiplasmodial activity, it is not a key factor in activity. Rather, as noted in section 3.3.5, the 
ability of this group to inhibit parasite growth hinges dominantly on their lipophilicity. 
Table 3.5: The vacuolar accumulation, βHI and antiplasmodial activity of the 7 pDBQs 
 
Compound R X VAR a βHIA IC50 
(µM) 
PfNF54 (nM) VAR x NF54 IC50 
(µM) 
1 Cl CH 169.8 13.4 ± 1.8 14.4 ± 4.2 2.45 
2 (meta-) Cl N 44.7 20.8 ± 0.6 30.1 ± 5.0 1.36 
3 (para-) Cl N 102.3 17.2 ± 0.3 38.5 ± 4.8 3.94 
4 (ortho-) Cl N 776.2 17.9 ± 3.2 54.4 ± 5.5 42.23 
5 (ortho-) CN N 997.2 16.6 ± 0.4 116.3 ± 17.2 115.97 
6 (para-) CN N 70.8 24.8 ± 2.1 76.4 ± 4.0 5.41 
7 (meta-) CN N 79.4 16.7 ± 0.1 79.1 ± 4.9 6.28 




3.3.7. Cellular Haem-Pyridine Fractionation Profiles 
3.3.7.1. Analysis of Chloroquine and Pyrimethamine standards 
As mentioned in Chapter 1, the processes of Hb degradation and inhibition of haem 
detoxification are potential targets of such antimalarial classes as quinolines, aryl alcohols, 
artemisinin, and other peroxides. The dose-dependent effect (if any) of an inhibitor on the 
fate of total haem in the parasite can be examined by investigating the different 
fractions/species of haem extracted from P. falciparum cells treated with varying doses of 
drug.89 Established inhibitors of HZ formation, like CQ, exhibit a dose-dependent signature 
characterised by a decrease in the fraction of HZ matched by a corresponding rise in both 
‘free’ haem and Hb. Inhibitors like pyrimethamine (PYR), however, that exert their 
antiplasmodial effect through other targets do not exhibit this pattern. The morphological 
effect of treating the cells with different drug concentrations can be visualised either on 
Giemsa-stained slides through microscopy or through flow cytometry (FACs) analysis. To 
ascertain the fidelity of the cellular fractionation assay, the haem profiles of CQ and PYR 
were first assessed according to the method detailed in Chapter 2. These profiles constitute 
each haem species (present as Hb, ‘free’ haem or HZ) expressed in terms of the amount of 
haem iron (Fe) per cell in femtogram (fg). The control amounts of ‘free’ haem and HZ 
indicate the levels of each that are produced and tolerated by the parasite under normal 
physiological conditions, and in the absence of drug. A significant dose-dependent decrease 
in HZ and corresponding significant increase in ‘free’ haem, compared to the control, is 
therefore representative of HZ inhibitors. Significant differences in measured amounts of 
haem Fe (fg) relative to the control were calculated using Student’s 2-tailed t-test at the 95% 
confidence interval, and plotted with asterisks to indicate statistical significance, where * p< 
0.05; ** p< 0.01; *** p< 0.001. 
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FACs analysis of the trophozoites shows clear differences in cell size and complexity, 
between untreated cells and those treated with 3x CQ IC50 (Figure 3.6). The side-scattered 
(SSC) shift shows that CQ treated cells are less complex and dense, compared to the control 
cells while the forward-scattered (FSC) shift shows that treated cells are smaller than the 
untreated controls. The shift in SYBR Green I fluorescent intensity shows that the CQ-treated 
cells have less nucleic acid content than the control cells, indicating the presence of less 
mature cells. These observations provide evidence of stunted maturity of cells from CQ 
treatment compared to untreated, and that there are fewer trophozoites present in the 
treated sample. This indicates that at higher concentrations of CQ, and a significantly raised 
level of ‘free’ haem, CQ-treated cells are unable to mature and survive to the same extent as 
the untreated cells. Since the process of Hb uptake and digestion is active in early stages of 
the parasite as rings,189 inhibition of HZ formation through CQ treatment therefore impairs 
the cells’ ability to competently transition into the succeeding cycle stages, consequently 
impacting on their morphology and DNA-making ability.  
PYR-treated cells, on the other hand, did not appear to be radically affected by drug 
treatment, with the FSC, SSC and SYBR Green shifts appearing comparable to the untreated 
controls. A plausible explanation for this would be that since PYR has a slow speed-of-kill 
that mainly acts on the late trophozoite and schizont stages,190 the 32 h treatment assay is 
unlikely to capture the inability of the abnormal schizonts to mature and release viable 




a) Forward scatter                     b)   Side scatter    c)  SYBR Green 
          
        
Figure 3.6: Flow cytometry histograms showing changes in cell size (FSC plot), complexity 
(SSC plot) and nucleic acid content (SYBR Green plot) of PfNF54 trophozoite population 
treated with 3x IC50s of CQ (blue) and PYR (green) overlaid against untreated control (red). 
 
The haem profiles showed a dose-dependent increase in ‘free’ haem, which was significant 
from 2 to 3x CQ IC50, compared to the control (Figure 3.7). The average (± SE) amount of 
‘free’ haem present in the control was 3.54 ± 0.52 fg of haem Fe per cell while the amount 
present at 3x CQ IC50 was 6.91 ± 0.77 fg. This increase in toxic ‘free’ haem corresponded to a 
significant decreased in HZ, at the equivalent IC50 multiples (Figure 3.7a-b). The parasite 
survival curve overlaid with ‘free’ haem Fe levels showed a trend of increasing ‘free’ haem 
corresponding to a decreasing parasite survival (Figure 3.7c), thus confirming that CQ is 
indeed an inhibitor of HZ formation. 
As a negative control, PYR, was included to illustrate the robustness of this haem-pyridine 
fractionation assay. The ‘free’ haem and HZ profiles for PYR-treated PfNF54 cells show a 
plateau in haem levels with increasing PYR concentration. In addition, no significant 
differences in haem Fe were observed relative to the control. Unlike CQ-treated cells, PYR 
treatment did not lead to a dose-dependent increase in ‘free’ haem and a corresponding 
decrease in HZ (Figure 3.7d-e). Even at higher PYR concentrations, there was no significant 
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increase in ‘free’ haem compared to the untreated cells, indicating that cells are able to grow 
and survive, as they would under normal physiological conditions. The parasite survival 
curve overlaid with ‘free’ haem Fe levels shows no correlation between the two parameters 
(Figure 3.7f). These results corroborate the observations with the FACs analysis where PYR-
treated cells did not appear to differ from untreated controls in size, complexity or nucleic 
acid content, and correlate with PYR’s MoA involving inhibition of the trophozoite-specific 
dihydrofolate reductase–thymidylate synthetase,191 an event only marginally captured 
within the 32-h PYR incubation period of these cells. This data demonstrates that PYR is not 
















          
Figure 3.7: Haem fractionation profiles of CQ and PYR in synchronised drug-treated and control PfNF54 parasites. Plots a, d) and b, e) respectively show ‘free’ haem and 
HZ represented in terms of iron (Fe) measured in fg/cell with asterisks indicating statistical significance relative to control (*p < 0.05; **p < 0.01 and ***p < 0.001). Plots c) 
and f) represent parasite survival (blue) overlaid against ‘free’ haem Fe (red) plots and clearly show an unambiguous trend of increasing levels of ‘free’ haem 
corresponding with parasite death only in CQ (true inhibitor) but not in PYR. 
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3.3.7.2. Analysis of Cellular Haem Fractionation Profiles 
All the compounds showed similar morphological profiles on analysis using flow 
cytometry, and on this rationale, FACs histogram data is presented for three compounds (1, 
2 and 6) which respectively represent all the various modifications of the scaffold’s SAR. 
Similar to the CQ profiles discussed in section 3.3.7.1, the flow cytometry analysis of the 
trophozoites treated with the three compounds showed shifts in cell size and complexity 
between the untreated cells and those treated with 3x IC50 of the test compounds. However, 
these differences were not as extreme (Figure 3.8) as those observed in CQ-treated PfNF54 
cells, and could be indicative of differential sensitivity of the parasite strain to CQ and these 
test compounds (CQ IC50 = 11.1 nM; compound 2 IC50 = 30.1 nM and compound 6 IC50 = 
116.3 nM). The SSC shifts showed that treated cells were less complex and dense for all the 3 
compounds compared to the control (Figure 3.8b, e and h) while the FSC shifts revealed that 
they were comparatively smaller (Figure 3.8a, d and g). There were slight shifts in SYBR 
Green I fluorescent intensities indicating that treated cells had less nucleic acid content than 
untreated cells (Figure 3.8c, f and i). Put together, these observations indicate that the cells 






Compound 1    a)     b)     c) 
    
 
Compound 2    d)     e)     f) 
  
 
Compound 6   g)     h)     i) 
   
 
Figure 3.8: Flow cytometry histograms showing changes in cell size (FSC plot: a, d and g), complexity (SSC 
plot: b, e and h) and nucleic acid content (SYBR Green plot: c, f and i) of PfNF54 trophozoite population 
treated with 3x IC50s of compound 1 (blue), 2 (green) and 6 (grey) overlaid against untreated controls (red).
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The ‘free’ haem profiles show a dose dependent increase in ‘free’ haem, which was 
significant from 0.5x IC50 (in compound 6 and 7) to 3x IC50 (all compounds), compared to the 
control (Figure 3.9). These increases in ‘free’ haem corresponded to significant decreases in 
HZ, at the equivalent IC50s in most of the compounds. In compound 2 and 5, however, this 
decrease was only significant at 3x compound IC50 even though declining trends in HZ 
levels were observed.  Two lines of evidence strongly support the fact that this anomaly is 
likely an artefact of experimental error rather than absence of inhibitory activity. First, βHI 
results provide a baseline hint that these two compounds are likely to inhibit HZ formation 
in a physiological setting as they had marginally higher activity (compound 2 and 5 βHI 
IC50: 20.8 µM and 16.6 µM, respectively) compared to CQ (βHI IC50: 26.0 µM) in the 
detergent-based assay (Table 3.4). Second, there were marked error margins, (denoted by 
the standard deviations on the plots), on the recorded levels of HZ in the treated cells, which 
could have statistically masked the decrease. Nonetheless, the parasite survival curves for all 
the compounds overlaid with the ‘free’ haem levels showed that an increase in ‘free’ haem 
Fe indeed corresponded to a decrease in parasite survival (Figure 3.9). In general, these 
results clearly demonstrate that the pDBQs, as a class, are inhibitors of HZ formation. 
However, possible existence of other auxiliary modes of action for these compounds cannot 
be discounted. Indeed, though it is widely accepted that such quinoline-containing 
compounds act primarily by preventing haem detoxification, other mechanisms for the 
action of quinoline-based and related compounds have been proposed and include 
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Compound 4    j)       k)       l) 
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Figure 3.9: Haem fractionation profiles of compounds 1-7 in synchronised drug-treated and 
control PfNF54 parasites. Plots a, d, g, j, m, p and s), show levels of toxic ‘free’ haem 
represented in terms of  iron(Fe) measured in fg/cell while plots b, e, h, k, n, q and t) show 
haemozoin levels. The asterisks indicate statistical significance relative to control (*p < 0.05; 
** p < 0.01 and *** p < 0.001). Plots c, f, i, l, o, r and u) represent parasite survival (blue) 
overlaid against ‘free’ haem Fe (red) plots and clearly show unambiguous trends of 
increasing levels of ‘free’ haem corresponding with parasite death in all the compounds. 
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3.3.8. Potential for hERG Channel Inhibition 
As noted in Chapter 1, acquired long-QT syndromes occur quite often, and are commonly 
caused by pharmacologically and structurally diverse compound classes that reduce 
currents through hERG channels. Consequently, lead compounds are routinely tested early 
in the drug development process to flag any potential risk for hERG channel inhibition.195 
3.3.8.1. In silico Prediction of hERG Channel Toxicity 
Prediction of hERG inhibition is very challenging, in part due to the promiscuity of the 
larger inner vestibule of the hERG channel, which provides more space for structurally 
diverse drugs to block this channel. Also, there is no detailed X-ray crystal structure for the 
hERG protein, hence structural details for the hERG channel are inferred by analogy with 
other ion channels, computational analyses, and mutagenesis studies. In silico prediction 
therefore provides a guide into likelihood of toxicity potential. All predictions of hERG 
channel inhibition potential of the derivatives were done using StarDropTM software. One of 
the challenges for hERG blockage prediction is the lack of a definite threshold for 
discrimination of hERG blockers from non-blockers.196, 197 Halofantrine (HLF) and its major 
metabolite N-desbutylhalofantrine (dbHLF) have previously been associated with QT 
interval prolongation and with fatal and non-fatal arrhythmias in patients without known 
underlying cardiac abnormalities.198, 199 Though considered safe antimalarials, HLF and 
dbHLF have been shown to block wildtype hERG channels stably expressed in HEK 293 
cells in a concentration-dependent manner with IC50s of 0.018 µM and 0.072 µM, 
respectively.198, 200 This nanomolar range toxicity suggests that the gain in the safety margin 
for QT interval prolongation-related cardiotoxicity is minimal, and as such, HLF and dbHLF 
were included in the analysis and scored as known controls with high inhibition indices 
while CQ and dihydroartemisinin (DHA) were included as low-inhibition controls. DHA 
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has previously been reported to have little cardiac toxicity 141 and low in vitro inhibition IC50 
of 9.62 µM 200 while CQ IC50 have been reported between the range of 1.0 - 2.5 µM.198 
Inhibition potency was reported as pIC50, which is modelled in the program using the 
negative logarithm of literature IC50 values (in molar units) of 168 chemically diverse 
molecules with patch-clamp inhibition data. Therefore, more potent compounds present 
with higher pIC50 values. The test compounds had pIC50s within a narrow range of 6.22 – 
6.55, with the controls HLF and dbHLF predictably more potent than the pDBQs while CQ 
and DHA had lower inhibition values as expected (Table 3.6).  
Discernibly, there was a trend in potency relative to substituent orientation whereby the 
para-substituted compounds 3 and 6 exhibited highest pIC50s (6.43 and 6.39, respectively) 
compared to the other analogues in the group with a pyridine ring substitution on the RA 
side chain. This implies that the para- aromatic substitution potentially increases access into 
of the high-affinity internal binding site of the hERG channel to exert stronger blockage. 
Interestingly, the possibility of reducing hERG potency by modifying the pattern of aromatic 
substitution on compounds has been previously explored, and results from mutagenesis and 
molecular modeling studies on clofilium and ibutilide analogues suggested that phenyl 




Table 3.6: Predicted hERG inhibition IC50s versus molecular weights and lipophilicity of the 
7 pDBQ derivatives and 4 reference antimalarials 
 
Compound R X pIC50 a Mol. Weight Log P 
b Log D7.4 b 
       
1 Cl CH 6.55 439.4 5.67 4.04 
2 (meta-) Cl N 6.23 402.9 4.51 4.01 
3 (para-) Cl N 6.43 402.9 4.51 4.01 
4 (ortho-) Cl N 6.28 402.9 4.51 4.00 
5 (ortho-) CN N 6.23 395.5 3.80 3.47 
6 (para-) CN N 6.39 395.5 3.80 3.47 
7 (meta-) CN N 6.22 395.5 3.80 3.48 
Chloroquine   6.00 319.9 3.81 0.88 
Dihydroartemisinin   4.27 284.4 2.84 2.84 
Halofantrine   7.37 500.4 8.06 5.46 
N-desbutylhalofantrine   6.52 444.3 6.35 3.90 
a pIC50 values were determined using StarDropTM  
b cLogP and LogD7.4 were predicted using MarvinSketch v5.9.4  
 
Previously, it has been hypothesised that compounds with lower lipophilicity and MW are 
likely to exhibit less toxicity to the hERG potassium channel.144 While the substitution of a 
chloro with a nitrile at the C7 position in this series allowed for retention of their βHI 
potential, it simultaneously yielded a set of compounds with reduced MW and lipophilicity 
(Table 3.6), thus permitting an opportunity to test the predicted hERG inhibition versus 
lipophilicity and MW hypothesis. A liner regression analysis of hERG pIC50s versus both 
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measures of lipophilicity on the derivatives yielded a positive correlation between 
increasing potency of inhibition and lipophilicity. This association was, however, stronger in 
the cLogP analysis (R2 = 0.5052; p = 0.0734) compared to LogD (R2 = 0.1722; p = 0.3545) but 
significant in neither. When the 4 control compounds were included in the analysis, the 
strength of the association markedly improved, and was significant in the cLogP analysis 
(Figure 3.10a), suggesting that the weak correlations observed with the derivatives alone are 
likely a statistical reflection of small sample size with a narrow range of pIC50 values, rather 
than lack of association. Analysis of the association between hERG pIC50 and MW similarly 
showed a strong trend of diminishing potency with decreased MW. Note, however, these 
correlations must be treated with caution, since lipophilicity and MW may be parameters 
used by the StarDropTM program in predicting hERG pIC50s. 







Figure 3.10: Linear regression analysis plots showing the correlation between hERG pIC50s 
and LogD7.4 (solid red circles) and cLogP (solid blue circles) in a) as well as molecular 
weights (solid black circles) in b).  
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3.3.8.2. Experimental Determination of hERG Channel Toxicity 
While in silico predictions play an important role in providing an approximate indication of 
a compound’s potential for the hERG liability, they can only model to a limited degree the 
physiological contributions of ventricular repolarisation, channel promiscuity, potential 
interactions with other ion channels and compound MoA towards hERG channel inhibition. 
Owing to these complexities, complementation of computational predictions with 
experimental analysis is customarily recommended.  
Due to cost constraints and in silico results that showed no significant differences in the 
pIC50s of the compounds, one derivative (compound 4) was selected as representative for 
experimental analysis to determine hERG inhibition potential of this scaffold. Using 
verapamil hydrochloride as positive control, compound 4 was screened at four 
concentrations (0.3, 1, 3 and 10 μM) against a minimum of three separate CHO cells stably 
expressing hERG and the percent inhibition values from each cell was used to construct 
concentration-response curves. There was a concentration-dependent blockade of hERG 
protein by compound 4. At 0.3 µM, the compound was half as inhibitive as the control 
(mean %Inhibition ± SE: 16.6 ± 0.55 vs 33.9 ± 4.15), and this difference was significant (p < 
0.0001, unpaired t-test). However, at higher test concentrations, there was no significant 
difference between the toxicity of compound 4 and verapamil (Figure 3.11), In fact, at 10 µM, 
compound 4 was marginally more toxic – causing 96.2% inhibition compared to the control 
(94.3%), though this could be indicative of residual inhibition whereby the concentration is 




Figure 3.11: Mean percent inhibition of hERG protein expressed in CHO cells at varying 
concentrations of compound 4 and verapamil hydrochloride. 
 
For compound 4 and the control, this inhibition was further quantified by measuring the 
IC50 values of at least three separate cells (n >3). Data from individual cells were then pooled 
to obtain mean inhibition IC50s (± SD mean), and are presented in Table 3.7. Compound 4 
(IC50: 0.87 μM) seemed to inhibit hERG at a comparable potency to verapamil (IC50: 0.56 μM) 
under the test conditions and these values, on conversion to pIC50s, were consistent with the 
predicted values obtained from StarDropTM analysis in Table 3.6. The IC50 of verapamil 
under the assay conditions was within range of previously published values of 0.143 – 0.831 
µM obtained using heterologous expression systems in HEK 293 and CHO cells.202-205 This 
wide range in in vitro activity possibly reflects properties of the different expression systems 
and highlights the problem of endogenous influences in heterologous expression systems. 
Determination of the approximate free therapeutic serum level ranges of the pDBQs would 
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activity of compound 4 on hERG occurs at clinically relevant concentrations. Nevertheless, 
the caveat that data from in vitro experiments must be extrapolated to the clinical situation 
with caution must still be upheld. 
 
Table 3.7: Experimental and predicted hERG inhibition for compound 4 and verapamil 
Compound 
 Experimental 




Structure IC50 ± SD pIC50  pIC50 b 
      
4 
 
0.87 ± 0.08 6.060  6.279 
Verapamil  0.56 ± 0.08 6.252  6.155 
 a Experimental IC50 were determined from inhibition of hERG protein expressed in CHO cells and 
corresponding pIC50 obtained as negative logarithm of these IC50 values converted to milimolar units. 
b Predicted pIC50s were determined using StarDropTM  
 
3.3.9. In vitro Metabolism Studies in Mouse Liver Microsomes 
3.3.9.1. Microsomal Metabolic Stability 
Extensive and rapid metabolism of a compound to less active or inactive metabolites is a 
liability as it can lead to reduced efficacy. Though in vitro metabolic stability can be assessed 
using recombinant CYP enzymes, microsomes, hepatocytes or liver fractions,206 microsomes 
are the most widely preferred due to their ease of preservation, amenability to HTS and 
stability of their enzymatic activity even after prolonged storage.207 The microsomal 
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metabolic stability of the 7 derivatives was assessed in mouse liver microsomes (MLMs) 
using a single point assay. All the compounds were rapidly metabolised with less than 5% of 
the parent remaining after 30 minutes of incubation at 0.1 mg/mL microsomal protein 
(Table 3.8). The compounds exhibited short degradation half-lives (Mean t1/2: 5.65 min) and 
high hepatic clearance ratios (>0.90), suggesting significant susceptibility to hepatic 
metabolism. 
 
Table 3.8: In vitro metabolic stability of analogues 1 - 7 in mouse liver microsomes (MLMs) 
 
Compound R X % remaining 









       
1 Cl CH 3.57 6.15 1107 0.92 
2 (meta-) Cl N 2.96 5.89 1139 0.93 
3 (para-) Cl N 2.08 5.35 1250 0.93 
4 (ortho-) Cl N 2.32 5.49 1224 0.93 
5 (ortho-) CN N 2.08 5.35 1249 0.93 
6 (para-) CN N 3.63 6.22 1101 0.90 
7 (meta-) CN N 1.91 5.10 1349 0.94 
Midazolam   1.33 4.74 1425 0.94 
MMV390048   93.55 172.25 42 0.32 
 
This high rate of metabolism was comparable to the benzodiazepine, midazolam (1.33% 
remaining after 30 min). No metabolism occurred in the absence of NADPH or microsomes 
in the control set ups, implying that the observed bioactivation was primarily a function of 
cytochrome p450 enzyme-mediated phase 1 metabolism. Varying the position of the 
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dibenzylmethylamine side chain from ortho-, to meta- or para- did not seem to influence 
compound stability as would sometimes be expected, whereby substituent orientations 
would sterically hinder or permit enzyme access into metabolically labile sites of the 
molecule. This high metabolic susceptibility has implications on in vivo efficacy as plasma 
exposure of the compounds is likely to be poor and bioavailability low upon dosing. 
3.3.9.2. Metabolite Identification 
To further understand the structural basis of this rapid compound clearance, all the 
compounds were subjected to metabolite identification studies. In this analysis, mass 
spectroscopy data from the metabolic stability assay of each compound were screened for 
the presence of fragments corresponding to putative metabolites and routes/sites of 
metabolism inferred. Notably, the fragmentation pattern appeared to be conserved in all 
derivatives in the series regardless of the substitution at C7 on the quinoline ring or 
orientation of the side group, with N-dealkylation on the tertiary amine appearing to be the 
most predominant route of metabolism as metabolite 2 was present in highest proportion in 
all compounds. Other metabolites detected included products from oxidation of either the 
quinoline or pyridyl ring, denoted by a +16 shift in mass (metabolite 5). N-dealkylation and 
a combination of oxidative deamination (metabolite 6) and aldehyde reduction (metabolite 
3) and oxidation of aldehyde to carboxylic acid (metabolite 4) were also observed as 
depicted in Figure 3.12. The physicochemical, biological and mechanistic properties of the 




Figure 3.12: Fragmentation patterns of the prototype molecule with putative metabolite structures and masses (in positive mode)
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3.4. Summary and Conclusion 
This chapter evaluated the physicochemical properties, biological activities and mechanistic 
inhibition potential against βH/HZ of seven rCQ compounds bearing a 
dibenzylmethylamine side group hybridised to a quinoline ring. The results from these 
analyses have been supplemented by microsomal metabolism as well as predicted and 
experimental hERG data.  
In summary, the compounds exhibited moderate to high solubility at pH 6.5, with 
significant improvement in compounds 2 – 7 which, unlike 1, bore a pyridine ring 
substituent in place of one of the phenyl rings thus allowing for enhanced H-bonding to 
water molecules. The compounds also exhibited high membrane permeability at the 
physiologically-relevant pH 6.5, indicating that greater permeation and absorption would be 
expected in the lower GIT. As predicted, cLogP analysis showed that compound 1, lacking 
the less lipophilic pyridyl group and having higher MW, was most lipophilic followed by 
the 7-chloro analogues. There was a correlation between decreasing predicted solubility and 
increasing cLogP, though the strength of this association diminished when the analysis was 
extended to experimental solubility data. Additionally, the compounds exhibited a narrow 
range in LogD at both cytosolic and vacuolar pH, presumably due to the minimal variation 
in their acid dissociation constants. LogD values at pH 5.0 were markedly lower with even 
less variation since the vacuolar acidic environment results in substantial ionisation of the 
aromatic and aliphatic N of these compounds, hence reducing lipophilicity while 
correspondingly enhancing solubility. 
The compounds also showed antiplasmodial activity in the low nanomolar range against 
CQS and CQR strains of P. falciparum, with no discernible cross-resistance with CQ and the 
chloro-substituted analogues having higher potency across all strains. However, though all 
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the compounds were more potent than CQ against PfDd2, only 1, 2 and 7 exhibited 
indiscriminate activity with clear potency against PfNF54, PfDd2 and Pf7G8 probably 
consistent with their designation as rCQs. Antiplasmodial activity directly correlated with 
lipophilicity, meaning that the most lipophilic compounds were likely to diffuse through the 
intracellular membrane barriers and into the site of action.  
Mechanistically, the compounds possessed active inhibition of βH formation, with a mean 
IC50 comparable to AQ. This βH inhibition potential did not, however, correlate with 
antiplasmodial activity, presumably due to the requirement for vacuolar accumulation for 
the latter. Predicted VAR was highest in compound 5 and lowest in 2, and this strongly 
correlated with antiplasmodial activity against Pf7G8 but not PfNF54 or PfDd2. No 
association was observed, however, between in vitro βHIA and the IC50-scaled equivalent of 
VAR, highlighting the dominance of lipophilicity in biological activity. Analysis of the 
cellular haem-pyridine fractionation profiles of the compounds revealed that they all exhibit 
CQ-like signatures when incubated with synchronised ring stage P. falciparum cells. First, 
this was characterised by impaired cell morphology and DNA-synthesising ability of 
cultures treated with 3x compound IC50, implying damage to the cells’ competence to 
mature and transition into the next cycle. Secondly, the compounds exhibited a dose-
dependent decrease in the fraction of haem present as HZ and this matched a corresponding 
rise in the ‘free’ haem fraction. Overlay plots revealed diminishing parasite survival directly 
correlating with increasing amounts of ‘free’ haem for each compound, further affirming 
their activity as inhibitors of HZ formation. However, possible existence of other MoAs for 
these compounds cannot be discounted. 
Predictive analyses of hERG inhibition potential indicated that though the compounds’ 
activities were in the same order of magnitude as CQ - and significantly better than HLF, 
they still exhibited a notable hERG liability in comparison to DHA. Fitting with a previous 
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hypothesis, predicited activity against hERG correlated with both lipophilicity and 
compound MW. Experimental evaluation of the hERG inhibition potential on compound 4, 
elected to represent the whole series, illustrated a verapamil-like liability, which would need 
to be addressed if the compound was to be progressed further. Finally, the compounds also 
showed a high susceptibility to microsomal metabolism, with < 5% of the parent compound 
remaining after 30 minutes incubation with mouse liver microsomes. The metabolic 
modification pattern appeared to be conserved in all the derivatives in the series regardless 
of the substitution at C7 on the quinoline ring or orientation of the side group, with N-
dealkylation on the tertiary amine appearing to be the predominant route of metabolism, 
even though other metabolites were also observed. 
In conclusion, the evaluation of the physicochemical, biological and mechanistic properties 
of the seven pDBQs illustrates room for improvement of their activity and reduction in their 
hERG and metabolic liabilities, while retaining their inhibitory mechanistic potency against 
HZ formation. In the next chapter, a similar spectrum of analysis will be extended to the 
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4.1 Chapter Overview 
In this chapter, the biological activities, drug-like properties and mechanistic inhibition of 
βH and HZ by the pDBQ metabolites are examined. These profiles are compared to, and 
contrasted with, the parent pDBQ compounds. As introduced in Chapter 3, CYP-mediated 
NADPH-dependent phase 1 microsomal metabolism can either generate active or 
inactive/less active metabolites. Instructively, the Food and Drug Administration (FDA) 
guideline on “Safety Testing of Drug Metabolites” defines a ‘pharmacologically active 
metabolite’ as one with pharmacological activity at the target receptor, and whose activity 
may be greater than, equal or less than the parent drug exposure.208 In malaria 
chemotherapy, it is not uncommon for these biotransformations to result in more active 
agents, as evident in literature with examples of antimalarial metabolites with enhanced 
activity or drug-like features superior to their parents. For instance, dihydroartemisinin 
(DHA) is the principal metabolite and most active of all artemisinin derivatives and is 
considered to be responsible for the antimalarial activity of artesunate (AS).209 The 
proguanil-related PS-15 is metabolised to its putative metabolite, WR99210 (Figure 4.1), 
whose potency and lack of in vivo cross-resistance with CQ, PYR, and cycloguanil has been 
documented.210 The activity of primaquine (PMQ) is also thought to depend on the 
formation of active metabolite(s), as evidenced by the observation that PMQ remains 





Figure 4.1: Chemical structures of artesunate and PS-15 and their respective active 
metabolites, dihydroartemisinin and WR99210 
The FDA guideline further defines a ‘major metabolite’ as one that accounts for plasma 
levels greater than 10% of the administered dose or systemic exposure in humans.208 
Although all the metabolites generated in Chapter 3 technically fit within the definition of 
pharmacologically active metabolites, only the products of N-dealkylation were consistently 
observed in all compounds and constituted ~65% of the metabolites in each compound. As 
such, these were the compounds that were considered the major metabolites, and 
consequently prioritised for synthesis and analysis in this chapter.  
The contention that the aforementioned metabolites are likely to possess enhanced biological 
activity and favourable drug-like features was informed by two hypotheses. First, 
phenylequine (PQN), a structural phenyl analogue of ferroquine (FQ), which retains the 
requisite components for efficacy of a 4-aminoquinoline (i.e. the 7-chloro group and weakly 
basic amino groups), has been previously reported to be potent against the CQS and CQR 
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strain of P. falciparum.211 The metabolite scaffold assessed in this chapter bore a striking 
structural likeness to PQN, with the tertiary nature of the terminal nitrogen in PQN 
representing the only difference between them in the case of the 7-chloro derivatives (Figure 
4.2). Secondly, since biotransformation through  N-dealkylation effectively lowers the 
molecular weight, and by extension lipophilicity, this would potentially improve aqueous 
solubility while also potentially minimising the likelihood for inhibition of the hERG 
channel, decrease plasma protein binding and lower CYP enzyme inhibition.144  
 
Figure 4.2: Structures of (a) phenylequine and (b) the major metabolite scaffold evaluated in 
this Chapter. 
The seven compounds evaluated in this section of the thesis were synthesised as free bases 
and are structurally represented in Figure 4.3. This chapter details the experimental and 
computational characterisation of the physicochemical properties and biological activity of 
these 7 pDBQ metabolites and, as with the parent compounds, assesses the HZ-inhibiting 
MoA of each. In addition, further biotransformation analyses of the metabolites in both 
MLMs and HLMs are reported, as is experimental hERG channel inhibition data. All results 








4.2. Materials and Methods 
All materials and methods used in this chapter are described in detail in Chapter 2. The 
compounds discussed herein were synthesised and characterised by Dr. Malkeet Kumar. 
4.3. Results and Discussion 
4.3.1. Physicochemical Properties and drug-likeness. 
The results of the predicted and experimentally determined physicochemical properties are 
shown in Table 4.1. In general, the metabolites had good solubility that ranged between 
medium (50 -150 µM) for 8, 10, 11 and 14 to high (≥ 150 µM) for 9, 12 and 13. This kinetic 
solubility (pH 6.5) profile was comparable to that observed in the parent compounds. 
Permeability of the pDBQ metabolites was determined using the PAMPA assay at pH 6.5 
and a permeability class assigned as described in section 2.4.5 in Chapter 2. Apart from 
compound 12, which had low membrane permeability, the remaining metabolites either had 
moderate (8 and 14) or high permeability (9, 10, 11 and 13) as shown in Table 4.1 As with 










Table 4.1: Solubility, membrane permeability and lipophilicity of the pDBQ metabolites 
 
 
  Kinetic 
Solubility a 
(µM) 
 Permeability Log 
Papp (SD) 
 Lipophilicity b 
Compound R R’ Observed  pH 6.5  cLogP LogD7.4 LogD5 
           
2 (meta-) Cl 
 
59.8  -4.10 (0.26)  4.46 2.47 0.82 
8 (meta-) Cl 
 
122.3  -5.90 (0.02)  3.06 0.84 -0.896 
9 (meta-) Cl 
 
200.0  -5.00 (0.12)  3.49 0.95 -0.918 
4 (ortho-) Cl 
 
164.7  -4.56 (0.03)  4.46 3.79 0.90 
10 (ortho-) Cl 
 
90.0  -5.20 (0.06)  3.49 0.95 -0.918 
11 (ortho-) Cl 
 
125.0  -4.30 (0.04)  3.06 0.85 -0.862 
3 (para-) Cl 
 
196.6  -4.56 (0.10)  4.46 2.85 0.84 
12 (para-) Cl 
 
165.0  -7.00 (0.10)  3.06 0.69 -0.833 
13 (para-) Cl 
 
200.0  -4.00 (0.20)  3.49 0.69 -0.991 
7 (meta-) CN 
 
72.4  -3.60 (0.16)  3.71 2.75 0.85 
14 (meta-) CN 
 
53.5  -6.50 (0.21)  2.31 0.54 -0.908 
          Warfarin     -3.80 (0.35)     
Propranolol     -4.40 (0.28)     
Testosterone     -3.70 (0.33)     
Reserpine   <5        
Hydrocortisone   >150      1.50  
Verapamil         2.50  
a Kinetic solubility was determined at pH 6.5  
b cLogP was predicted using MarvinSketch v5.9.4 while LogD was experimentally determined using 
HPLC analysis (for pH 7.4) and shake-flask method with UV-spectroscopy (for pH 5). 
Data on the parent compounds is included for comparison and highlighted in blue font  
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The high lipophilicity observed for the parent pDBQs in the previous chapter was partly 
attributable to the presence of the largely nonpolar quinoline core and heterocyclic rings in 
the side chain. The microsomal cleavage of one of the side chain rings would be anticipated 
to yield molecules with lower lipophilicity. This was interrogated through prediction of 
cLogP using MarvinSketch v5.9.4 and experimental determination of LogD at pH 5 and 7.4. 
cLogP values for the metabolites ranged between 2.31 and 3.49, and were markedly lower 
compared to the parent pDBQs (range: 3.71 - 5.60). Compound 14 exhibited the lowest 
cLogP of all the metabolites due to the less lipophilic nitrile substitution at C7 unlike the 
chloro substituent at the same position. These metabolites thus conform to Lipinski’s “rule 
of five’” with respect to lipophilicity, cLogP of <5. Correlation of cLogP and predicted 
solubility yielded a strong and significant association of increasing solubility with 
diminishing cLogP (R2 = 0.7824; p < 0.0082), and this was consistent with the observed 
association in the parent pDBQs (R2 = 0.8085, p = 0.0061). LogD7.4 ranged from 0.54 – 0.95 
(mean ± SE: 0.79 ± 0.06), with compound 14 again exhibiting the lowest distribution 
coefficient (Table 4.1). LogD5.0 values were even lower (mean ± SE: -0.90 ± 0.02) and showed 
minimal differences. These favourable partitioning and distribution coefficients in the 
metabolites, which correlate with improved aqueous solubility, represent an improvement 
over the parent compounds. 
 
4.3.2. Antiplasmodial Activity. 
The antiplasmodial effects of the metabolites were then determined against CQS (PfNF54) 
and CQR (PfDd2) P. falciparum strains and are summarised in Table 4.2. Against PfNF54, all 
the compounds, except 12, were potent with IC50s below 41 nM. Apart from 12, each of the 
metabolites was either comparably or more active than the parent pDBQ against PfNF54, 
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with the potency of 9, 10 and 13 within the range of CQ and AS activity. Though this 
potency was maintained against PfDd2, the activity of 8, 12 and 14 diminished and mirrored 
that of CQ. While it was expected that the parent pDBQs maintained activity against CQR 
strains due to their RA side chains, the observed activity of the metabolites against PfDd2 
may be speculated to be on the basis of dissimilar interaction with resistance proteins or 
higher toxicity in their MoA as discussed later. While the drop in activity against PfDd2 
suggests an influence of resistance mechanism against the molecules, the potency of 9, 10, 11 
and 13, and the resistance indices suggest that this is not similar in extent to that influencing 
CQ activity. 
There was no association between aqueous solubility and antiplasmodial activity against 
CQS (R2 = 0.0153) or CQR (R2 = 0.0001) parasite strains. However, there was a trend of 
increased activity against both strains with high compound cLogP, though this was weak 
and not significant in either strain (CQS: R2 = 0.0495; p = 0.6316 and CQR: R2 = 0.1392; p = 
0.4097). The same pattern was observed when LogD7.4 was substituted into the analysis 
instead, suggesting that antiplasmodial activity may depend on lipophilicity in these 
compounds as with the parents and possibly reflects the ability of the most lipophilic 
compounds to best diffuse through intracellular membranes to the site of action, but the 
effect is dramatically diminished in the metabolites. It was therefore of interest to investigate 
the possible MoA of these derivatives. 
The selectivity indices of these metabolites ranged from 58.4 to 4,983.6, with compound 12 
showing highest likelihood of toxicity in the CHO cells (S. Index = 58.4). Notably, except for 
14, atleast one of each metabolite pair showed an improvement in cytotoxicity index 
compared to the parent compound, with the greatest improvement observed between 
compound 8 (S. Index = 4,983.6) and it parent, 2 (S. Index = 275.1).  
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Table 4.2: Antiplasmodial activity and cytotoxicity profiles of the pDBQ metabolites 
 
   IC50 (nM) 
 Cytotoxicity 
Compound R R’ PfNF54 PfDd2 R. Index PfDd2 CHOIC50 (μM) S. Index 
         
2 (meta-) Cl 
 








11.5 78.2 6.8 5.0 432.7 
4 (ortho-) Cl 
 








24.7 63.0 2.6 7.4 298.8 
3 (para-) Cl 
 








9.2 55.3 6.0 5.7 616.8 
7 (meta-) CN 
 




40.7 335.6 8.2 12.5 307 
        
CQ b   8.3 226.4 27.3   
Artesunate   5.6 14.3 2.6   
Emetine       0.095  
R. Index = Resistance index = [IC50 CQR strain] / [IC50 CQS strain]; CHO = Chinese Hamster Ovarian 
cells; S. Index= Selectivity index = [IC50 CHO] / [IC50 PfNF54];  
Chloroquine diphosphate salt b 




4.3.3. Mechanistic Evaluation  
Interestingly, though the biotransformation of the parent pDBQs led to various 
modifications to the compounds (in addition to N-dealkylation), the fundamental 
pharmacophore responsible for βH/HZ inhibition i.e. chloro/nitrile- substitution at C7 and 
planar 4-aminoquinoline nucleus was still intact in the resultant metabolites. Moreover, the 
quinoline rings and the attached benzylamine/benzylmethylamine side groups in the 
metabolites are still capable of adopting a planar conformation thus leaving the metabolites 
potentially capable of inhibition of βH and HZ formation. 
 
4.3.3.1. β-Haematin Inhibition and Correlation with Antiplasmodial Activity 
All the metabolites retained potency against the formation of βH, with IC50 values ranging 
from 15.0 to 24.2 µM, and comparable to those of AQ and CQ (Table 4.3). There was no 
significant difference between the mean inhibition IC50s of the metabolites and the parent 
compounds (Mean ± SEM: 19.1 ± 1.6 vs 18.2 ± 1.4; p = 0.6641, unpaired t-test), a likely result 












Table 4.3: βH inhibition (βHI) and antiplasmodial activity of the pDBQ metabolites 




 βHIA IC50 (SD) 
 
PfNF54 IC50 
Compound R R’ µM 
 
µM 
      
2 (meta-) Cl 
 








15.0 (2.7)  0.012 
4 (ortho-) Cl 
 








24.2 (2.9)  0.025 
3 (para-) Cl 
 








23.8 (4.2)  0.009 
7 (meta-) CN 
 




18.6 (1.8)  0.041 
      
Chloroquine   26.0 (3.4)  0.008 
Amodiaquine   13.9 (2.3)   
Pyrimethamine   No inhibition  0.021 
Data on the parent compounds is included for comparison and highlighted in blue font  
 
As observed with the parent compounds, analysis of the association between βH inhibition 
and antiplasmodial activity against PfNF54 did not yield any significant association (Figure 
4.4). Again, this could either be due to the cell-free design of the βH inhibition assay that 
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limits true reflection of the environment involved in whole cell parasite inhibition including 
factors such as membrane permeation or accumulation or that instead, antiplasmodial 
activity better correlates with other indicators of MoA. In summary, the metabolites proved 
as potent as the parent pDBQs against formation of βH albeit this did not correlate with 
their in vitro antiplasmodial activity thus motivating analysis of their accumulation potential 
as a possible factor in their parasite growth inhibition activity. 
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Figure 4.4: Correlation between βHI and antiplasmodial activity for the pDBQ metabolites in 
CQS (black plot) and CQR parasites (blue plot). 
 
4.3.3.2. Vacuolar Accumulation 
The cleavage of the ethylpyridine/ethylbenzene moiety from the chemosensitising side 
group of the parent pDBQs during metabolism would be expected to disrupt the optimal 
chemosensitisation SAR of these molecules. While an unsurprising CQ-like diminished 
activity against PfDd2 was observed for 8, 12 and 14, the remaining metabolites still 
maintained significant activity against the CQR strain in spite of this structural distortion in 
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ability to circumvent the parasite resistance machinery. Thus, an investigation predicting 
whether these derivatives accumulate to higher concentrations was conducted and 
correlated with antiplasmodial and βHI activity.  
As shown in Table 4.4, the compounds (unlike the parent pDBQs) had only two 
protonatable centers and their predicted VAR ranged between 28.1 and 73.8. The metabolites 
(mean VAR ± SE: 51.9 ± 6.7) seemed to accumulate to a lesser degree than their parent 
compounds (mean ± SE: 320.1 ± 149.0), with compounds 10 and 11 exhibiting ~10-fold less 
accumulation potential compared to their parent derivative, 4. This could be due to the 
difference in the number of protonatable centres between the metabolites (2 centres) and the 
parent pDBQs (3 centres) or differences in pKa of equivalent centres. The VAR correlated 
with antiplasmodial activity against both PfNF54 (R2 = 0.3084; p = 0.1956) and PfDd2 (R2 = 
0.4110; p = 0.1207), although none of these associations was significant. Analysis of the VAR-
normalised IC50s with βHI activity still yielded weak and non-significant associations in both 
the CQS (R2 = 0.2476; p = 0.2558) and CQR (R2 = 0.4370; p = 0.1059) strains, implying that 
accumulation – though important in achieving threshold inhibitory concentrations, may not 
be the driving determinant of the potent activity of these metabolites. The lack of correlation 
between the normalised accumulation ratios and βH inhibition suggests that the mechanism 
of drug accumulation is complex, even in the CQS PfNF54 strain, and cannot be captured by 
the simple pH trapping hypothesis. These results further suggest that the antiplasmodial 
activity of these HZ inhibitors is not necessarily reduced by the loss of the basic pyridine 






Table 4.4: The vacuolar accumulation, βHI and antiplasmodial activity of the 7 pDBQ 
metabolites 
 
Compound R R’ VAR a βHIA IC50 
(µM) 
PfNF54 (nM) VAR x NF54 
IC50 (µM) 
       
2 (meta-) Cl 
 
44.7 20.8 ± 0.6 30.1 ± 5.0 1.36 
8 (meta-) Cl 
 
54.5 15.3 ± 0.2 33.8 ± 0.1 5.74 
9 (meta-) Cl 
 
73.8 15.0 ± 2.7 11.5 ± 1.5 0.51 
4 (ortho-) Cl 
 
776.2 17.9 ± 3.2 54.4 ± 5.5 42.23 
10 (ortho-) Cl 
 
73.8 21.9 ± 1.7 9.8 ± 1.1 1.00 
11 (ortho-) Cl 
 
51.5 24.2 ± 2.9 24.7 ± 5.9 19.17 
3 (para-) Cl 
 
102.3 17.2 ± 0.3 38.5 ± 4.8 3.94 
12 (para-) Cl 
 
33.3 15.1 ± 0.6 230.8 ± 24.0 230.15 
13 (para-) Cl 
 
48.0 23.8 ± 4.2 9.2 ± 4.0 0.65 
7 (meta-) CN 
 
79.4 16.7 ± 0.1 79.1 ± 4.9 6.28 
14 (meta-) CN 
 
28.1 18.6 ± 1.8 40.7 ± 1.6 3.23 
a VAR values were calculated using the equation VAR = Antilog(LogD7.4 – LogD5.0) 
Data on the parent compounds is included for comparison and highlighted in blue font  
 
It has previously been hypothesised that the ability of quinoline analogues to accumulate to 
high inhibitory concentrations in the DV can be attributed to their ability to avoid 
recognition by the CQ resistance mechanism altogether or directly block PfCRT-mediated 
extrusion thus enabling toxic levels of the drug to accumulate in both CQS and CQR 
strains.212 In the latter scenario, the drug may exert a second antiplasmodial effect in CQR 
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parasites as a consequence of inhibiting the normal function of the transporter. Employing 
kinetic analyses to investigate the interaction of PfCRT with CQ, QN, QND and verapamil, 
Bellanca and colleagues showed that different drugs are likely to interact with distinct sites 
within a poly-specific substrate recognition cavity of PfCRTDd2, resulting in different levels 
of affinity and transport efficiency.213 This suggests that even with modest modification to 
the structure, there may be scope for minimisation or complete elimination of a drug’s 
interaction with PfCRTDd2, thus allowing the drug to escape the resistance mechanism 
altogether. It is not unreasonable to speculate that the biotransformation of the parent 
pDBQs inadvertently introduce subtle structural modifications to afford metabolites with 
dissimilar interactions with PfCRTDd2 to the parent compounds. This, however, can only be 
directly tested with investigations of the interactions of the parent pDBQs and the 
metabolites with PfCRT, for example, in a Xenopus laevis oocyte expression system.214 
The VAR-normalised IC50s ranged from 0.52 to 3.41, consistent with the parent compounds. 
However, this parameter only yielded negative associations when correlated with βHI 
activity in both CQS (R2 = 0.2701; p = 0.2318) and CQR (R2 = 0.4898; p = 0.0800) strains, 
implying that accumulation – though important in achieving threshold inhibitory 
concentrations, may not be the driving determinant of the potent activity of these 
metabolites especially against PfDd2. The lack of correlation between the calculated or 
normalised accumulation ratios and βH inhibition suggested that the mechanism of drug 
accumulation is far complex, even in the CQS PfNF54 strain, than can be captured by the 
simple pH trapping model. These results further showed that antiplasmodial activity of HZ 





4.3.3.3. Morphological Effect of Treating Synchronised Cultures 
Since the cycle stage at which compounds interfere with plasmodial growth can give an 
insight into their MoA, the morphological effect of treating cells with a high concentration of 
the metabolites was investigated through FACs analysis with the aim of ascertaining if these 
derivatives impair growth of plasmodial cells in the same manner and stage as their parents. 
FACs histogram data presented in Figure 4.5 reveal that all the compounds caused similar 
shifts in cell size, complexity and nucleic acid content when cells where treated with 3x 
compound IC50. The SSC shifts showed that treated cells were less complex and dense for all 
the compounds compared to the control (Figure 4.5a) while the FSC shifts revealed that they 
were comparatively smaller (Figure 4.5b). There were slight shifts in SYBR Green I 
fluorescent intensities indicating that treated cells had less nucleic acid content than 
untreated cells (Figure 4.5c). These observations suggest that, in a manner not unlike the 
profiles of CQ and the pDBQ parent compounds, the metabolite-treated cells had stunted 
growth and matured to a lesser degree than the untreated cells. 
 









c) SYBR Green 
 
 
Figure 4.5: FACs histograms showing changes in cell size (a), complexity (b) and nucleic 
acid content (c) of PfNF54 trophozoite population after treatment of synchronised rings with 
3x IC50s of each metabolite overlaid against untreated controls. The red plot represents the 
untreated control cells while the treated population are represented by the cyan plot 
(compound 8), yellow (compound 9), green (compound 10), orange (compound 11), blue 
(compound 12), purple (compound 13) and fluorescent green (compound 14) 
 
4.3.3.4. Haem-Pyridine Fractionation Profiles 
As follow up on the βH inhibition results to ascertain if these metabolites are genuine 
inhibitors of HZ formation in the cells, a haem-pyridine fractionation assay was conducted. 
The haem profiles show a dose-dependent increase in ‘free’ haem, which was significant 
from 0.5x IC50 (in compound 8) to 3x IC50 (all compounds), compared to the control (Figure 
4.6). As with CQ and the parent pDBQs, these increases in ‘free’ haem levels corresponded 
to significant decreases in HZ in all the metabolites. In compound 11, this decrease was, 
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however, only significant from between 2.5 and 3x compound IC50 even though declining 
trends in HZ levels were observed.  The parasite survival curves for all the compounds 
overlaid with the ‘free’ haem Fe showed corresponding increases in ‘free’ haem Fe with a 
drop in parasite survival. While not discounting the possible existence of other MoAs, these 
results together with in vitro βH inhibition data suggest that these pDBQ metabolites are 
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Figure 4.6: Haem fractionation profiles of compounds 8-14 in synchronised drug-treated and 
control PfNF54 parasites. Plots a, d, g, j, m, p and s), show levels of toxic ‘free’ haem 
represented in terms of  iron(Fe) measured in fg/cell while plots b, e, h, k, n, q and t) show 
haemozoin levels. The asterisks indicate statistical significance relative to control (*p < 0.05; 
** p < 0.01 and *** p < 0.001). Plots c, f, i, l, o, r and u) represent parasite survival (blue) 
overlaid against ‘free’ haem Fe (red) plots and clearly show unambiguous trends of 
increasing levels of ‘free’ haem corresponding with parasite death in all the compounds. 





























































































4.3.3.5. Effect of ‘Free’ Haem Levels 
In an attempt to further explain the enhanced activity of these metabolites against the CQS 
strain relative to their parents, a comparative analysis of the ‘free’ haem levels produced in 
the parasites at different drug concentrations was performed. In this analysis, the mean ‘free’ 
haem Fe (fg/cell) present at each drug concentration was obtained for the metabolites and 
parent pDBQs, analysed using an unpaired t-test for possible differences and plotted in 
Figure 4.7. Though compounds belonging to the quinoline scaffold customarily require only 
a small increase in “free” haem to induce parasite death, the metabolites seemed to require 
comparatively lower levels of ‘free’ haem than the parent pDBQs to induce killing, though 
they both encompassed the quinoline scaffold. In fact, omission of 12 as an outlier (mean 
‘free’ haem range: 4.54 – 13.60 fg/cell and IC50: 230.8 nM) yields significant differences in all 
but the 2x IC50 dose, thus highlighting that the effectiveness of these metabolites over their 
parents could be due to formation of a more toxic and soluble ‘drug-haem’ complexes. 
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Figure 4.7: Comparative mean levels of ‘free’ haem Fe measured in fg/cell in synchronised 
parasites treated with varying doses of metabolites and parent pDBQs. Asterisks denote 
statistical significance relative to parent drug (*p < 0.05; **p < 0.01 and ns = not significant). 
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4.3.4. Metabolic Stability in Mouse and Human Liver Microsomes 
As further assessment of the biological activity of the metabolites in light of their drug-like 
potential and owing to the extensive and rapid metabolism of the parent pDBQs, it was 
imperative to test the metabolic stability of the metabolites. In addition to investigations of 
stability in MLM, the metabolites were also assessed in human liver microsomes (HLM). All 
compounds exhibited a high metabolic stability in both MLM and HLM with >75% 
remaining after 30 min of incubation with the liver microsomes (Table 4.5).  
The observed high microsomal metabolic stability was a significant improvement from the 
poor metabolic stability observed in the parent compounds described in the previous 
chapter. Compound 9 however, showed an anomalous result in MLM, with only 19% of the 
compound remaining after 30 min of incubation. While this still represented a substantial 
improvement from compounds 1 and 2 (its parents), it was unclear why this was 
inconsistent with the MLM incubation results for the other metabolites. Nonetheless, the 
good microsomal stability of these metabolites suggested that further efforts on metabolite 










Table 4.5: Metabolic stability of the metabolites in mouse and human liver microsomes 
 
Compound R R’ Species % remaining 









        
2 (meta-) Cl 
 
Mouse 3.57 5.9 1139 0.93 
8 (meta-) Cl 
 
Mouse 99.9 >150   
   Human 91.3 >100   
9 (meta-) Cl 
 
Mouse 19.0 12.5 545 0.86 
   Human 86.2 >100 14 <0.42 
4 (ortho-) Cl 
 
Mouse 2.32 5.5 1224 0.93 
10 (ortho-) Cl 
 
Mouse 97.0 >100 10 <0.33 
   Human 98.9 >100 1 <0.42 
11 (ortho-) Cl 
 
Mouse 98.5 >100 5 <0.33 
   Human 95.0 >100 4 <0.42 
3 (para-) Cl 
 
Mouse 2.08 5.4 1250 0.93 
12 (para-) Cl 
 
Mouse 91.5 >100 60 0.40 
   Human 98.9 >100 1 <0.42 
13 (para-) Cl 
 
Mouse 90.4 >100 33 <0.33 
   Human 94.6 >100 15 <0.42 
7 (meta-) CN 
 
Mouse 1.91 4.7 1349 0.94 
14 (meta-) CN 
 
Mouse 99.0 >150   
   Human 87.9 >100   
Midazolam   Mouse 1.33 4.74 1425 0.94 
   Human     
MMV390048   Mouse 93.55 172.25 42 0.32 
   Human     
Data on the parent compounds is included for comparison and highlighted in blue font 
a Data not corrected for protein binding 
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4.3.5. Inhibition of the hERG Channel 
Metabolites likely to be in circulation, and structurally related to the parent drugs require 
investigation for activity against any off-target receptor to which the parent drugs possess 
activity.215 Since it is likely that the high in vitro activity, good aqueous solubility and 
microsomal metabolic stability of these compounds could translate to good in vivo efficacy 
from high systemic exposure, these metabolites may cause effects on off-target 
receptors/enzymes by virtue of their inadvertently high concentration. Coupled with a 
nominal affinity by weak bases, this risk is particularly heightened for the hERG channel. In 
silico and experimental hERG inhibition studies were therefore extended to these 
metabolites. 
4.3.5.1. In silico Analysis of hERG Channel Inhibition 
The metabolites had pIC50s ranging between 4.98 (compound 14) and 5.70 (compound 13). 
This predicted inhibition range was more favourable than CQ and the standard high 
inhibition controls, halofantrine (HLF) and desbutyl-halofantrine (dbHLF). In fact, the 
inhibition potential of 14 was not significantly different from DHA, and mirrored their 
comparable molecular weight and partitioning coefficients (Table 4.6). Crucially, each 
metabolite was predicted to possess a reduced risk for hERG channel inhibition compared to 
its corresponding parent compound and, collectively, the mean pIC50 for the metabolites was 
significantly lower than that of the parent pDBQs (mean ± SE: 5.29 ± 0.11 vs 6.33 ± 0.05; p < 





Table 4.6: Predicted hERG inhibition IC50s versus molecular weights and predicted 
lipophilicity of the metabolites compared to the parent pDBQs and 4 reference antimalarials 
      
Compound R R’ pIC50 a Mol. Weight cLogP b Log D7.4 b 
       
2 (meta-) Cl 
 








5.53 311.8 3.49 1.06 
4 (ortho-) Cl 
 








5.04 297.8 3.06 0.84 
3 (para-) Cl 
 








5.70 311.8 3.49 1.05 
7 (meta-) CN 
 




4.98 288.4 2.31 0.27 
       
Chloroquine   6.00 319.9 3.81 0.88 
Dihydroartemisinin   4.27 284.4 2.84 2.84 
Halofantrine   7.37 500.4 8.06 5.46 
N-desbutylhalofantrine   6.52 444.3 6.35 3.90 
a pIC50 values were determined using StarDropTM  
b cLogP and LogD7.4 were predicted using MarvinSketch v5.9.4 




Because  the interaction of drugs with membrane phospholipids is driven, in part, by 
lipophilicity as well as electrostatic interactions with both acidic and basic moieties on 
phosphate head groups,216, 217 correlation analysis between cLogP/LogD and pIC50s, similar 
to those performed on the parent compounds were extended to these metabolites. There was 
a direct and significant correlation between predicted hERG channel inhibition and these 
lipophilicity indices, with the association stronger in cLogP than LogD (Figure 4.8a). Indeed, 
apart from flexibility (number of rotatable bonds) and topological surface area, lipophilicity 
has been successfully used in predicting hERG blockage in some models.218 A similar 
observation was made for compound molecular weight (Figure 4.8b), and confirms findings 
of a recent study that positively correlated the most potent hERG inhibitors to increased 
cLogP, rotatable bonds and molecular weight on approximately 300 000 compounds 
contained in Molecular Library Small Molecular Repository library.219 These predictive 
analyses thus demonstrate that hERG liability tends to be more pronounced in compounds 
that are more hydrophobic with high molecular weight, features more observed in the 
parent compounds than metabolites. Again, care must be taken, given that these factors are 
probably used in the prediction software. 
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Figure 4.8: Linear regression analysis plots of the correlation between predicted hERG pIC50s 
and LogD7.4 (red) and cLogP (blue) in a) as well as molecular weights (black) in b) 
 
4.3.4.2. Experimentally-determined hERG Channel Inhibition 
In addition to compound 4 described in Chapter 3, the experimental inhibition potentials of 
two of its metabolites, 10 and 11, were also determined using similar assay conditions thus 
allowing for direct comparison of the toxicity of the metabolites in relation to the parent 
compound. As with 4, there was a concentration-dependent blockade of hERG by 
compounds 10 and 11. This is in agreement with a previous clinical study where a high dose 
regimen of HLF (72 mg kg−1) was reported to induce dose-dependent QT prolongation in all 
61 patients treated,220 and in vitro findings of a concentration-dependent block of hERG 
channels by HLF and dbHLF.198, 199 There was no significant difference in the levels of 
channel inhibition between the two metabolites in all the four tested concentrations, perhaps 
suggestive of the fact that there were no radical differences in the lipophilicities and MW.  
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At 0.3 µM, the metabolites were 3-fold less toxic compared to the control (%Mean Inhibition 
± SD: 10.4 ± 0.65 vs 33.9 ± 4.15), and this difference was significant (p < 0.0001, unpaired t-
test). In fact, a similar fold difference between the metabolites and verapamil was still 
observed at 1.0 µM test concentration (%Mean Inhibition ± SD: 22.4 ± 0.74 vs 64.9 ± 3.21). At 
3.0 µM, there was a significant 2-fold toxicity difference between the metabolites and their 
parent, 4 (%Mean Inhibition ± SD: 43.6 ± 0.64 vs 87.6 ± 2.70; p < 0.0001, unpaired t-test). 
Though the metabolites still maintained comparatively lower hERG channel inhibition at the 
highest test concentrations (10.0 µM), this was not significantly different from the toxicity 
observed from compound 4 or verapamil (Figure 4.9). 
 
Figure 4.9: Percent mean inhibition of hERG protein expressed in CHO cells at varying 
concentrations of the metabolites (10 and 11), their parent compound (4) and verapamil. 
Similar to the analysis conducted on 4 in the previous chapter, these proportional inhibitions 
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and presented as mean inhibition IC50s (± SD mean) in Table 4.7. Again, the metabolites 
were approximately 5-fold less toxic (Mean IC50 ± SD: 3.56 ± 0.16) compared to their parent 
(Mean IC50 ± SD: 0.87 ± 0.08) or verapamil (Mean IC50 ± SD: 0.56 ± 0.08), and the pIC50 
equivalents of these discreet experimental IC50s were in agreement with the predicted 
values. 
 
Table 4.7: Experimental and predicted hERG inhibition for compounds 10 and 11 compared 
to 4 and verapamil 
 
Compound  R R’ 
 Experimental Inhibition  Predicted 
Inhibition 
 IC50 ± SD (µM) pIC50  pIC50 
        
10 (ortho-) Cl 
 
 3.67 ± 0.70 5.44  5.55 
11 (ortho-) Cl 
 
 3.45 ± 0.50 5.46  5.04 
4 (ortho-) Cl 
 
 0.87 ± 0.08 6.06  6.28 
Verapamil  
 
 0.56 ± 0.08 6.25  6.16 
 a Experimental IC50 were determined from inhibition of hERG protein expressed in CHO and 
corresponding pIC50 obtained as negative logarithm of these IC50 values converted to milimolar units. 
b Predicted pIC50s were determined using StarDropTM 
Data on the parent compounds is included for comparison and highlighted in blue font 
 
Obviously, this diminished risk of potential cardiotoxicity by the metabolites is of clinical 
significance, and would make even better sense if interpreted in a pharmacokinetic context. 
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Curiously, in HLF, it has been shown that QT interval significantly correlates with high 
plasma levels of the parent drug, but not its major metabolite, dbHLF.221 In fact, in an earlier 
report of serious HLF cardiotoxicity, plasma concentration was measured at syncope or time 
of death and approximated to be 1.6 μM in the two study patients.220 Tellingly, therapeutic 
plasma HLF concentration in patients receiving HLF treatment is 1.67 - 2.98 μM,222, 223 thus 
highlighting the possibility of drug-induced cardiotoxicity occurring at therapeutic 
concentrations of the drug. Owing to their in vitro potency, good solubility and metabolic 
stability in liver microsomes, these metabolites, unlike their parent compounds, could 
potentially achieve therapeutic levels at lower plasma concentrations that do not border the 
hERG inhibition range. However, it is important to urge caution especially when 
extrapolating to in vivo settings. First, these in vitro analyses do not comprehensively account 
for the proportion of drug bound to serum proteins versus the free fraction likely to elicit 
therapeutic or toxic effects.  Secondly, it is indeed conceivable that the potency of blockade 
of the native human hERG channel by these metabolites (and the parent pDBQ) may be 
different from that observed against the hERG protein expressed in heterologous cell lines. 
Nonetheless, these data encouragingly show a favourable cardiotoxicity profile for the 
metabolites relative to the parent pDBQ, hence confirming their drug-likeness and potential 
for further development. The molecular basis of this lowered risk of potential cardiotoxicity 
by the metabolites compared to the parent compounds is beyond the scope of this thesis. 
Nevertheless, it is noteworthy that the number of compounds evaluated is limited and 




4.4. Summary and Conclusion 
In this chapter, seven metabolites arising from N-dealkylation of the parent pDBQ 
compounds were investigated for their biological activity and drug-like physicochemical 
properties as well as their mechanistic potential to inhibit formation of βH and HZ. In 
chapter 3, the parent compounds were shown to possess moderate to high permeability, 
moderate to high aqueous solubility at pH 6.5 and high lipophilicity. The metabolites 
maintained similar solubility and permeability profiles, though with significantly reduced 
lipophilicity. The metabolites also exhibited improved biological activity and cytotoxicity 
profiles. The compounds were active against both CQS and CQR strains in the nanomolar 
range, though activity against CQR parasites seemed to diminish in compounds 12 and 14 
compared to the parent drugs (Figure 4.10). This antiplasmodial activity, as with the 
parents, was shown to be a function of lipophilicity and possibly reflected the ability of the 
most lipophilic compound to best diffuse through the multiple intracellular membranes to 
the site of action. 
 
Figure 4.10: Chemical structures of compound 12 and 14 and their activity against PfDd2 
 
Though a mechanistic investigation of this activity noted potent inhibition of βH formation 
in these compounds, there was no correlation between this phenomenon and antiplasmodial 
activity or predicted vacuolar accumulation of the metabolites in the parasite DV. It is 
possible therefore that upon high accumulation within the DV, these metabolites interact 
with PfCRTPfDd2 in a manner dissimilar to their parents or CQ, resulting in different levels of 
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affinity and transport efficiency. This suggests that modest structural modifications could 
result in minimising drug interaction with PfCRTPfDd2, allowing for evasion of the resistance 
machinery. Cellular haem-pyridine fractionation analyses further showed profiles of dose-
dependent increases in ‘free’ haem significantly corresponding to decreases in HZ levels in 
the metabolites. The mean levels of ‘free’ haem Fe were significantly lower in these 
metabolites than the parents, suggesting that their potency could be due to the formation of 
more soluble and toxic drug-heam complexes than the parent pDBQs. These haem Fe levels 
overlaid on parasite growth showed an inverse trend, which confirmed these metabolites as 
genuine inhibitors of HZ formation in the parasite, though possible existence of auxiliary 
MoAs cannot be conclusively ruled out. 
Microsomal metabolic stability analyses showed that all the metabolites were highly stable 
in both MLM and HLM with >75% remaining after 30 min of incubation, a significant 
improvement from the high microsomal metabolic lability of the parents described in the 
previous Chapter. Compound 9 however, registered an anomalous result in MLM, with only 
19% of the compound remaining after 30 min of incubation. Predictive and experimental 
analyses of hERG inhibition potential highlighted a significant improvement in the 
cardiotoxicity risk profiles of compounds 10 and 11 (Figure 4.11). These compounds were on 
average 5-fold less toxic (Mean IC50: 3.56 ± 0.16) compared to their parent (Mean IC50: 0.87 ± 
0.08) or verapamil (Mean IC50: 0.56 ± 0.08), a reduction in toxicity likely attributable directly 
to reduction in lipophilicity and compound mass, and possible disruption of the binding 




Figure 4.11: Chemical structures of compounds 9, 10 and 11 
 
In conclusion, the data collected on the physicochemical, biological and mechanistic 
properties of these seven pDBQ metabolites highlight favourable drug-like features 
comprising good aqueous solubility, permeability and a lowered lipophilicity. Further 
analyses on the interaction between these compounds and PfCRT in situ as well as insight on 
the nature of the complex they form with ‘free’ haem would be instructive. The improved 
microsomal metabolic stability, cardiotoxicity profiles and other drug-like features of the 
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PYRIDO[1, 2-a]BENZIMIDAZOLE: A PLANAR NON-






5.1 Chapter Overview 
Though inhibition of haem detoxification has been extensively explored against P. falciparum 
through classical aminoquinolines and other scaffolds known to interact with ‘free’ haem 
molecules, the detoxification machinery is also present in Schistosoma mansoni and other 
hematophagous organisms as described in Chapter 1. As noted in Chapters 3 and 4, the 
quinoline-based pDBQs and their metabolites are endowed with a SAR profile that allows 
for inhibition of βH/HZ formation and they are able to structurally adopt a planar 
conformation crucial for haem-drug complex formation. This chapter explores the 
physicochemical features, biological activities and mechanistic profiles of ten (10) novel 
pyrido[1,2-a]benzimidazole (PBI) derivatives in P. falciparum and S. mansoni. The PBIs were 
hypothesised to potentially inhibit HZ formation in both organisms owing to their structural 
likeness to CQ, which includes a planar heterocyclic moiety, a halo-substituent and a basic 
amine side group, which would make them candidates for π-π interactions - another 
hallmark feature of haem-drug complex formation. 
PBIs, previously investigated for antibacterial, antifungal, antiviral and antitumor 
activities,169 were recently shown to be a novel antimalarial chemotype.170 In this study by 
Ndakala et al., the lead compound, 15 (Figure 5.1), showed high in vitro antiplasmodial 
activity (IC50 PfNF54: 0.11 μM and IC50 PfK1: 0.12 μM) and promising in vivo oral efficacy 
(95% reduction in parasitemia at 4 x 50 mg/kg p.o) in the rodent P. berghei model. However, 
pharmacokinetic (PK) studies indicated saturation in oral absorption at low doses, 




Figure 5.1: Original lead compound, 15, with activity against the CQS (PfNF54) and 
CQ/multidrug-resistant (PfK1) P. falciparum strains. 
 
Ten derivatives were therefore selected for SAR investigations around the basic structure of 
compound 15 (Figure 5.2) and synthesised to explore the biological and physicochemical 
effects of modifications around parts of the scaffold not previously investigated. SAR1 
comprised replacement of the alkylamino side chain in 15 with various moieties containing 
water-solubilising H-bonding groups, encompassing imidazole (16), hydroxypyrrolidine 
(17) or piperidinyl (18). SAR2 involved introduction of small hydrophobic substituents at C2, 
which were envisaged to result in distortion of molecular planarity thus lowering the crystal 
packing energies, and consequently potentially improving aqueous solubility.171 In this 
regard, to afford 19, fluorine was preferred since, due to its small size, it is less likely to 
interfere with protein-drug interactions but more likely to increase the dihedral angle 
without loss of biological activity.171 SAR3 comprised two derivatives bearing replacement of 
the 4-trifluoromethylphenyl (4-CF3Ph) at C3 with meta- (20) or di-substituted (21) phenyl 
rings. Finally, SAR4 involved introduction of substituents on the previously unexplored left 
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hand side (LHS) aromatic ring, including mono- (22) and di-chloro substituents (23 and 24) 
at C7, C8 and C9. 
 
Figure 5.2: Chemical structure of the prototype PBI molecule showing the different SAR 
exploration that afforded the various compounds analysed in this chapter 
 
All derivatives, shown in Figure 5.3, were first evaluated for aqueous solubility and 
membrane permeability at pH 6.5 and lipophilicity at pH 7.4. This was followed by 
assessment of their cytotoxicity in CHO cells, in vitro antiplasmodial activity against both 
CQS and CQR strains and in vivo efficacy in P. berghei-infected mice for 3 derivatives. 
Inhibition of βH/HZ as their potential MoA, the killing kinetics, hERG channel inhibition 
potential and the metabolic stability of these PBIs in MLMs and HLMs were also explored. 
Additionally, the in vitro and in vivo antischistosomal activity of these compounds is also 




    
Figure 5.3: Chemical structures of the 10 PBIs obtained from SAR1 (red), SAR2 (pink), SAR3 




5.2 Materials and Methods 
All materials and methods used throughout this chapter are listed and exhaustively 
described in Chapter 2. The compounds discussed herein were synthesised and characterised 
by Dr. Kawaljit Singh, Mr. Ferdinand Ndubi, Ms. Linley Barnard and Mr. Chad Wilkinson, 
and have been reported elsewhere in published literature.224, 225 
5.3 Results and Discussion 
5.3.1 Solubility, membrane permeability, lipophilicity and metabolic stability 
Though the lead compound (15) in the Ndakala et al. study showed good antiplasmodial 
activity and promising oral efficacy, pharmacokinetics (PK) hinted at saturation in oral 
absorption at low doses, presumably due to poor dissolution.  This necessitated further 
optimisation of the lead PBI to identify derivatives with better PK profiles - hypothetically 
achievable through improving aqueous solubility and/or permeability while maintaining 
metabolic stability. Results of the evaluation of the physicochemical properties of these 
derivatives are presented in Table 5.1. Generally, none of the SAR1 modifications led to any 
improvement in aqueous solubility as all the compounds exhibited low solubility (<5 µM). 
However, relative to 15, solubility improved for all the other analogues. For instance, fluoro- 
substitution at C2 (compound 19) resulted in significant improvement in solubility (80 µM). 
This was unsurprising since introduction of the fluoro substituent at this position was 
anticipated to distort the planarity of the compound and thus lower the energy barrier to 
dissolution in aqueous media. Replacement of the 4-CF3Ph group at C3 with a fluoro-
substituted phenyl ring (20) also led to moderate improvement in solubility (25 μM), while 
only subtle improvements were observed in the chloro- analogues of SAR4 (21; 10 µM, 23; 10 
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20 3.56 3.01 -5.3, (0.26) 
Reserpine     <5    
Hydrocortisone     >150 1.50 1.28  
Verapamil      2.50 2.79  
Warfarin        -3.8, (0.35) 
Propranolol        -4.4, (0.28) 
a Kinetic solubility was determined at pH 6.5. 
b Experimental LogD was determined using HPLC analysis at pH 7.4 while the predicted values were 
obtained from MarvinSketchTM version5.9.4. 
c Low permeability; log Papp <-6.5; moderate; log Papp -6.5 to -5.5; high; log Papp >-5.5 
159 
 
Membrane permeability generally ranged from moderate to high at pH 6.5 for all the 
derivatives and the different substituents did not have any significant influence on this 
parameter. Considering only passive diffusion, this range of permeability suggests that 
permeation through the lower GIT is unlikely to be a limiting factor in the oral absorption of 
these compounds.  Experimental LogD7.4 ranged from 1.89 to 3.62, and was observed to be 
relatively higher (mean ± SE: 3.03 ± 0.18) compared to the quinoline scaffold described in 
Chapter 3 and 4. The experimental values correlated well with predicted data (R2 = 0.6348; p 
= 0.0058). Since all the SAR1 derivatives gave poor solubility signals below 5 μM, correlation 
analysis with LogD7.4 were restricted to SAR2 – SAR4 compounds, and these yielded no 
association (R2 = 0.0039; p = 0.9063). 
From the hepatic extraction ratios, which are normalised for blood flow and incubation time, 
there was no significant interspecies difference in microsomal stability in the compounds 
Table 5.2. All compounds tested in HLMs (15, 18, 20, 21, 22, 23 and 24) were stable while 
only 5 retained stability (> 75% remaining) after 30 min incubation in MLMs. Fluoro-
substitution at C2 (19) was detrimental to metabolic stability in MLMs (37%) compared to its 
unsubstituted counterpart 15. Dichloro- substitution on the phenyl ring (21) in SAR3 was not 
favorable in either MLMs or HLMs, while fluoro-substitution at the para position on the 
phenyl ring yielded a derivative (20) stable in both microsomal species. Halo-substitution on 
the LHS of molecules (SAR4) proved efficient in improving microsomal metabolic stability as 




Table 5.2: Metabolic stability of the PBI derivatives in mouse and human liver microsomes 
 
Compound 
     Single Point Metabolic Stability 
(30 min)      










Mouse 97 >100 <0.17 















Mouse 63 60 0.58 










Mouse 100 >100 <0.17 





Mouse 65 51 0.62 





Mouse 75 73 0.54 





Mouse 81 >100 0.39 






Mouse 87 >100 0.34 
     Human 87 >100 0.41 
         
Midazolam     Mouse 1.3 4.7 0.94 
     Human 0.1   
MMV390048     Mouse 94 172.3 0.32 
     Human 93 >100 0.22 
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5.3.2 Antiplasmodial activity and cytotoxicity 
Though subsequent SAR analyses around the compounds identified by Ndakala et al. were 
primarily aimed at improving physicochemical properties that would boost oral 
bioavailability, it was essential to maintain, or possibly enhance the antiplasmodial activity 
and selectivity of the subsequent analogues. The derivatives were therefore evaluated for in 
vitro activity against the CQS strains, PfNF54 and CQR strains, PfDd2 and PfK1 as well as 
against CHO cells for cytotoxicity. Against PfNF54, all the compounds exhibited IC50 values 
less than 1µM, with compound 24 being most active (IC50; 20 nM) and 18 least (IC50; 440 nM). 
Against the CQR strains, IC50s ranged between 20 and 1,020 nM. 
With regard to SAR1, 17, bearing a 3-hydroxypyrrolidinyl replacement of the N-ethyl group 
of the aminoalkyl side chain was the most potent against in this series (IC50: 40 nM) with a 3-
fold improvement in activity compared to 15 (IC50; 120 nM). This compound still retained 
potent activity against both CQR strains (PfDd2 IC50; 40 nM and PfK1 IC50; 90 nM). 
Compounds 15 and 16 - bearing a terminal imidazole moiety also showed submicromolar 
potency against the two resistant strains (Table 5.3a). Since the aqueous solubility in this set 
of compounds was not encouraging, it is likely that their activity is due to their high 












  Cytotoxicity 
(CHO) 





IC50 (μM) S.I 
         
15 
 
120 440 110 3.7 0.9 1.56 13 
16 
 
380 570 790 1.5 2.1 10.5 28 
17 
 
40 90 30 2.3 0.8 6.12 153 
18 
 
440 900 1,020 2.0 2.3 5.98 14 
         
Chloroquine  8.0 240 230 30 28.8 35.8 4,475 
Artesunate  6.0 4.0 1.0 0.7 0.2 - - 
Emetine  nd nd nd - - 0.095 - 
 
CQS = PfNF54; CQR = PfDd2 and PfK1 
R.I. = Resistance index = IC50 CQR strain/IC50 CQS strain 
CHO = Chinese Hamster Ovarian cells. 
S.I. = Selective index = IC50 CHO/IC50 PfNF54 
 
Substitution with piperidinyl moiety (18) did not yield any change in compound selectivity 
compared to 15. However, there was a 2- and 12-fold increase in selectivity relative to 15 in 




In SAR2, activity of the 2-F derivative (19) against PfNF54 was improved by introduction of 
the 3-hydroxypyrrolidinyl side chain (Table 5.3b), consistent with the observations from 
SAR1 involving compound 17. The compound showed comparable activity to 15, with 
significantly better selectivity. Though activity dropped against PfDd2, potency was still 
maintained against PfK1, highlighting the different genomic backgrounds of resistance 
alleles in the two strains. 










  Cytotoxicity 
(CHO) 





IC50 (μM) S.I 
          
15 
 
H 120 440 110 3.7 0.9 1.56 13 
19 
 
F 190 620 170 3.3 0.9 207.1 1,090 
          
Chloroquine   8.0 240 230 30 28.8 35.8 4,475 
Artesunate   6.0 4.0 1.0 0.7 0.2 - - 
Emetine   nd nd nd - - 0.095 - 
 
CQS = PfNF54; CQR = PfDd2 and PfK1 
R.I. = Resistance index = IC50 CQR strain/IC50 CQS strain 
CHO = Chinese Hamster Ovarian cells 
S.I. = Selective index = IC50 CHO/IC50 PfNF54  
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Replacing the 4-CF3Ph in 15 with meta- and di-chloro substituted derivatives in SAR3 led to 
retention of activity against PfNF54 as shown in Table 5.3c. Compound 21 was equipotent 
against both strains of the parasite while the activity of 20 only diminished against PfK1. 
There was, however, no improvement in selectivity in this series. 









  Cytotoxicity 
(CHO) 





IC50 (μM) S.I 
         
15 
 
120 440 110 3.7 0.9 1.56 13 
20 
 
380 420 1,000 1.1 2.6 5.18 13 
21 
 
110 380 120 3.5 1.1 1.55 14 
         
Chloroquine  8.0 240 230 30 28.8 35.8 4,475 
Artesunate  6.0 4.0 1.0 0.7 0.2 - - 
Emetine  nd nd nd - - 0.095 - 
 
CQS = PfNF54; CQR = PfDd2 and PfK1 
R.I. = Resistance index = IC50 CQR strain/IC50 CQS strain 
CHO = Chinese Hamster Ovarian cells. 




Regarding SAR4, mono- (22) or dichloro- substitutions (23 and 24) at C7, C8 or C9 were well 
tolerated, providing significant improvements in selectivity and antiplasmodial activity 
against all strains tested (Table 5.3d). This could be due to their high lipophilicity (mean ± 
SE: LogD7.4; 3.47 ± 0.09), and attendant ability to permeate through phospholipid 
membranes 








  Cytotoxicity 
(CHO) 





IC50 (μM) S.I 
         
15 
 
120 440 110 3.7 0.9 1.56 13 
22 
 
30 90 30 3.0 1.0 8.71 362 
23 
 
20 40 20 1.0 2.0 3.39 188 
24 
 
30 70 40 3.2 1.3 11.20 431 
         
Chloroquine  8.0 240 230 30 28.8 35.8 4,475 
Artesunate  6.0 4.0 1.0 0.7 0.2 - - 
Emetine  nd nd nd - - 0.095 - 
 
CQS = PfNF54; CQR = PfDd2 and PfK1 
R.I. = Resistance index = IC50 CQR strain/IC50 CQS strain 
CHO = Chinese Hamster Ovarian cells. S.I. = Selective index = IC50 CHO/IC50 PfNF54 
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There was no indication of significant cross-resistance between these PBIs and CQ in the two 
CQR strains as indicated by their low resistance indices (Tables 5.3a-d). RI values close to 
unity denoted activity regardless of parasite susceptibility while loss of activity due to 
resistance development or likelihood of resistance development would be characterised by 
large RIs. As depicted in Figure 5.4A and B, the PBIs show little deviation from the diagonal 
line which represents a RI value of 1, and are clearly differentiated from CQ in the analyses 
of both CQR strains. Promising drug leads would customarily have low RI, implying they 
are less recognised by the parasite’s resistance machinery. Therefore, the difference in RI 
between these compounds and CQ suggests that their mechanism of resistance may be 
different from one involving reduction in vacuolar accumulation (like CQ), which would 
make them affected by the protein transporters responsible for lower accumulation of CQ 
within the parasite. 
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Figure 5.4: Resistance index (RI) expressed as the correlation of the in vitro antiplasmodial 




5.3.3 In Vivo Efficacy against P. berghei-infected mice 
 
Based on their potent blood stage antiplasmodial activity, high selectivity, moderate 
solubility and high microsomal stability, 20, 23 and 24, were selected for in vivo efficacy 
studies. Testing was conducted at the Swiss Tropical and Public Health Institute where the 
compounds were initially administered four times in daily oral doses of 50 mg/kg. If mice 
were cured, lower doses (4 x 30 mg/kg, 4 x 10 mg/kg and 4 x 3 mg/kg) were subsequently 
evaluated. 
 
Suppression of parasitemia as a percentage of the untreated control and the effects of the test 
compounds on mouse survival is shown in Table 5.4, with compound considered curative if 
the animal survived to day 30 after infection with no detectable parasites. Compound 20 
showed weak efficacy (61%) with a single cure at 4 x 50 mg/kg, while 23 and 24 were 
completely curative at 4 x 50 mg/kg, with 23 in fact proving better at 4 x 30 mg/kg.  At 
lower doses (4 x 10 mg/kg and 4 x 3 mg/kg), the mice were not cured (mean survival days ± 
SE: 17.5 ± 0.5) although parasitemia was still reduced by > 99%. The potent oral in vivo 
efficacy of the two analogues was encouraging and indicative of good oral bioavailability 
possibly due to the lack of first pass metabolism. It could also imply a reasonably low 
volume of distribution, which affords sufficient free unbound drug concentration in 
systemic circulation to achieve parasitemia reduction in parasitised erythrocytes. The ideal 
profile for new antimalarials comprises orally active compounds that can cure the disease 
with a 3-day regimen using once-a-day dosing.2 Indeed, these analogues demonstrate the 

























       
20 
   
4 x 50 61.0 (24) 1/3 







4 x 50 98.0 (30) 3/3 
4 x 30 99.7 (30) 3/3 
4 x 10 












4 x 50 98.0 (30) 3/3 
4 x 30 99.4 (30) 2/3 
4 x 10 99.4 (18) 0/3 
4 x 3 99.4 (16) 0/3 
       
Chloroquine    4 x 30 99.9 (24) 0/10 




a Test compounds were formulated in 90/10 Tween80/ethanol (v/v), diluted 10 times with water and 
administered orally once per day on 4 consecutive days (4, 24, 48, and 72 h after infection). 
b MSD = mean survival time in days. 
c Mice with < 40 % parasitemia reduction were euthanised on day 4 to prevent death otherwise 





5.3.4. Possible Mechanism(s) of Action 
Following the good in vitro antiplasmodial activity and in vivo oral efficacy of compounds 
based on this scaffold, investigations on potential MoAs were conducted. These comprised 
analyses on the speed of action of these compounds when P. falciparum cultures were 
incubated with fixed drug concentrations to obtain insights into possible lifecycle stage at 
which the compounds are likely to be most active. Further, their CQ-like planar architecture 
allowed for studies on in vitro inhibition of βH formation and cellular haem fractionation 
experiments. 
5.3.4.1. Analysis of Speed of Killing  
Standard in vitro parasite growth inhibition assays expose parasites to drugs for specific 
periods of time and assess the viability of the remaining parasites by measuring labelled 
nucleic acids or enzymatic activity. The rapidity of parasite killing in these assays is crucial 
as it can hint at the MoA of different compounds.226 The effect of 8 PBIs (15, 16, 17, 18, 19, 20, 
22 and 23), representing all the four SAR groups, on parasite viability over time was 
measured to determine their speed of action as described in detail in section 2.4.11 of 
Chapter 2. Correlation analyses were further performed between compound killing rate and 
potency against PfNF54. The IC50 values of PYR, 17 and 19 were 6-, 18- and 22- fold, 
respectively, higher at 24 h than at 72 h (Figure 5.5), indicating that these compounds 
possess a slow-acting parasiticidal effect and likely impair late-stage processes in the 
parasite’s 48-h cycle. CQ, AS, 15, 18 and 20 seemed to exhibit fast-acting modes (24 h/IC50 72 
h IC50 ratios < 1.5) hence likely inhibit ring stage and trophozoite-associated events. 
However, compounds 16, 22 and 23 could neither be classified as fast or slow since they had 
an activity ratio between 1.5 and 2. Since these PBIs share a common core scaffold, it is 
plausible that the observed differences in the speed of parasiticidal effect are a consequence 
of the various modifications introduced onto the prototype molecule, 15, hence enabling 
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acces or binding to different protein or enzymes and consequently eliciting distinct MoAs as 
hinted by the disparate IC50s in both CQS and CQR strains. In fact, both slow-acting 
derivatives (17 and 19) contain the 3-hydroxypyrrolidine group indicating that they could 
share a similar MoA different from the other derivatives. 




















Figure 5.5: Plot showing fold change in activity of compounds at different speed assay 
durations relative to 72 h assay. 
 
Overall, there was neither a bias in the phenotypic screen for any particular killing speed 
nor significant correlation between compound speed of action and their antiplasmodial 
potency against PfNF54 (Figure 5.6), implying that the PBIs display a fairly broad spectrum 
of killing speeds that cannot directly be predicted by their efficiency in blocking [3H] 
hypoxanthine incorporation. However, the number of compounds evaluated in this analysis 








p  =  0 .3 2 6 2
p  =  0 .2 4 7 7















Figure 5.6: Compound killing rate versus potency against PfNF54 compared between 
groups to determine if potency could be a predictor for speed of action. 
 
5.3.4.2. Inhibition of β-haematin Formation and Haem-Pyridine Speciation 
As earlier mentioned, the ability to adopt a flat conformation makes this class of compounds 
candidates for π-π interactions, which alongside hydrogen bonding and direct coordination 
to the Fe(III) centre of the haem monomer, constitute the key interactions between inhibitors 
and Fe(III)PPIX during haem-drug complex formation.90 The compounds were therefore 
first evaluated for their ability to inhibit βH formation. 
All derivatives except 19 (βHIA IC50; 119.9 µM) were active against formation of βH, with 
IC50s below 100 µM. Among the actives, compound 24 was the most potent (βHIA IC50; 7.0 
µM) and 17 the least (βHIA IC50; 85.3 µM) as shown in Table 5.5. Due to their planarity, 
these compounds are presumed to be able to π-stack with ferriprotoporphyrin IX leading to 
formation a haem-drug complex. The presence of the fluoro- group at C2 in 19 possibly 
disrupts the planarity of the molecule hence accounting for the observed low activity. It 
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could also relate to the 3-hydroxyprolidine side chain common to both compounds 17 and 
19, which are the least active in the group. 






Compound R R1 R2 R3 
 
βHIA IC50 (Mean ± SE) 
µM 


















































6.8 ± 1.6 
      
Chloroquine     25.0 ± 2.2 
Amodiaquine     15.9 ± 1.4 




However, without a detailed structural investigation of these intramolecular interactions, 
this remains only speculative. There was no discernible trend in activity that could be 
correlated to the substituents. However, though analysis of the βHI activity with speed of 
kill of the molecules did not reveal any direct statistical trends, it was noted that the 
hydroxypyrrolidine-bearing compound 17 and 19, which grouped together in the ‘slow-
acting’ category also showed the weakest βHI activity. The abilities of these compounds to 
inhibit βH formation therefore appear to depend on the presence of a planar ring system, 
aliphatic hydrophobicity and the availability of a protonation site (ionisability) in a fashion 
too complex to predict from the limited number of compounds evaluated in this chapter and 
without the guide of an X-ray crystal structure. 
Though the analysis of the association between in vitro antiplasmodial activities versus 
inhibition of βH formation indicated a general trend of decreasing antiplasmodial potency 
as βH inhibition activity decreases, this correlation was extremely weak and not significant 
(Figure 5.7). Again, this could possibly reflect the limitations in comparing data from the 
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Figure 5.6: Correlation between PBI activity against PfNF54 and βH inhibition activity. 
 
To further interrogate if these βH inhibition signals are genuine reflections of potential for 
intracellular inhibition of HZ formation, a set of four PBI derivatives were subjected to the 
cellular haem fractionation assay used to characterise pDBQs and their metabolites in the 
previous two chapters. Five compounds, 15, 17, 19, 21 and 22, were chosen as 
representatives of all the four different SAR groups. Compound 19, in addition, represented 
a negative control with no observed inhibitory activity in the detergent-based assay. 
Only compounds 15 and 22 showed significant changes in ‘free’ haem that were associated 
with both decrease in levels of HZ in a dose-dependent manner relative to untreated 
controls. Similarly, increases in ‘free’ haem were correlated with parasite survival in only 
these two derivatives (Figure 5.7). No significant changes in toxic ‘free’ haem or HZ levels 
with increasing drug concentrations were, however, observed for 17, 19 and 21 (Figure 5.7). 
The lack of HZ inhibition by 17 and 19, which both show weak to negligible βH inhibition 
activity is consistent with the results of the βH inhibition assay, and thus further validates 
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the fidelity of this haem fractionation assay in identifying true negatives especially in non-
quinoline scaffolds. Interestingly, this is consistent with speed of killing results which also 
alludes to a different target for these compounds. Taken together, the discordant results 
observed from these derivatives representing different SAR groups suggests that inhibition 
of HZ formation could be one but not the sole or primary target of this class of compounds; 
their flat conformation possibly allowing for weak haem-drug complex formation through 
only π-π interactions as was recently reported for certain benzamide analogues.227 This 
would be unlike HLF and QN, for instance, which reportedly exhibit hydrogen bonding and 
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Figure 5.7: Haem fractionation profiles of compounds 15, 17, 19, 21 and 22 in synchronised 
drug-treated and control PfNF54 parasites. Plots a, d, g, j and m), show levels of toxic ‘free’ 
haem represented as Fe measured in fg/cell while plots b, e, h, k and n) show HZ levels. 
The asterisks indicate statistical significance relative to control (*p < 0.05; ** p < 0.01 and *** 
p < 0.001). Plots c, f, i, l and o) represent parasite survival (blue) overlaid against ‘free’ haem 
Fe (red) plots. 





























































































This leaves the intriguing prospect that the PBIs could act, at least in part, through an as yet 
unidentified mechanism. Indeed, some PBI compounds have previously been reported to 
inhibit the biosynthesis of β-1,6-glucan, a key component of the mycetes cell wall.229 
Although the possible presence of β-glucan synthase orthologue(s) in P. falciparum or S. 
mansoni cannot be excluded, plasmodial and schistosomal genomes do not appear to contain 
genes encoding the enzymes traditionally associated with β -glucan synthesis due to the 
evolutionary irrelevance of cell walls in the two organisms. In addition, inhibition of the 
pore-forming protein perforin in mammalian cells by 1-amino-2, 4-dicyanopyrido[1,2-
a]benzimidazoles has also been reported.230 This is interesting as the P. falciparum proteome 
harbours perforin-like proteins (PLPs) known to be involved in permeabilising the 
erythrocyte membrane during egress of either gametocytes or merozoites.231 More recently, 
an hydroxyl derivative 2-ethyl-1-hydroxy-3-methyl-pyrido[1,2-a]benzimidazole-4-
carbonitrile (GNF7686) with potent in vitro activity against Trypanosoma cruzi, was also 
shown to act through inhibition of cytochrome b - a component of cytochrome bc1 or 
complex III 232 and a well-established antimalarial target. All these different MoAs by 
various PBI derivatives highlight a scenario where some PBIs may inhibit HZ formation 
while others inhibit other different targets. 
 
5.3.5 Antischistosomal Activity 
5.3.5.1. In vitro Antischistosomal Activity against Juvenile and Adult Worms 
As earlier mentioned, S. mansoni like P. falciparum, has evolved the biocrystallisation of haem 
molecules into HZ as a detoxification mechanism to rid themselves of the toxicity of ‘free’ 
haem.233, 234 Inhibition of this pathway therefore presents a vulnerable target and towards 
this aim, organometallic complexes, natural products and a number of repositioned 
antimalarial agents have variously been explored as antischistosomal agents and recently 
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reviewed.235-237 On the basis of the previously discussed hypothesis that PBIs can inhibit 
formation of βH due to their structural conformation, and results from the in vitro NP-40 
assay, the antischistosomal activity of 9 of the derivatives was evaluated against newly 
transformed schistosomula (NTS) and adult worms as described in section 2.4.13 in Chapter 
2. Analogues that showed favourable in vitro activity were examined for in vivo efficacy in 
experimental mice. 
All derivatives tested exhibited an inhibition range of 95.7 to 100% against NTS 
proliferation, thus allowing for subsequent evaluation against adult worms where 7/9 
derivatives still retained >60% worm mortality (Table 5.6). IC50 determination was also 
carried out for these compounds, and ranged between 0.32 to 3.94 μM and 1.62 to 10.14 μM, 
against NTS and adult worms, respectively. Compounds 24 and 21 were the most potent 
(IC50s: 1.62 and 1.69 μM, respectively) against the adult worms, which could suggest 
presence of chloro- group(s) on either side of the ring system is favoured for activity. 
Analogues based on piperidine (18) or imidazole (16) substitutions in place of the 
ethylamine group were inactive, implying these modifications are not tolerated for 
antischistosomal activity. Though all derivatives seemed more potent against the juvenile 
parasites (mean IC50 ± SE: 1.97 ± 0.36), activity diminished against the adult worms (mean 
IC50 ± SE: 4.38 ± 1.49). This could be due to presence of completely developed proteins 
and/or pathways in the adult worms that can tolerate drug pressure or even extrude it, 











     Against NTS  Against Adult Worms 

































































PZQ     100   100 0.02 
PZQ = Praziquantel 
nd = Not determined 
 
It is worth noting that compounds 17, 18 and 19, which had the least potency against both 
juvenile and adult worms, were also observed in section 5.3.4.2 as weakest βH inhibitors. A 
correlation of in vitro βH activity with antischistosomal activity revealed a general trend of 
increasing βH activity with antischistosomal activity against adult S. mansoni (Figure 5.8). 
Though positive, these associations were weak and not significant, implying either possible 
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presence of additional mechanisms involved in the antischistosomal activity of this class of 
compounds, or factors that affect the localisation of these compounds in the worm gut. This 
is consistent with recent findings involving the antimalarials CQ, MFQ and QN, which were 
shown to exhibit antischistosomal activity that did not correlate with their HZ inhibition 
property,238 with MFQ in fact demonstrated to interfere with glycolysis in NTS.239 It is 
noteworthy that, unlike in P. falciparum, HZ formation proceeds extracellularly in S. mansoni 
and is thought to be possibly initiated by, or involve proteins, lipids and other hydrophobic 
components in the gut of the parasite.40 It is therefore conceivable that these PBIs inhibit HZ 
formation in Schistosoma in a manner dissimilar to Plasmodium by interacting with any of 
these targets, resulting in the perturbation of the crystal growth microenvironment. 
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Figure 5.8: Correlation between PBI antischistosomal and βH inhibition activity of a) 9 PBI 
compounds exhibiting a broad spectrum of anti-NTS activity and b) 7 compounds with 
activity against adult worms. 
 
5.3.5.2. In vivo efficacy against S. mansoni-infected mice 
Compounds 15, 21, 23 and 24, which showed the best in vitro activity against NTS (IC50 
range: 0.32 to 0.78 μM) and adult worms (IC50 range: 1.62 to 2.41 μM) were evaluated for 
efficacy against S. mansoni-infected mice as described in section 2.4.13 in Chapter 2. 
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Compound 15 showed no reduction in total worm burden at 400 mg/kg (Table 5.7). Though 
all compounds showed only weak activity with < 50% reduction in both total and female 
worm burden, there was nonetheless a general trend of higher female worm reduction 
(FWR) which further corroborates their impressive in vitro IC50s and could, by extension, be 
indicative of a sex-specific inhibition mode not uncommon among antischistosomal 
inhibitors.240 
 
Table 5.7: Effect on worm burden following single 400 mg/kg oral doses of 4 PBIs 







































         
Control -  9 - 17.3 (8.7) 14.2 (8.4) - - 
15 4-CF3 H 3 0 18.7 (3.1) 14.3 (6.8) 0.0 0.0 
21 3,4-diCl H 4 0 8.0 (2.6) 8.3 (2.2) 48.3 41.9 
23 4-CF3 6,7-diCl 4 0 12.8 (5.3) 10.3(4.8) 26.7 27.8 
24 4-CF3 6,8-diCl 4 0 12.0 (2.7) 7.5 (3.9) 38.1 47.2 
SD = Standard deviation 
TWR = Total worm reduction 






5.3.6. Predicted hERG Channel Inhibition Potential 
Like the quinoline-based pDBQs and their metabolites, these PBIs also classify as weak bases 
whose molecular weights and lipophilicity can influence a range of absorption-related 
parameters, including likelihood for hERG channel inhibition.144 Predictions were therefore 
made on the ability of these molecules to inhibit the hERG channel and this risk was 
correlated with their molecular weights and lipophilicity. Compared to the pDBQs and their 
metabolites, the PBIs had higher pIC50s that ranged from 6.11 to 7.50 and averaged 6.66 ± 
0.14 (Table 5.8). This comparatively elevated risk for cardiotoxicity was however not 
associated with cLogP (R2 = 0.1773; p = 0.2256), LogD (R2 = 0.0689; p = 0.4639) or molecular 
weight (R2 = 0.1133; p = 0.3416). Considering the structural and pharmacological diversity of 
hERG inhibitors and the flexibility of the hERG protein, there are likely to be several modes 
and sites of interaction, making the prediction of ligand–protein interaction extremely 
complex. Indeed, it has been shown that other molecular properties like aromaticity,241 polar 
surface area and hydrogen bond donors/acceptors 242 also constitute key features of hERG-
inhibiting compounds. Therefore, it is important to remember that the predictions are not 
solely based on differences in these parameters since these, on their own, cannot sufficiently 
elucidate the dynamics of hERG channel inhibition.    
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Table 5.8: Predicted hERG inhibition IC50s and predicted lipophilicity of the PBIs 
      
Compound R R1 R2 R3 pIC50 a Mol. Weight cLogP b LogD7.4 b 



















































6.40 492.3 5.31 3.01 
                  
Chloroquine     6.00 319.9 3.81 0.88 
Dihydroartemisinin     4.27 284.4 2.84 2.84 
Halofantrine     7.37 500.4 8.06 5.46 
N-desbutylhalofantrine     6.52 444.3 6.35 3.90 
a pIC50 values were determined using StarDropTM  
b cLogP and LogD7.4 were predicted using MarvinSketch v5.9.4  
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5.4. Summary and Conclusion 
In this chapter, 10 derivatives of the PBI scaffold, identified in a previous study as having 
promising antimalarial potential, were evaluated for their biological as well as 
physicochemical properties, and characterised for their mechanistic potential to disrupt HZ 
inhibition in P. falciparum and S. mansoni. Investigations were based on SAR analyses 
referenced on the frontrunner compound, 15, and showed that though the compounds had 
an overall high permeability, only SAR 2-4 modifications led to modest improvements in 
solubility. Lipophilicity was measured by experimental determination of LogD at pH 7.4 
and averaged (± SE) 3.04 ± 0.18. These values correlated well with computationally 
predicted LogD results (R2 = 0.6348; p = 0.0058). Moderate to excellent metabolic stability 
was observed in mouse and human liver microsomes, particularly in 20 (Figure 5.9) and the 
3 SAR4 compounds. 
 
 
Figure 5.9: Chemical structures of compounds 18, 20, 23 and 24.  
 
All compounds except 18 (Figure 5.9) had submicromolar activity against both CQS and 
CQR strains, with the SAR4 derivatives bearing halo-substitutions on the LHS of the PBI 
core, showing the best antiplasmodial activity and highest selectivity. There was no 
indication of cross resistance between these derivatives and CQ, hinting at possible 
divergence in their MoA, and by extension mechanism of resistance. This antiplasmodial 
activity data, coupled with solubility and metabolic stability results, informed the selection 
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of 15, 23 and 24 for in vivo efficacy studies in P. berghei-infected mice where 23 and 24 
resulted in >99% suppression of parasitemia and complete cures in treated mice. 
 
To gain greater insight into the potential antiplasmodial MoA of these compounds, killing 
kinetics were quantified using viability time-course profiles, which were compared with 
antimalarials known to have fast (CQ, AS) or slow (PYR) rates of action. Of the 8 analogues 
selected for investigation, 3 were fast-acting, 2 were slow while the other 3 showed 
intermediate activity. Fast-acting compounds have already been a focus in therapeutic 
development as they rapidly stop disease progression, avoid severe complications and have 
recently been shown to have reduced propensity for evolution of resistance.243 This would 
make 15, 18 and 20, which likely inhibit early-stage events in the P. falciparum life cycle, 
attractive candidates for future antimalarial development in this regard. The fairly even 
distribution in speeds of activity highlighted a non-preferential killing signature and hinted 
at a broad spectrum in the activity and MoA of this class compounds. Mechanistic 
characterisation to explore βH potential of these compounds, owing to their ability to adopt 
a planar conformation, was also explored. All compounds had IC50s within an active range 
of inhibition except 19, hypothesised to harbour disrupted planarity from the 2-F 
substitution. Though no direct statistical association was observed between βH inhibition 
and speed of parasite growth inhibition, a pattern was noted whereby the weakest βH 
inhibiting compounds (17 and 19) grouped together as slow-acting derivatives and both 
bore the 3-hydroxypyrrolidine substituent. Further, correlations were compound-specific as 
21 (Figure 5.10), which was determined to have βH and antiplasmodial IC50 activity, did not 
appear to inhibit HZ formation in CQS P. falciparum as shown in the cellular haem 
fractionation results (Figure 5.7). Although HZ inhibition may occur with some derivatives 
(as evidenced by the mechanistic profiles of 15 and 22), the PBIs as a class of compounds 
most likely have alternative (and perhaps even more dominant) MoA(s) occurring elsewhere 
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in the lifecycle where HZ inhibition is not involved. A complete understanding of the 
correlation between antiplasmodial activity and HZ inhibition would require more detailed 
chemical information on the nature of solid-state aggregates of haem and these PBIs. 
 
 
Figure 5.10: Chemical structures of compounds 17, 19, 21 and 22 
 
Finally, 9 derivatives were tested for their antischistosomal activity based on the presence of 
comparable haem detoxification machinery in S. mansoni. All the derivatives showed good 
activity against the juvenile worms (mean IC50 ± SE: 1.97 ± 0.36) but were less active against 
adult worms (mean IC50 ± SE: 4.38 ± 1.49), probably due to complete assembly of the 
proteome in the adult worms. There was a positive but weak correlation between in vitro 
antischistosomal activity and βH inhibition, suggesting that inhibition of HZ formation 
could be a contributing mechanism through which these compounds exert their 
antischistosomal effect. Further, encouraging efficacy in S. mansoni-infected mice was noted 
in compound 21 (48% TWR and 41% FWR) suggesting further optimisation efforts can 
deliver derivatives with improved efficacy. The observed antischistosomal property of these 
PBIs further complements the already-known broad antimicrobial potency of this 
compound class. The predicted risk of hERG channel inhibition by the PBIs was, however, 
higher (mean pIC50 ± SE: 6.66 ± 0.14) than that of the pDBQs (mean pIC50 ± SE: 6.33 ± 0.05) or 
their metabolites (mean pIC50 ± SE: 5.29 ± 0.11), a concern that would need to be addressed 
in their future development. Evaluation of more PBI derivatives is necessary to delineate 
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meaningful SAR while direct correlation of anti-parasitic activity and actual inhibition of HZ 
formation in the worm needs to be established, as do any other additional MoAs involved.  
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  Chapter 6 
 
 
CONCLUSION AND RECOMMENDATIONS 




6.1 Summary and Conclusion 
Despite reports of declining incidence and deaths related to malaria,3 the disease still 
remains a major public health concern particularly due to the challenges posed by 
asymptomatic (chronic) infections 5 and reduced sensitivity to ACTs.54, 55 There is, therefore, 
an urgency to explore novel scaffolds to which parasites may not have been exposed and, 
hence, are less likely to be prone to resistance. In addition, it is important to exploit the 
merits of established drugs through chemical modifications that harness their 
pharmacological and pharmacokinetic advantages to help overcome theµir therapeutic 
shortcomings. CQ represents an excellent example of such known drugs. CQ resistance has 
been shown to be a consequence of reduced vacuolar concentrations due to the efflux 
activity of the transmembrane transporter, PfCRT, rather than alterations within the HZ 
formation process – the actual target of the drug. Antimalarial drug design based on 
molecules that can adopt a CQ-like SAR but remain unrecognisable to the efflux machinery 
or built on the CQ sub-structure but permit local accumulation has the potential to address 
the challenge of antimalarial drug resistance. Crucially, these compounds should have 
favourable physicochemical and ADME properties that not only make them efficacious, but 
safe and convenient to administer. 
 
The aim of this project was to establish the physicochemical, biological and mechanistic 
profiles of a set of molecules within the pyrido-dibemequine (pDBQ) and pyrido [1,2-a] 
benzimidazole (PBI) series in the context of antiplasmodial and antischistosomal activity. 
The structural framework of the pDBQ and PBI derivatives analysed in this project was 
informed by prototype molecules previously reported by Zishiri et al. and Ndakala et al., 
respectively.127, 170 Specifically, the project set out to i) investigate the solubility, permeability, 
lipophilicity, metabolic stability and potential for cardiotoxicity of pDBQs, their metabolites 
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and PBIs using computational and experimental techniques, ii) determine their in vitro and 
in vivo antiplasmodial/antischistosomal activity and correlate these with their respective 
physicochemical properties and, iii) as part of mechanistic investigations, ascertain their βH 
inhibiting potential and extend this probe to intracellular inhibition of HZ formation. 
 
Due to the presence of two hydrophobic aromatic rings (the dibenzylmethylamine side 
group) and a hydrogen bond acceptor (quinoline N-atom), consistent with the proposals of 
Bhattacharjee et al.,126 the pDBQs were hypothesised to possess resistance reversal activity. 
Moreover, the intact 4-amino-7-chloroquinoline moiety was envisaged to facilitate haem-
binding and inhibition of HZ formation in line with the requirements in the SAR model 
proposed by Egan et al. for the activity of CQ-like molecules.99 Modification of this original 
molecule by replacing one of the aromatic rings on the dibenzylmethylamine side chain with 
a pyridine and substituting the –Cl at C7 with –CN afforded compounds 2 – 7 (Figure 6.1).  
 
 
Figure 6.1: Chemical structure of the pDBQ molecules (1 – 7) analysed in this project 
 
The compounds exhibited moderate (50 – 150 µM) to high (> 150 µM) aqueous solubility, 
with the introduction of a pyridine for one of the aromatic rings in the RA side group 
appearing to be responsible for the improved aqueous solubility, presumably due to the 
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availability of the pyridine nitrogen for H-bonding with water molecules. All the pDBQs 
also had high permeability (> -4.5) at pH 6.5, suggesting the possibility of enhanced 
permeation and absorption in the lower GIT if only passive diffusion is considered. The 
mean (± SE) LogD for the compounds at pH 7.4 was 3.15 ± 0.55 and even lower (0.93 ± 0.19) 
at pH 5.0. Analysis of cLogP showed compounds 5 - 7 had the lowest cLogP, presumably 
due to the greater electron-withdrawing but less lipophilic nature of the –CN compared to –
Cl group at C7. There was also a strong inverse correlation between cLogP and predicted 
solubility (R2 = 0.8085, p = 0.0061). The compounds additionally displayed nanomolar 
antiplasmodial activity, and though their activity against PfDd2 was better (mean IC50: 121.8 
nM) than CQ (IC50: 226.4 nM) it was comparatively lower than other rCQs reported 
elsewhere. The resistance indices of the compounds further indicated a lack of cross 
resistance between these compounds and CQ. All compounds further showed potent 
inhibition of βH formation in vitro, and this mechanistic feature was confirmed through 
inhibition of HZ formation in a cellular haem fractionation experiment. The predicted and 
experimentally-determined hERG inhibition potential of the compounds showed that while 
compound 4 might present a hERG liability, the rapid metabolism would probably mean 
that it is unlikely to be present at toxic levels thus easing out concerns of hERG liability. 
Besides, the pDBQs exhibited very low metabolic stability with <5% of compound 
remaining after 30 min of incubation in mouse liver microsomes, with N-dealkylation 
identified as the main route of metabolism. 
 
The resultant metabolites represented a set of compounds with reduced molecular weight 
yet retaining the fundamental SAR of CQ (Figure 6.2). They exhibited an aqueous solubility 
profile at pH 6.5 that was comparable to that of the parent compounds and also showed a 





Figure 6.2: Chemical structure of the pDBQ metabolites (8 – 14) analysed in this project 
 
As anticipated, the microsomal cleavage of one of the side chain rings of the parent pDBQs 
contributed to the low lipophilicity among these metabolites as evidenced by the reduced 
cLogP (mean: 3.14) and LogD7.4 (mean: 0.79). Interestingly, 4/7 of these metabolites showed 
improved activity against PfDd2 (IC50 < 80 nM) even though they no longer had the RA side 
group in their structures. It could be speculated that this is because they interact with PfCRT 
in a dissimilar manner to either CQ or their parent compounds, or that they are better at 
haem-drug complex formation. Indeed, like the parent pDBQs, the metabolites effectively 
inhibited formation of βH and further confirmed this mechanistic feature by inhibiting HZ 
formation in a CQ-like manner within the cell. Intriguingly, though quinoline-based 
compounds ordinarily require only a small increase in “free” haem to induce parasite death, 
the metabolites seemed to require comparatively lower levels of ‘free’ haem than the parent 
pDBQs to induce killing. This phenomenon could probably explain, at least in part, their 
potency even against CQR strains. The metabolites were additionally stable in both human 
and liver microsomes, with >75% of compound remaining after 30 min of incubation with 




Table 6.1: Comparative summary of the physicochemical and biological features between 
the parent pDBQs and their metabolites 
 
 
Experimental and in silico analyses revealed a significantly improved hERG channel 
inhibition profile among this set of compounds relative to their parent compounds, and 
mirrored their reduced molecular weights and lipophilicity. Each metabolite was predicted 
to possess a reduced risk for hERG channel inhibition compared to its corresponding parent 
compound and, collectively, the mean pIC50 for the metabolites was significantly lower than 
that of the parent pDBQs (Mean ± SE: 5.29 ± 0.11 vs 6.33 ± 0.05; p < 0.0001, unpaired t-test). 
Experimentally, the metabolites (10 and 11) were approximately 5-fold less toxic (Mean IC50 
± SD: 3.56 ± 0.16) compared to their parent, 4 (Mean IC50 ± SD: 0.87 ± 0.08) or verapamil 
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(Mean IC50 ± SD: 0.56 ± 0.08), and the pIC50 equivalents of these experimental IC50s were 
consistent with predicted values. As a caveat, however, this data is best evaluated in the 
context of cardiac safety indices which consider these discrete IC50 values in the light of the 
free therapeutic plasma levels of the compounds. These favourable physicochemical and 
biological features in the metabolites position them as improved molecules relative to the 
parent compounds (Table 6.1). 
 
In an aim to explore non-quinoline scaffolds with potential to inhibit the same HZ formation 
pathway as CQ-like compounds, investigations were centred on SAR analyses on the 




Figure 6.3: Structure of compound 15 showing the different SAR exploration around it 
 
The PBIs tested showed only modest improvement in aqueous solubility, relative to 15 and 
had moderate lipophilicity with an average LogD value of 3.04 ± 0.18 at pH 7.4. The 
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compounds similarly had moderate to excellent metabolic stability in mouse and human 
liver microsomes, particularly 20 and the 3 SAR4 compounds, 22, 23 and 24. All derivatives, 
except 18, had submicromolar activity against both CQS and CQR strains, with the SAR4 
derivatives (22, 23 and 24) – bearing halo-substituents on the LHS of the PBI core, showing 
the best antiplasmodial activity (mean IC50 against PfNF54 = 26.7 nM and PfK1 = 30.0 nM) 
and highest selectivity (188 – 341). Based on antiplasmodial activity, solubility and metabolic 
stability data, compounds 15, 23 and 24 were evaluated for in vivo efficacy in P. berghei-
infected mice where 23 and 24 led to >99% suppression of parasitemia and complete cures of 
the mice. Analysis of the killing kinetics of a select set of derivatives revealed an even 
distribution in speeds of activity thus highlighting a non-preferential killing signature and 
hinting at a broad spectrum in activity. Due to their ability to adopt a planar conformation, 
the PBIs showed βH inhibiting activity though this did not translate into intracellular 
inhibition of HZ formation in all the derivatives as only two (15 and 22) of the five 
compounds tested exhibited increases in ‘free’ haem levels that corresponded with reduction 
in HZ. Since the HZ formation pathway also exists in S. mansoni, derivatives were tested for 
antischistosomal activity against young and adult worms. All the derivatives showed 
excellent in vitro activity against the juvenile worms (Mean IC50 ± SE: 1.97 ± 0.36 µM) but 
were less active against adult worms (Mean IC50 ± SE: 4.38 ± 1.49 µM).  Additionally, in vivo 
efficacy in S. mansoni-infected mice was noted in compound 21 (48% TWR and 41% FWR), 
suggesting further lead optimisation efforts can potentially deliver derivatives with 
improved in vivo activity. 
 
In conclusion, the pDBQs analysed in this project represent a set of compounds which 
exhibit potent antiplasmodial activity and target a vulnerable pathway in P. falciparum yet 
are compromised by poor microsomal metabolic stability and potential for cardiotoxicity. 
The resultant metabolites, on the other hand, appeared to be endowed with improved 
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features while crucially still retaining the ability to inhibit HZ formation. The metabolites 10 
and 11, in particular, showed good solubility, low lipophilicity, high metabolic stability in 
MLM and HLM), sub-100 nM potency against CQS and CQR strains as well as an improved 
hERG toxicity profile compared to their parent. The observed antiplasmodial and 
antischistosomal properties of the PBIs in this project further confirm and complement the 
already-known broad antimicrobial potency of this class of compounds. Specifically, 
compounds 21 – 24 would be of interest for further optimisation due to their high selectivity 
and in vivo antimalarial and antischistosomal efficacy in relevant animal models. The 
potential hERG inhibiting risk of these compounds would, however, need to be addressed. 
 
 
6.2. Recommendations for Future Studies 
 
6.2.1. Evaluation of In vivo Efficacy of the Metabolites in P. berghei-infected models 
 
As earlier shown, the pDBQ metabolites share high structural similarity to phenylequine 
(PQN) whose hydrochloride salt, in a previous report, showed 100% and 99.5% suppression 
of parasitemia at 4 x 30mg/kg against P. berghei ANKA strain and P. yoelli, respectively.211 It 
would be worth investigating the in vivo efficacy of these metabolites in animal models. 
Compound 10 (Figure 6.4) would be of particular interest since it ranked as the most potent 
against both PfNF54 and PfDd2, and its solubility (90 µM), permeability (high) and 
metabolic stability (>90%) are likely to enhance bioavailability and hence contribute to 







Figure 6.4: Chemical structure and summary physicochemical and biological properties of 
compound 10 that favour consideration for in vivo efficacy testing. 
 
6.2.2. Target Identification in the PBIs 
While their ability to adopt a planar architecture possibly allows the PBIs to interact with 
haem molecules and, in the process, even inhibit formation of HZ formation, this study did 
not find conclusive evidence that this is the irrefutable MoA of this class of compounds. It 
would be thus prudent to explore different approaches to identify their genuine targets. 
Some ideas include; 
 
6.2.2.1. Analysis of stage-specificity. 
 Coupling the speed of kill experiment with an assay to determine the blood stage specific 
activity of the PBIs would give insight into whether the compounds are more potent during 
early (rings) or late stages (trophozoites and schizonts). This is informative in two ways as, 
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first, it would provide clues as to which proteins the compounds target due to stage-specific 
expression in the P. falciparum proteome.244 Secondly, it is a window into the potential 
mechanism of resistance as a particular stage of the parasite may be able to be quiescent to 
the effect of the drug only to resume growth later, a phenomenon aptly illustrated by 
quiescent ring stage parasites tolerant to artemisinin.245 
 
6.2.2.2. Analysis of DNA Intercalation. 
At least at non-physiologically relevant concentrations, CQ can interact with DNA. Using 
proton nuclear magnetic resonance (H-NMR) technique, CQ was observed to preferentially 
bond with the double-stranded DNA, with the G-C base pairs as its special binding sites.246 
Though this hypothesis of intercalation no longer holds as the MoA of CQ, it can still be 
extended to, and tested in, other planar molecules, which might possess a CQ-like ability to 
intercalate into DNA and compromise replication. A practical approach to investigate this 
would involve treating parasite-extracted DNA with PBIs followed by polymerase chain 
reaction (PCR) amplification of the DNA fragment and finally calculating the percent 
amplification efficiency relative to positive (known DNA binder like centanamycin) and 
negative (DMSO) controls. Drug: DNA adducts would block Taq polymerase activity and 
prevent amplification by PCR of the treated DNA. An alternative approach would involve 
staining of nucleic acid with a DNA-specific intercalating dye such as methyl green. Agents 
that displace methyl green from DNA-methyl green complex, would constitute binders, and 
can subsequently be detected spectrophotometrically by a decrease in absorbance at 620 nm 
and loss of colour.247 
 
6.2.2.3. Investigation of Inhibition of Permeation Pathways in P. falciparum. 
Within the host cell membrane, P. falciparum induces new permeation pathways (NPPs) 
which have the characteristics of anion-selective channels and are permeable to chemically 
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diverse inorganic and organic ions essential for its survival. Such NPPs are also likely to be 
crucial for egress of mature parasites from the erythrocyte to facilitate re-invasion. Some 
antiplasmodial compounds have been shown to inhibit these NPPs (and subsequent 
haemolysis),248 and because inhibition of pore-forming proteins constitutes a putative target 
for PBIs, it would be of interest to test this hypothesis. In theory, since the channels induced 
in the infected cell membrane would allow in sorbitol when parasitised erythrocytes are 
suspended in an isosmotic sorbitol solution leading to cell swelling and haemolysis, 
blockage of these parasite-induced transport channels in P. falciparum-infected erythrocytes 
would demonstrate a mechanistic inhibition property by the PBIs. 
 
6.2.2.4. Drug Affinity Responsive Target Stability (DARTS) Studies 
A more holistic and comprehensive strategy involving identification of the target of small 
molecules through exploiting drug-protein binding interaction without chemical 
modification is drug affinity responsive target stability (DARTS).249 This strategy provides a 
platform where small molecules stabilise their target protein structures, resulting in 
resistance to protease treatment as depicted in Figure 6.5. The PBIs (ligands) would be 
incubated with parasite lysate (containing global Plasmodium proteome) and through 
negative enrichment, non-target proteins would be degraded by proteolysis leaving behind 
bound target proteins rendered protease-resistant. Inhibitor and control (vehicle)-treated 
proteins would be resolved by sodium dodecyl sulphate - polyacrylamide gel 
electrophoresis (SDS-PAGE) to identify bands whose abundance differ between the 
inhibitor-treated and control sample - which would then be excised, digested with enzyme 




Figure 6.5: Model illustration of DARTS approach whereby cell lysates are incubated with 
native drug and then treated with proteases. The ‘target’ proteins are negatively enriched 
due to their drug-induced protease resistance while non-target proteins are digested away. 
 
6.2.2.5. In vitro Selection of Mutants 
This experiment is premised on the hypothesis that the resultant ‘resistant’ phenotype 
would be a consequence of gene amplification/deletion or point mutations either in target 
genes or related ones that offset the mutational costs on the target genes. Drug pressure 
would therefore be induced using variously substituted PBIs for a specific number of cycles 
(at least 30) and global genomic changes investigated using whole genome sequencing and 
real time PCR (RT-PCR) to probe mutations and gene amplification events. The use of 
different derivatives is argued for on the basis that common mutations observed (if any) 
would be a consequence of the core scaffold and not the side group modification, and thus 
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